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Résumé 
Le diabète maternel est un facteur de risque majeur pour le développement de  
malformations congénitales. Dans le syndrome de l’embryopathie diabétique, 
l’exposition prolongée du fœtus à de hautes concentrations ambientes de glucose 
induit des dommages qui peuvent affecter plusieurs organes, dont les reins. Les 
malformations rénales sont la cause de près de 40 pourcent des cas d’insuffisance 
rénale infantile. L’hyperglycémie constitue un environnement utérin adverse qui nuit 
à la néphrogenèse et peut causer l’agenèse, la dysplasie (aplasie) ou l’hypoplasie 
rénale. Les mécanismes moléculaires par lesquels les hautes concentrations 
ambientes de glucose mènent à la dysmorphogenèse et aux malformations demeurent 
toutefois mal définis. 
Le diabète maternel prédispose aussi la progéniture au développement d’autres 
problèmes à l’âge adulte, tels l’hypertension, l’obésité et le diabète de type 2. Ce 
phénomène appelé ‘programmation périnatale’ a suscité l’intérêt au cours des 
dernières décennies, mais les mécanismes responsables demeurent mal compris.  
Mes études doctorales visaient à élucider les mécanismes moléculaires par 
lesquels le diabète maternel ou un environnement in utero hyperglycémique affecte la 
néphrogenèse et programme par la suite la progéniture a développer de 
l’hypertension par des observations in vitro, ex vivo et in vivo. Nous avons utilisé les 
cellules MK4, des cellules embryonnaires du mésenchyme métanéphrique de souris, 
pour nos études in vitro et deux lignées de souris transgéniques (Tg) pour nos études 
ex vivo et in vivo, soient les souris HoxB7-GFP-Tg et Nephrin-CFP-Tg. Les souris 
HoxB7-GFP-Tg expriment la protéine fluorescente verte (GFP) dans le bourgeon 
urétérique (UB), sous le contrôle du promoteur HoxB7. Les souris Nephrin-CFP 
expriment la protéine fluorescente cyan (CFP) dans les glomérules, sous le contrôle 
du promoteur nephrin spécifique aux podocytes. 
Nos études in vitro visaient à déterminer si les hautes concentrations de glucose 
modulent l’expression du gène Pax2 dans les cellules MK4. Les cellules MK4 ont été 
traitées pendant 24h avec du milieu contenant soit 5mM D-glucose et 20mM 
D-mannitol ou 25mM D-glucose et avec ou sans antioxydants ou inhibiteurs de p38 
MAPK, p44/42 MAPK, PKC et NF-kB. Nos résultats ont démontré que le D-glucose 
élevé (25mM) augmente la génération des espèces réactives de l’oxygène (ROS) dans 
les cellules MK4 et induit spécifiquement l’expression du gène Pax2. Des analogues 
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du glucose tels le D-mannitol, L-glucose ou le 2-Deoxy-D-glucose n’induisent pas 
cette augmentation dans les cellules MK4. La stimulation de l’expression du gène 
Pax2 par le D-glucose dans les cellules MK4 peut être bloquée par des inhibiteurs des 
ROS et de NF-kB, mais pas par des inhibiteurs de p38 MAPK, p44/42 MAPK ou 
PKC. Ces résultats indiquent que la stimulation de l’expression du gène Pax2 par les 
concentrations élevées de glucose est due, au moins en partie, à la génération des 
ROS et l’activation de la voie de signalisation NF-kB, et non pas via les voies PKC, 
p38 MAPK et p44/42 MAPK. 
Nos études ex vivo s’intéressaient aux effets d’un milieu hyperglycémique sur la 
morphogenèse de la ramification du bourgeon urétérique (UB). Des explants de reins 
embryonnaires (E12 à E18) ont été prélevés par micro-dissection de femelles 
HoxB7-GFP gestantes. Les explants ont ensuite été cultivés dans un milieu contenant 
soit 5mM D-glucose et 20mM D-mannitol ou 25mM D-glucose et avec ou sans 
antioxydants, catalase ou inhibiteur de PI3K/AKT pour diverses durées. Nos résultats 
ont démontré que le D-glucose stimule la ramification du UB de manière spécifique, 
et ce via l’expression du gène Pax2. Cette augmentation de la ramification et de 
l’expression du gène Pax2 peut être bloquée par des inhibiteurs des ROS et de 
PI3K/AKT. Ces études ont démontré que les hautes concentrations de glucose 
altèrent la morphogenèse de la ramification du UB via l’expression de Pax2. L’effet 
stimulant du glucose semble s’effectuer via la génération des ROS et l’activation de 
la voie de signalisation Akt. 
Nos études in vivo visaient à déterminer le rôle fondamental du diabète maternel 
sur les défauts de morphogenèse rénale chez la progéniture. Dans notre modèle 
animal, le diabète maternel est induit par le streptozotocin (STZ) chez des femelles 
HoxB7-GFP gestantes (E13). Les souriceaux ont été étudiés à différents âges 
(naissants et âgés de une, deux ou trois semaines). Nous avons examiné leurs 
morphologie rénale, nombre de néphrons, expression génique et les événements 
apoptotiques lors de cette étude à court terme. La progéniture des mères diabétiques 
avait un plus faible poids, taille et poids des reins, et possédait des glomérules plus 
petits et moins de néphrons par rapport à la progéniture des mères contrôles. La 
dysmorphogenèse rénale observée est peut-être causée par l’augmentation de 
l’apoptose des cellules dans la région du glomérule. Nos résultats ont montré que les 
souriceaux nés de mères diabétiques possèdent plus de podocytes apoptotiques et 
plus de marquage contre la caspase-3 active dans leurs tubules rénaux que la 
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progéniture des mères contrôles. Les souriceaux des mères diabétiques montrent une 
augmentation de l’expression des composants du système rénine angiotensine (RAS) 
intrarénal comme l’angiotensinogène et la rénine, ainsi qu’une augmentation des 
isoformes p50 et p65 de NF-kB. Ces résultats indiquent que le diabète maternel 
active le RAS intrarénal et induit l’apoptose des glomérules, menant à une altération 
de la morphogenèse rénale de la progéniture. 
 En conclusion, nos études ont permis de démontrer que le glucose élevé ou 
l’environnement in utero diabétique altère la morphogenèse du UB, qui résulte en un 
retard dans la néphrogenèse et produit des reins plus petits. Cet effet est dû, au moins 
en partie, à la génération des ROS, à l’activation du RAS intrarénal et à la voie NF-kB. 
 Nos études futures se concentreront sur les mécanismes par lesquels le diabète 
maternel induit la programmation périnatale de l’hypertension chez la progéniture 
adulte. Cette étude à long terme porte sur trois types de progénitures : adultes nés de 
mères contrôles, diabétiques ou diabétiques traitées avec insuline pendant la gestation. 
Nous observerons la pression systolique, la morphologie rénale et l’expression de 
divers gènes et protéines. Nous voulons de plus déterminer si la présence d’un système 
antioxydant (catalase) peut protéger la progéniture des effets néfastes des ROS causés 
par l’environnement in utero hyperglycémique. Les souris Catalase-Tg expriment la 
catalase spécifiquement dans les tubules proximaux et nous permettrons d’explorer 
notre hypothèse sur le rôle des ROS dans notre modèle expérimental de diabète 
maternel. 
Mots-clés: diabète maternel; hyperglycémie; néphrogenèse; système rénine 
angiotensine; Pax2; apoptose; espèces réactives de l’oxygène; programmation 
périnatale 
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Abstract 
Maternal diabetes is a major risk factor for congenital malformations. When the 
fetus is exposed to high, sustained, ambient glucose levels, widespread fetal damage 
may affect multiple organs, including the kidneys, evoking diabetic embryopathy 
syndrome. Renal malformations account for up to 40% of childhood renal failure 
cases. Hyperglycemia constitutes an adverse in utero environment that dynamically 
impairs nephrogenesis, resulting in renal agenesis, dysplasia, aplasia or hypoplasia. 
However, the molecular mechanisms by which high, ambient glucose levels lead to 
renal dysmorphogenesis and birth defects have not yet been delineated. 
Maternal diabetes also programs the offspring to develop other problems later in 
life, such as hypertension, obesity and type 2 diabetes. This phenomenon, called 
‘perinatal programming’, has attracted worldwide attention in recent decades, yet the 
mechanisms by which it occurs are incompletely understood. 
 My PhD studies are designed to elucidate the underlying molecular pathways by 
which maternal diabetes or hyperglycemic environments in utero impair 
nephrogenesis and subsequently make the offspring develop perinatal programming of 
hypertension in vitro, ex vivo and in vivo. We employed mouse embryonic metanephric 
mesenchyme cells, namely MK4 cells, for our in vitro experiments, and 2 transgenic 
(Tg) mouse lines, Hoxb7-GFP-Tg and Nephrin-CFP-Tg mice, for ex vivo and in vivo 
investigations. Hoxb7-GFP-Tg mice specifically express green fluorescent protein 
(GFP) in ureteric buds (UB), driven by the Hoxb7 promoter. Nephrin-CFP-Tg mice 
express cyan fluorescent protein (CFP) in glomeruli, driven by the podocyte-specific 
nephrin promoter. 
 In our in vitro studies, we examined whether high glucose alters Pax2 gene 
expresson in MK4 cells. The cells were treated with either 5 mM D-glucose plus 20 
mM D-mannitol or 25 mM D-glucose media with or without reactive oxygen species 
(ROS) blockers (DPI, rotenone), and inhibitors of p38 mitogen-activated protein 
kinase (MAPK) (SB203580), p44/22 MAPK (PD98059), protein kinase C (PKC) 
(GF109203X), or nuclear factor kappa B (NK-kB) (PDTC) for 24-hr incubation. Our 
data showed that high D-glucose (25 mM) increased ROS generation and specifically 
induced Pax2 gene expression, but not other glucose analogs such as D-mannitol, 
L-glucose or 2-deoxy-D-glucose in MK4 cells. The stimulatory effect of high 
D-glucose on Pax2 gene expression could be blocked by ROS and NF-kB inhibitors in 
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MK4 cells but not by inhibitors of p38 MAPK (SB203580), p44/22 MAPK 
(PD98059), and PKC (GFX) in MK4 cells. These data indicated that the stimulatory 
effect of high glucose on Pax2 gene expression is mediated, at least in part, via ROS 
generation and activation of NF-κB, but not via the PKC, p38 MAPK and p44/42 
MAPK signalling pathways. 
 In our ex vivo studies, we investigated the influence of a high-glucose milieu on 
UB branching morphogenesis. Kidney explants (E12 to E18) were microdissected 
from timed-pregnant Hoxb7-GFP mice and cultured with either 5 mM D-glucose plus 
20 mM D-mannitol or 25 mM D-glucose media with or without ROS blockers (DPI, 
rotenone), catalase and phosphoinositide-3-kinase (PI3K)/AKT inhibitor at different 
time points, depending on the experiment. We found that high D-glucose specifically 
stimulated UB branching in a time-dependent manner. High D-glucose stimulation of 
UB branching morphogenesis was mediated via Pax2 gene expression. High 
D-glucose-induced UB branching and Pax2 gene expression could be blocked by ROS 
and PI3K/AKT inhibitors. These studies demonstrated that high glucose alters UB 
branching morphogenesis via Pax2 gene and protein expression. The stimulatory effect 
of high glucose seems to be mediated via ROS generation and activation of the AKT 
signalling pathway.   
In our in vivo studies, we explored the fundamental role of maternal diabetes on 
renal morphogenesis impairment in offspring. In our experimental model, maternal 
diabetes was induced by streptozotocin in pregnant Hoxb7-GFP mice at embryonic 
day 13. The offspring were examined at several time points after birth (neonatal, 1 
week, 2 weeks, and 3 weeks) with follow-up of kidney morphology, nephron number, 
gene expression, and apoptotic events in this short-term postnatal experiment. We 
observed that the offspring of diabetic mice had lower body weight, body size, kidney 
weight, small volume of glomeruli and a reduced number of nephrons in comparison 
to non-diabetic control offspring. Renal dysmorphogenesis may have been the result of 
increased cell apoptosis in glomeruli. Our findings showed that the offspring of 
diabetic mice displayed significantly more apoptotic podocytes as well as augmented 
active caspase-3 immunostaining in renal tubules compared to control mice offspring. 
Diabetic mice offspring presented heightened expression of intrarenal 
renin-angiotensin system (RAS) components, such as angiotensinogen and renin, with 
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upregulation of p50 and p65 NF-kB isoforms. These data indicated that maternal 
diabetes activates the intrarenal RAS and induces glomerular apoptosis, resulting in 
impairment of renal morphogenesis in diabetic offspring. 
 In conclusion, our findings indicated that a high-glucose milieu in utero or 
maternal diabetic alters UB morphogenesis, culminating in retardation of 
nephrogenesis with smaller kidney size. The underlying mechanism(s) is mediated, at 
least in part, via ROS generation and activation of the intrarenal RAS and NF-kB 
pathways. 
 In the future, we aim to investigate the underlying mechanism(s) of how maternal 
diabetes induces perinatal programming of adult hypertension in offspring in vivo. 
This long-term postnatal study will be undertaken in 3 groups: adult offspring (20 
weeks) of control mice, adult offspring of diabetic pregnant mice, and adult offspring 
of insulin-treated, diabetic, pregnant mice. We will follow-up by tracking 
hypertension, kidney morphology, and gene expression. Furthermore, we also plan to 
determine whether an antioxidant system (catalase) can protect against an 
hyperglycemic environment in utero that affects embryonic organogenesis via an 
increase in ROS generation. Catalase-Tg mice that specifically overexpress catalase 
in proximal tubules will be tested. Such Tg mice with catalase overexpression 
represent a model for exploring our hypothesis on the role of ROS in gestational 
diabetes.  
 
Keywords : maternal diabetes, hyperglycemia, nephrogenesis, renin-angiotensin 
system, Pax2, Apoptosis, perinatal programming 
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CHAPTER 1 : MATERNAL DIABETES 
1. Maternal Diabetes or Gestational Diabetes Mellitus  
Diabetes during pregnancy is associated with an increased risk of maternal and 
neonatal morbidities. Maternal diabetes includes pre-gestational diabetes mellitus 
(PGDM) and gestational diabetes mellitus (GDM). PGDM refers to pre-existing 
diabetes (Type 1 or Type 2) when women become pregnant. GDM occurs only 
during pregnancy.  
  
1.1. PGDM 
PGDM is defined as carbohydrate intolerance diagnosed prior to pregnancy. 
About 0.2-0.5% of all pregnancies are complicated by PGDM and are associated 
with adverse maternal and neonatal outcome (1;2). 
  
1.2. GDM 
GDM is formally defined as any degree of carbohydrate intolerance with onset 
or first recognition during pregnancy (3). It is classically diagnosed by oral glucose 
challenge during weeks 24-28 of gestation (4), because insulin resistance increases 
during the second trimester of pregnancy, and glucose levels will rise in women who 
do not have the ability to produce enough insulin to adapt to this resistance. GDM is 
a problem that affects a significant number of women during pregnancy. It could 
have lasting health impacts on both mother and fetus (as discussed below).  
  
1.3. Prevalence and Epidemiological Studies of GDM 
GDM affects 3-10% of pregnancies, depending on the population studied, and 
ranges from 1% to 14% among different racial/ethnic groups (5). Most commonly, it 
has been demonstrated that GDM complicates nearly 5-7% of all pregnancies, 
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accounting for more than 200,000 pregnancies annually in the U.S.A. (5;6). Several 
studies have provided evidence to support the assertion that the prevalence of GDM 
is strongly related to race, as consistently higher rates have been reported in 
African-Americans, Native Americans, Hispanics, Pacific islanders, and South and 
East Asians (7-10). In a Los Angeles survey, Baraban et al. (11) observed that the 
prevalence of GDM increased from 14.5 cases per 1,000 women in 1991 to 47.9 
cases per 1,000 women in 2003. In another study, it was estimated that, between 
1994 and 2002, among women of varied ethnic/racial backgrounds living in 
Colorado, the overall prevalence of GDM doubled from 2.1% in 1994 to 4.1% in 
2002 (12). The prevalence of GDM was 12.8% among James Bay Cree women in 
northern Quebec in 1995-96 (13). 
 
1.4. Risk Factors Related to GDM  
The traditional and most common risk factors for GDM include high maternal 
age, obesity, parity, previous delivery of a child weighing more than 9 lbs at birth or 
with birth defects, stillbirth (fetus death in uterus), previous pregnancy with GDM, 
impaired glucose tolerance, and family history of diabetes. These and other reported 
risk factors are summarized in Table 1-1 (7). Being overweight or obese before 
pregnancy has also been associated with a high prevalence of GDM (14;15). Some 
studies have revealed a positive correlation between increasing pre-pregnancy body 
mass index (BMI) and the augmented rate of GDM (16;17). In a meta-analysis, the 
risk of developing GDM doubled in overweight women (BMI 25.0-30.0 kg⁄m2), 
quadrupled in obese women (BMI 30.0-35.0 kg⁄m2), and rose 8-fold in women with 
severe obesity (BMI >35.0 kg⁄m2) (18). Women with a history of GDM have an 
heightened risk of recurrent GDM in subsequent pregnancies. It has been found that 
GDM recurs in 30-69% of subsequent pregnancies after a pregnancy with GDM 
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(19). MacNeill et al. (20) demonstrated that the rate of GDM recurrence was 35.6% 
in a retrospective, longitudinal study performed in Nova Scotia, Canada. In addition, 
twin pregnancy has also been associated with a high prevalence of GDM (21). 
 
Table 1-1. Risk Factors for Gestational Diabetes (7). 
 
 
1.5. Pathophysiology of GDM 
The precise mechanisms underlying GDM remain unknown. Chronic insulin 
resistance is a central element in the pathophysiology of GDM. Insulin resistance 
during pregnancy stems from various factors, including alteration of placental 
steroid and peptide hormone levels (e.g., estrogens, progesterone), human placental 
lactogen (hPL) and human placental growth hormone (hPGH) (22). During the 2nd 
and 3rd trimesters of pregnancy, rising estrogen and progesterone levels confer 
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increasing tissue insulin resistance, contributing to the disruption of glucose-insulin 
balance (23). hPL, the key hormone mediating insulin resistance in pregnancy, is 
produced by the placenta, affects fatty acid and glucose metabolism, promotes 
lipolysis, and decreases glucose uptake (24). However, hPL increases up to 30-fold 
during normal pregnancy and induces insulin release from the pancreas in pregnancy 
(25). Brelje et al. (25) reported that hPL stimulated the growth of pancreatic islets 
and insulin secretion during pregnancy, suggesting that it influences beta-cell 
function and peripheral tissue sensitivity to insulin.  
 hPGH is another major hormone that may be involved in the pathogenesis of 
insulin resistance during pregnancy (26). It increases 6- to 8-fold during pregnancy 
and replaces normal pituitary growth hormone in the maternal circulation (24). 
hPGH overexpression in transgenic (Tg) mice causes severe peripheral insulin 
resistance (27). It has been demonstrated that the cytokine tumor necrosis 
factor-alpha (TNF-α), produced in the placenta, is one of the potential mediators of 
insulin resistance during pregnancy (28). Incubation of human tissue explants, such 
as the placenta and adipose tissue, in different glucose concentrations, showed that 
women with GDM release greater amounts of TNF-α in response to a glucose 
stimulus than those with normal glucose tolerance (29). Kirwan et al. (30) 
determined that TNF-α levels were higher in women with GDM than in those with 
normal glucose tolerance in late pregnancy. TNF-α levels were inversely correlated 
with insulin sensitivity. Studies have also disclosed increased circulating levels of 
leptin and decreased adiponectin in women with GDM (31;32). Autoimmune 
destruction of pancreatic beta cells is another potential cause of GDM. Type 1 
diabetes mellitus (T1DM) resulting from pancreatic beta cell destruction is 
characterized by circulating immune markers against pancreatic islets, such as 
anti-islet cell antibodies or beta cell antigens, such as glutamic acid decarboxylase. 
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A small minority of women with GDM have been shown to present the same 
markers in their circulation, indicating that they most likely have inadequate insulin 
secretion due to autoimmune destruction of pancreatic beta cells (33;34). 
  
1.6. Maternal diabetes Complications 
Maternal diabetes complications affecting mother and fetus have been well 
demonstrated. This risk is largely related to high blood glucose and its consequences. 
Maternal complications include preterm labor and T2DM development, among 
others. Fetal complications comprise congenital anomalies, macrosomia, etc. 
 
1.6.1. Maternal Complications of Maternal Diabetes 
 The maternal complications of maternal diabetes are diabetic retinopathy, 
diabetic nephropathy (DN), hypertension, preterm labor, infections, cesarean section, 
T2DM development, and so on. 
  
1.6.1.1. Diabetic Retinopathy 
Diabetic retinopathy is one of the diabetic microangiopathy complications 
generally occurring in T1DM and T2DM. It is the result of microvascular retinal 
changes. Hyperglycemia-induced pericyte death and basement membrane thickening 
lead to incompetence of the vascular walls. This damage changes the formation of 
the blood-retinal barrier and makes the retinal blood vessels more permeable. 
Studies have demonstrated worsening of retinopathy in diabetes during pregnancy 
(35;36). The risk factors for diabetic retinopathy during pregnancy include the 
duration of diabetes mellitus, metabolic control before and during pregnancy, and 
the presence of coexisting hypertension, as summarized in Table 1-2 (37). 
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Table 1-2. Risk factors for worsening of diabetic retinopathy during pregnancy 
 
  
1.6.1.2. DN 
DN is one of the diabetic complications generally occurring in T1DM and 
T2DM. DN, the leading cause of end-stage renal disease (ESRD), complicates 
approximately 5% of insulin-dependent diabetic pregnancies (38). Normal 
pregnancy is marked by increases of approximately 30-50% in the glomerular 
filtration rate (GFR) and proteinuria. Generally, women with underlying 
nephropathy can expect varying degrees of renal function deterioration during 
pregnancy. For example, an elevated GFR accompanying pregnancy may cause 
microvascular renal injury leading to glomerular changes; enhanced protein 
excretion can also cause renal damage. Kitzmiller et al. (39) reviewed 35 
pregnancies complicated by nephropathy and found that proteinuria increased in 
69% of all cases with a decline in 65% of them after delivery. Other complications, 
including preeclampsia, premature labor and hypertension, are all significantly more 
common in women with DN during pregnancy. The prevalence of preeclampsia in 
pregnant women with T1DM is higher than in pregnant women without diabetes 
(40). Pregnancy-induced hypertension is also twice more frequent in patients with 
T1DM than in non-diabetic women (41). Kidney disease can significantly raise the 
risk of high blood pressure problems during pregnancy. 
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1.6.1.3. Hypertension 
Hypertensive disorders complicating 5-10% of all pregnancies (42) are classified 
into 4 categories, as recommended by the National High Blood Pressure Education 
Program Working Group on High Blood Pressure in Pregnancy: 1) chronic 
hypertension, 2) preeclampsia-eclampsia, 3) preeclampsia superimposed on chronic 
hypertension, and 4) gestational hypertension (43). Like pregnancy-induced 
hypertension, GDM is also relatively common and affects 3-5% of pregnancies (44). 
Chronic hypertension complicates nearly 1 in 10 diabetic pregnancies, and diabetic 
pregnant women with underlying renal or retinal vascular disease are at high risk 
(45). Women with diabetes and preexisting chronic hypertension are prone to 
developing preeclampsia. Preeclampsia and gestational hypertension are obviously 
more frequent in women with GDM. In a large population-based cohort in 
Washington State reported by Bryson et al. (46), GDM was more common in each 
of the pregnancy-induced hypertension case groups than in the controls. Another 
cohort study of 10,666 women in Sweden disclosed a significantly increased risk of 
preeclampsia among mothers with GDM compared to mothers without GDM (47). 
In Canada, a cohort study in Alberta showed that women with GDM are at 2-fold 
higher risk of presenting with preeclampsia than normal pregnant women (48). 
Recently, Lykke et al. (49) demonstrated that women who had severe preeclampsia 
in a first pregnancy ran a 7.58-fold increased risk of subsequent hypertension 
compared to women with no hypertensive disorder. 
  
1.6.1.4. Development of T2DM 
 GDM affects nearly 5 to 7% of all pregnancies and increases the risk for women 
with a history of GDM of developing T2DM later in life. The factors that are 
associated with T2DM include increased BMI, history of impaired glucose tolerance, 
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gestational age at diagnosis of GDM, and insulin use during pregnancy. During 
pregnancy, women with GDM display metabolic abnormalities similar to those of 
people with T2DM, such as insulin resistance and reduced beta cell compensation 
(50). In a population-based study assessing all deliveries in the province of Ontario, 
Canada, Feig et al. (51) found that T2DM developed within 9 years after the index 
pregnancy in 18.9% of women with a history of GDM compared to 2.0% of women 
without GDM (Figure1-1) (51). 
  
Figure 1-1 Cumulative incidence rate of diabetes mellitus (51) 
 
Recently, in their meta-analysis of cohort studies, Bellamy et al. (52) reported 
an approximately 7.5-fold increased risk of T2DM in women who had gestational 
diabetes during pregnancy. In addition, Järvelä et al. (53) showed that about 10% of 
Finnish women with a history of GDM will incur diabetes over the next 6 years, and 
nearly half of them acquire T1DM while the other half develop T2DM. Their 
findings revealed that a small percentage of women with GDM may suffer from 
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T1DM postpartum. Taken together, the relationship between GDM and the risk of 
T2DM suggests that GDM can serve as a window to T2DM predisposition. 
1.6.1.5. Premature Labor 
Premature labor is defined as the beginning of labor before 37 weeks of 
gestation. Premature labor continues to be the leading cause of perinatal morbidity 
and mortality. It is estimated that approximately 6% of infants in the general 
population are born prematurely (54). Preterm labor occurs in approximately 12% of 
pregnancies and is the leading cause of neonatal mortality in the United States (55). 
Most women with GDM have normal labor and delivery but some with GDM may 
experience early or premature labor due to overstretching of the uterus by a 
macrosomic fetus or too much amniotic fluid (56). The rate of premature labor is 4 
to 5 times higher among pregnant women with GDM compared to the general 
population (40). In addition, the preterm delivery rate is significantly higher in 
pregnant women with PGDM than in a control population (57;58). 
  
1.6.1.6. Infection 
 Women with GDM have twice the number of urinary tract infections compared 
to women without GDM (22). This increased incidence of infection is thought to 
result from the high amount of glucose in urine during pregnancy. Nowakowaka et 
al. (59;60) found that the prevalence of fungi in the vagina is significantly higher in 
diabetic pregnant women with poor glycemic control compared to the controls. 
  
1.6.1.7. Cesarean Section   
An increasing number of newborns are being delivered by cesarean section, and 
GDM is among the high risk factors. Pregnancy weight gain, an important and 
modifiable risk factor for GDM, is also independently associated with elevated rates 
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of cesarean delivery (61). In the Tunisian population, Denguezli et al. (62) showed 
that the total cesarean rate was significantly higher in diabetic pregnancies (50.2%) 
than in the control group (28.2%). Fetal macrosomia was significantly correlated 
with the risk of cesarean delivery in diabetic women. In fact, women with diabetes 
often have macrosomic babies, and delivery can be difficult for both babies and 
mothers. In addition, the odds of requiring cesarean delivery can be much higher 
when babies are found to be macrosomic. Siggelkow et al. (63) noted a significantly 
higher number of secondary cesarean sections in the macrosomic group (27.4 vs. 
16.7% in the normal-weight group; P<0.002). Furthermore, complications, such as 
preterm labor and infections, may also increase the risk of cesarean delivery. 
 
1.6.2. Impact of Maternal Diabetes Complications on the Progeny 
 The maternal diabetic environment in utero has a serious impact on the fetus, 
neonate, child and adult, as shown in Figure 1-2 (64). I will briefly review the 
short-term (perinatal) and long-term complications that occur in the offspring of 
diabetic mothers (ODMs). 
  
 
Figure 1-2. Short- and long-term complications in the offspring of diabetic mothers 
(modified from Weintrob et al.: J Diabetes Complications) (64) 
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1.6.2.1. Short-term Impact of maternal diabetes Complications on ODMs  
1.6.2.1.1. Macrosomia 
   Fetal macrosomia is defined as birth weight of more than 4,000 g (8 lb, 13 oz) or 
birth at greater than the 90th percentile for gestational age. Based on these definitions, 
macrosomia affects 1-10% of all deliveries (65). Macrosomia arises in 
approximately 20% of GDM pregnancies with prevalence rates ranging from 10% to 
32% in Caucasian populations (66). Among North American Pima Indians, a 
population with high diabetes prevalence in pregnancy, fetal macrosomia rates as 
high as 80% have been found in women with GDM, 94% in those with impaired 
gestational glucose tolerance, 43% in those with pre-gestational diabetes, and 23% 
in women who were nondiabetic (67). Fetal macrosomia is associated with high 
perinatal morbidity, including shoulder dystocia, birth trauma, and neonatal 
asphyxia (68). 
Maternal diabetes is the most common cause of macrosomic babies. Augmented 
maternal plasma glucose levels produce fetal hyperglycemia, resulting in fetal 
hyperinsulinemia and elevated insulin-like growth factor values, which stimulate 
glycogen synthesis, fat deposition, and excessive fetal growth. Apart from glycemic 
control, various other factors, such as maternal overweight and obesity are likely to 
influence macrosomia. Olmos et al. (69) reported that the macrosomia in the infants 
of type-1 pregestational diabetics is mostly due to suboptimal glycemic control. On 
the other hand, the macrosomia in type-2 pregestational diabetic patients, who 
already have a near-optimal glycemic control, is related to maternal pre-pregnancy 
overweight/obesity. 
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1.6.2.1.2. Microsomia 
Fetal microsomia is defined as birth weight of less than 2,500 g (5 lb, 8 oz) or 
birth at less than the 10th percentile for gestational age. Some babies are small due to 
genetics, but most microsomic babies are small because of fetal growth problems 
occurring during pregnancy. Although most fetuses of diabetic mothers exhibit fetal 
macrosomia, fetal microsomia is significantly more frequent in pregnancies 
complicated by preexisting T1DM. A high frequency of intrauterine growth 
restriction (IUGR) has been demonstrated in 44% of fetuses from T1DM mothers, 
compared to 3% in the controls (70;71). In Pima Indians, maternal diabetes during 
pregnancy usually produces low birth weight (LBW) infants (72). Fetal microsomia 
carries an increased risk of morbidity and mortality both in the perinatal period and 
in later life. IUGR fetuses tend to have more congenital malformations at birth and 
are at heightened risk of cardiovascular complications, T2DM, and ESRD in later 
life (73;74). In African-Americans, LBW rates are 2.3 times greater than in 
Caucasians, with severe LBW being 3.1 times higher and paralleling the increased 
risk of ESRD (75).  
 Many microsomic babies have a condition called IUGR. Severe maternal 
diabetes is associated with IUGR, resulting from nutrient limitation associated with 
chronic maternal hypertension, advanced diabetic retinal or renal vasculopathy 
(76-78). The elevated glucose concentration in the mother, accompanying 
hyperglycemia in the fetus, leads to degranulation of the fetal β-cells, resulting in 
fetal hypoinsulinemia. Severe hyperglycemia in maternal rats results in 
hyperglycemia and hypoinsulinemia of the fetuses and IUGR. IUGR is most 
commonly caused by reduced uteroplacental circulation or by maternal malnutrition. 
Increased IUGR rates in women with diabetic vasculopathy are likely due to 
impaired and decreased uterine blood flow (79). 
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1.6.2.1.3. Stillbirth 
Stillbirth is the death of a baby still in the uterus. Every year, about 25,000 
babies are stillborn in the U.S.A. (80). Dunne et al. (81) reported a high rate of 
stillbirth in PGDM. Similarly, Goldenberg et al. (82) found that the rate of stillbirths 
was no different in women with either T1DM or GDM, but it was 5-fold higher in 
women with T2DM.  
  The pathophysiology of stillbirth in diabetic pregnancies is unclear. It is generally 
accepted that unexplained stillbirths in diabetic pregnancies are associated with poor 
glycemic control. Rackham et al. (83) reported that women with pregestational 
diabetes have higher risk of stillbirth, which was related to mean daily blood glucose 
values. Stillbirth can also result from severe placental insufficiency and fetal growth 
restriction, especially in the presence of maternal vascular complications. 
            
1.6.2.1.4. Birth Defects  
Birth defects, also called “congenital anomalies” or “congenital abnormalities”, 
are defined as aberrations of structure, function, or body metabolism present in a 
baby at or before birth and affecting many organs. The prevalence of birth defects is 
1-2% in the general population (45). In the U.S.A., 1 in 33 infants is born with a 
birth defect, the leading cause of infant deaths (84). The etiologies of most birth 
defects remain unknown. Environmental substances in utero that evoke birth defects 
are called teratogens, including alcohol, certain drugs/medications, cigarette 
smoking, and hyperglycemia. Hyperglycemia is a prominent teratogen for birth 
defects in diabetic pregnancies (85). When the fetus is exposed to high, sustained 
glucose concentrations, widespread damage to the fetus may affect multiple organs, 
including the cardiovascular, nervous, skeletal and urogenital systems, resulting in 
diabetic embryopathy syndrome (86). Experimental studies have shown a positive 
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correlation between the level of hyperglycemia during embryogenesis and the risk of 
birth defects (87). Cardiac anomalies occur 4 to 5 times more frequently in infants of 
diabetic mothers than in those of control mothers. The risk of neural tube defects in 
diabetic pregnancies is nearly 3 times greater than in control pregnancies (88). There 
is approximately a 200-fold increase in the rate of caudal regression syndrome (CSR) 
in diabetic offspring compared to control offspring (89). Clinical studies have 
reported high rates of congenital malformation in T1DM and T2DM pregnancies 
(90;91). GDM has also been associated with birth defects (91;92). The risk of birth 
defects is 2-4 times higher in PGDM compared to 3% in the general population. 
Becerra et al. (93) noted that infants of mothers with GDM who required insulin 
during the 3rd trimester of pregnancy were 20.6 times more likely to have major 
cardiovascular system defects than infants of non-diabetic mothers. Hemoglobin 
A1c (HbA1c) levels are a direct measure of glucose control in diabetic mothers: 
high HbA1c values are predictive of risk for congenital complications (94). Recently, 
Reece et al. (95) observed high HbA1c levels in association with an increased rate of 
infants with major malformations, indicating that birth defects correlate very 
strongly with blood glucose levels (Figure 1-3). It has been shown that good 
glycemic control in diabetic mothers reduces the prevalence of birth defects to that 
in the general population (96).  
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Figure 1-3. Blood glucose levels correlate inversely to birth defect risk (adapted 
from Reece EA: J Matern Fetal Neonatal Med) (95) 
 
In addition, some women diagnosed with GDM for the first time may actually 
have undiagnosed T2DM. Pre-pregnancy obesity, which is a risk for T2DM, has 
been found to be associated with birth defects (97). Maternal obesity and diabetes 
appear to increase the risk of birth defects through shared causal mechanisms. 
Studies have also shown that maternal smoking and alcohol intake during pregnancy 
are significant environmental causes of birth defects (98;99).  
 
1.6.2.1.5. Perinatal Morbidity 
 Perinatal morbidity in diabetic pregnancies has decreased since the discovery of 
insulin in 1922. However, current perinatal mortality rates in ODMs remain high 
compared to the general population. I will briefly review several perinatal 
morbidities that occur in ODMs. 
  
1.6.2.1.5.1. Neonatal Hypoglycemia 
 Neonatal hypoglycemia, defined as blood glucose values less than 40 mg/dl in 
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the baby in the first few days after birth, is a common neonatal problem in ODMs 
(100). The causes of neonatal hypoglycemia are many, such as premature birth, 
small or large for gestational age, maternal diabetes, and maternal hypertension, 
occurring more frequently in infants of diabetic mothers (IDMs). The most common 
risk factor for hypoglycemia in IDMs is hyperinsulinemia, a condition in which 
plasma insulin concentration exceeds 30 pmol/L. The pancreas of IDMs produces 
extra amounts of insulin in response to the high blood glucose levels of mothers 
with poorly-controlled diabetes mellitus. Since glucose supply from the mother is no 
longer present when the baby has been delivered, extra insulin remains and blood 
glucose can drop too low (hypoglycemia). About 10-25% of all IDMs have transient 
hypoglycemia during the first 4-6 hours after delivery. The frequency of neonatal 
hypoglycemia has been found to increase significantly if the maternal glucose level 
is greater than 90 mg/dl during delivery (101).   
      
1.6.2.1.5.2. Other Neonatal Metabolic Problems  
In addition to hypoglycemia, hypocalcemia and hypomagnesemia have been 
demonstrated to affect infants of women with T1DM (102). Neonatal hypocalcemia 
is a frequent event in the first hours of life of newborns from mothers with diabetes 
mellitus. Strict blood glucose control of diabetes during pregnancy seems to reduce 
the risk of neonatal hypocalcemia. Poor diabetic control leads to glucose excretion 
in urine with consequently increased urinary loss of magnesium, followed by low 
maternal blood magnesium concentration. Maternal hypomagnesemia causes fetal 
hypomagnesemia with consequent impairment of neonatal parathormone secretion, 
resulting in abnormally low calcium levels in blood of the fetus (103). 
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1.6.2.2. Long-term Impact of Maternal Diabetes Complications on ODMs 
 The long-term impact of maternal diabetes complications on ODMs has been 
well studied in animal models and clinical trials. There is increasing evidence that 
maternal diabetes augments the high risk for ODMs of developing obesity and 
diabetes mellitus later in life (104). 
    
1.6.2.2.1. Obesity 
According to the World Health Organization (WHO), obesity is defined as BMI 
>30 kg/m2 (105). In 2005, the WHO reported that at least 400 million adults are 
obese. The increasing prevalence of overweight and obese children is a major health 
problem. Gestational and perinatal factors have been shown to influence weight 
gained in childhood. Silverman et al. (106;107) demonstrated that the offspring of 
mothers with PGDM or GDM had a high BMI and developed childhood obesity in 
comparison to their controls. In another study, the offspring of Pima Indian mothers 
who had diabetes during pregnancy also had significantly higher body weight at 5 to 
19 years of age compared to the controls (108;109). These findings strongly suggest 
that the intrauterine diabetic environment raises the risk of obesity in childhood and 
early adulthood. 
  
1.6.2.2.2. Diabetes Mellitus  
 In utero exposure to high maternal glucose concentrations is a risk for the 
long-term development of diabetes mellitus in ODMs (110), but the underlying 
mechanisms remain unclear. Both insufficient insulin production and insulin 
resistance are important factors for long-term diabetes mellitus in ODMs. The 
insulin secretion response is defective and glucose tolerance is impaired in the adult 
offspring of mothers with T1DM (111). The offspring of mothers with T2DM or 
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GDM tend to develop insulin resistance or T2DM. Hunter et al. (112) showed that 
the offspring of mothers with T2DM were overweight with a trend towards reduced 
insulin sensitivity compared to normal controls. Pettitt et al. (113) studied the 
prevalence of T2DM among Pima Indians aged 20-24 years and found that 1.4% of 
non-ODMs developed T2DM versus 45% of ODMs. Similarly, among Pima Indian 
youth aged 5-19 years, about 40% of ODMs developed T2DM (114).  
  
1.6.2.2.3. Perinatal Programming 
Evidence indicates that many adult diseases originate from events that happen in 
utero (115). Exposure to alterations in the intrauterine and early postnatal nutritional, 
metabolic, and hormonal environment may predispose to diseases in later life (116). 
However, exposure of the embryo to either genetic influences or environmental 
changes during a critical period of development can evoke adaptive responses that 
have a significant impact on its physiology and metabolism. In the next section, I 
will discuss perinatal programming, perinatal programming-related hypotheses, 
clinical and experimental investigations of perinatal programming, and possible 
mechanisms. 
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CHAPTER 2: PERINATAL PROGRAMMING 
2.1. Perinatal Programming 
The concept that intrauterine and perinatal events can influence organ function 
later in life is called perinatal programming (117). Blood pressure, renal function, 
and general health later in childhood and adult life may be affected mostly before 
birth or during the perinatal period by the intrauterine and perinatal environment 
(118). 
  
2.2. Perinatal Programming-related Hypotheses 
2.2.1. Barker’s Hypothesis 
In the late 1980s, Barker et al. (119) reported the association between poor living 
standards and ischemic heart disease after a detailed geographic comparison of 
infant mortality in Britain between 1921 and 1925 and death in adults due to 
ischemic heart disease and coronary artery disease between 1968 and 1978. This led 
them to suggest that high infant mortality may be due to poor growth in utero, and 
insufficient fetal growth may be associated with the development of cardiovascular 
disease in adulthood. They observed that birth weight was inversely correlated with 
blood pressure and the frequency of cardiovascular diseases in adult life. Their 
findings became the basis for Barker’s hypothesis, also known as the “fetal origins 
of adult disease” (120). The underdevelopment of organs and tissues affects 
metabolism in the fetus, and the consequences are reflected in adult homeostasis and 
health. Epidemiological studies in humans have established correlations between 
impaired intrauterine growth and an increased incidence of cardiovascular, 
metabolic, and other diseases in later life (121). Barker et al. (122;123) showed a 
relationship between LBW or slow growth during infancy and the risk of impaired 
glucose tolerance or T2DM in adults.  
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2.2.2. Brenner’s Hypothesis  
In the late 1980s, Brenner et al. (124) postulated that deficiency in glomerular 
filtration surface area might be associated with essential hypertension. This 
hypothesis was based on observations in animal models that surgical ablation of 
kidney tissue or reductions in filtration surface area as a result of chronic kidney 
disease can cause hypertension. As illustrated in Figure 2-1, many studies (125;126) 
support their hyperfiltration hypothesis, in which a decrease in renal mass − either 
due to low nephron endowment or renal mass diminution because of renal disease or 
surgery − elicits glomerular hyperfiltration. Lower numbers of glomeruli lead to a 
higher single nephron GFR. Such hyperfiltering glomeruli spontaneously develop 
focal glomerulosclerosis, particularly after injury. Numerous studies have reinforced 
this hypothesis of “low glomerular endowment” (127;128). 
  
Figure 2-1. Hyperfiltration hypothesis (modified from Schreuder et al.: Kidney Int) 
(129) 
 
 
  
21
2.2.3 The “Thrifty Phenotype” Hypothesis 
The “thrifty phenotype” hypothesis proposed by Hales and Barker (130;131) 
suggests that the epidemiological associations between poor fetal and early 
post-natal growth and the increased risk of developing T2DM and metabolic 
syndrome result from the effects of poor nutrition in early life, which produce 
permanent changes in glucose-insulin metabolism (Figure 2-2) (131). In adapting, 
the fetus and infant have to be nutritionally “thrifty”, to increase fuel availability. 
For example, the fetus is programmed to store nutrients such as fat. If poor nutrition 
continues throughout life, these adaptations are not detrimental. On the other hand, 
if nutrition is improved in adulthood, the ability of the pancreas to maintain 
carbohydrate homeostasis is exceeded, causing adult insulin resistance, glucose 
intolerance, and finally T2DM. 
 
Figure 2-2. Original diagram of the “thrifty phenotype” hypothesis (131)   
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2.3. Clinical and Experimental Evidence of Perinatal Programming 
2.3.1. Clinical Studies of Perinatal Programming 
Epidemiological investigations in humans have shown that the offspring of 
obese mothers are at heightened risk of obesity and diabetes. Fetuses of obese 
women manifest increased obesity, insulin resistance, and have elevation in markers 
of inflammation. Catalano et al. (132) demonstrated that the fetuses of obese 
mothers had greater percent body fat and insulin resistance than those of lean 
women. Adults with LBW are at risk of chronic diseases, including high blood 
pressure, cardiovascular disease and chronic kidney disease. The Kidney Early 
Evaluation Program (USA) with 12,364 participants, whose mean age was 49.1 
years, established that men with LBW or high birth weight (HBW) had a 
significantly greater prevalence of chronic kidney disease, but there was no 
association among women (133). A Norway cohort study of 2,183,317 participants 
with a mean age of 21.2 years revealed that men and women with LBW had a high 
prevalence of ESRD (RR 1.7) and women with HBW had a high risk of ESRD (RR 
2.3) (134). The population-based Nord Trøndelag Health Study of 7,457 Norwegian 
adults aged 20 to 30 years reported a significant association between IUGR and 
reduced renal function in men with LBW (121). Recently, White et al. (135), in a 
systematic review of observational studies on birth weight and chronic kidney 
disease (CKD), determined that LBW is associated with an increased risk of 
decreased kidney function and kidney failure.   
 
2.3.2. Experimental Studies of Perinatal Programming 
Various animal models have been tested to examine the effects of IUGR on 
chronic adult diseases. The most common animal models of LBW and fetal 
programming of adult diseases are maternal nutrient restriction, uteroplacental 
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insufficiency, maternal glucocorticoids and experimentally-induced maternal 
diabetes. When total maternal food intake was limited to 50% of daily needs during 
pregnancy and lactation, adult prenatal restriction offspring presented increased 
microalbuminuria, decreased GFR, and hypertension (136). A low-protein diet is 
one of the most extensively studied models of early growth restriction. The male 
offspring of rat dams fed a low-protein diet during pregnancy and lactation 
developed impaired glucose tolerance at age 15 months and diabetes with insulin 
resistance at 17 months (137). The female offspring of rat dams fed a low-protein 
diet during pregnancy and lactation manifested hyperglycemia and impaired glucose 
tolerance at age 21 months (138). In a model of uteroplacental insufficiency induced 
by uterine vessel ligation that restricted fetal growth, the offspring were born small 
and glomeruli number was reduced at age 6 months without glomerular hypertrophy 
and glomerular hypertrophy was seen at age 18 months (139). Streptozotocin 
(STZ)-induced maternal diabetes is the most common model for studying the effects 
of gestational diabetes in the offspring. Low-dose STZ administration causes mild 
gestational diabetes and fetal macrosomia, whereas high-dose STZ elicits insulin 
deficiency and diabetes-associated growth restriction. The offspring of STZ-diabetic 
pregnant rats have low body weight and insulin resistance in adulthood (140). 
 
2.4. Possible Mechanisms of Perinatal Programming  
Numerous large studies have confirmed the relationship between LBW and high 
blood pressure. The number of nephrons is reduced in patients and animals with 
LBW (141;142). According to Brenner’s hypothesis, low nephron numbers may 
lead to arterial blood pressure elevation. LBW can be the consequence of numerous 
prenatal events. IUGR is certainly one of the mechanisms of LBW. Recent 
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experiments have confirmed the effect of IUGR on the development of hypertension 
in adults (143) . 
 
2.4.1. LBW and Low Nephron Numbers 
Infants who weigh 2,500 g or less at birth are classified by the WHO as having 
LBW. 7.8% of all infants born in the U.S.A. had LBW (144). LBW and IUGR often 
occur in disadvantaged communities and have been associated with higher risks of 
adult cardiovascular disease, hypertension, diabetes mellitus, and kidney disease 
(145). LBW is often accompanied by low glomeruli numbers and is associated with 
hypertension in adulthood (146-148). Renal disease may also be related to LBW as 
children less than 1,500 g at birth have an increased risk of renal tubular 
abnormalities at 7-8 years of age (149). Moderate LBW (<2,500 g) has been linked 
with renal disease in Australian Aboriginals (150). A study of thirty-five neonates 
who died within 2 weeks of birth showed that neonates with LBW had lower 
nephron numbers compared to those with normal birth weight (151). A study of 
autopsied kidneys revealed that LBW was associated with low nephron numbers in 
both African-Americans and Caucasians (141).  
 
2.4.2. Low Nephron Numbers and Hypertension  
In 1988, Brenner et al. (124) reported an inverse relationship between total renal 
filtration surface area and the risk of hypertension in rats. Reduced nephron numbers 
have been advocated as an explanation for the relationship between LBW and 
hypertension in later life. In an autopsy study specifically designed to examine the 
association between low nephron numbers and hypertension in West European 
adults, Keller et al. (152) found that 10 accident victims who were known to be 
hypertensive had lower glomeruli numbers and larger glomerular volume than 
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non-hypertensive controls. The development of albuminuria, hypertension, and renal 
failure in children with oligomeganephronia (OMN) (153) and the low number of 
nephrons in Australian Aboriginals also support the correlation between low 
nephron endowment and renal disease (150). On the other hand, in a mostly urban 
community from Senegal, low glomerular numbers or large glomerular volume was 
not correlated with hypertension and arteriosclerosis-associated kidney disease (154). 
In experimental models, congenital nephron deficiency is tied to the development of 
renal disease and hypertension in postnatal life. In a rat model, maternal iron 
deficiency led to offspring with reduced nephron numbers and hypertension in 
adulthood (155).  Fibroblast growth factor receptor 2 (FGFR2) mutant mice 
manifested decreased nephron numbers in utero and later developed hypertension 
and chronic renal failure in adulthood (142). 
  
2.4.3. Possible Mechanisms of Low Nephron Numbers Associated with Intrauterine 
Alteration 
2.4.3.1. Genetic Influence 
The genetic factors leading to low nephron endowment associated with 
hypertension in humans have not been completely identified. Congenital OMN, 
characterized by low nephron numbers, glomeruli with twice the normal size, and a 
tendency towards sclerosis, was correlated with heterozygous paired box gene 2 
(Pax2) mutations (156). Zeier et al. (157) reported that patients with congenital 
OMN had hypertension and a modest reduction of glomerular filtration. Suzuki et al. 
(158) found that body growth was retarded and mean blood pressure elevated in 
hypoplastic kidney (HPK) rats, a potential model of human OMN. Mice 
heterozygous for glial cell-line-derived neurotrophic factor (GDNF), that is essential 
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for kidney development, were born with 30% fewer nephrons than wild type mice 
and developed high arterial pressure in old age (159;160). 
 
2.4.3.2. Nutrition 
It is now widely accepted that maternal nutrition during pregnancy affects fetal 
growth and results in offspring with hypertension later in life (161;162). Maternal 
malnutrition is one of the causes of IUGR/LBW. In a Dutch famine cohort, people 
who were small at birth had high blood pressure in later life (163). Eriksson et al. 
(164) concluded that the development of hypertension was associated with reduced 
fetal growth and catch-up growth in early childhood in a Finnish cohort. Restriction 
of maternal protein intake during pregnancy in the rat produced offspring that 
developed hypertension in adulthood. Langley-Evans et al. (165) reported a 13% 
deficit in nephron numbers in rats exposed to a low-protein diet in utero, and these 
animals subsequently incurred elevated mean arterial blood pressure. Wood et al. 
(166;167) suggested that maternal dietary protein restriction may increase arterial 
blood pressure in the offspring later in life by decreasing the number of nephrons at 
birth, resulting in hypertension in adulthood. Similar observations have been made 
in other animal models. Low maternal caloric intake can reduce nephron numbers, 
cause glomerular hypertrophy and lead to postnatal glomerular fibrosis. Gilbert et al. 
(168) found that a 50% diminution of maternal calorie intake lowered nephron 
numbers by 11%, heightened angiotensin-converting enzyme (ACE) expression in 
the renal cortex, augmented medullary angiotensin II (Ang II) subtype 2 receptors 
(AT2R), and evoked metabolic dysregulation in sheep offspring. McGarvey et al. 
(169) noted that decreased maternal calcium intake during pregnancy can cause 
preterm delivery and adult hypertension. Crocker (170) reported that low potassium 
produced decreased ureteral bud branching, failure of nephron induction, and 
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occasional cystic dilatations of the ureteral bud in human embryonic kidneys organ 
culture. 
 
2.4.3.3. Vitamin A Deficiency  
Vitamin A (retinol) and its analogs (retinoids) are important regulators of cell 
proliferation, differentiation, immune function, and apoptosis (171). In the early 
1950s, Wilson et al. (172) demonstrated that maternal vitamin A deficiency resulted 
in renal hypoplasia that could be prevented by vitamin A administration to pregnant 
rats, indicating its direct involvement in kidney development. Studies on retinoic 
acid receptor (RAR) knockout mice revealed the specific role of vitamin A in renal 
organogenesis (173). In rats, maternal vitamin A deficiency was associated with the 
reduction of nephron numbers in the offspring (174). In addition, Goodyer et al. 
(175) observed a close correlation between nephron numbers and circulating vitamin 
A levels in humans. Maternal vitamin A deficiency leads to renal hypoplasia in 
native newborn Indians compared to their Canadian counterparts (175). 
 
2.4.3.4. ROS 
Free radicals are atoms or groups of atoms with one or more unpaired electrons 
and can be formed when oxygen interacts with certain molecules. Thus, oxygen 
plays a major role as an oxidant in the form of superoxide (O2−), hydroxyl (OH−), 
peroxyl (R–OO−) radicals and their derivatives, named reactive oxygen species 
(ROS) (176). Oxidative stress, an imbalance between the production of ROS and the 
antioxidant defense mechanisms of a cell or tissue, leads to lipid peroxidation, RNA 
and DNA rupture, and oxidation of proteins including inactivation of many enzymes. 
The mechanisms by which oxidative stress mediates hypertension and 
cardiovascular disease are not clear. Animal studies show that oxidative stress 
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affects blood pressure and renal disease. Clinical trials have established that 
antioxidant supplementation improves blood pressure and cardiovascular outcomes 
in humans (177;178). Oxidative stress programming from mother to fetus may be 
mediated directly by modulation of gene expression or indirectly through the effects 
of certain oxidized molecules. Epidemiological studies indicate that poor fetal 
growth is associated with elevated oxidative stress in maternal plasma and 
erythrocytes (179;180). Gupta et al. (181) demonstrated that intrauterine 
malnutrition is associated with significant oxidative stress in 
small-for-gestational-age neonates born at term to undernourished mothers. Indeed, 
oxidative stress may be the trigger for in utero programming of hypertension. 
Franco et al. (182) showed that intrauterine under-nutrition enhances oxidative stress, 
resulting in endothelium dysfunction and, consequently, hypertension. 
   
2.4.3.5. Apoptosis 
Several studies have determined that apoptosis plays an important role in kidney 
development and in the pathogenesis of fetal programming. The offspring of 
pregnant rats fed a low-protein diet had LBW and low kidney weight at birth, low 
nephron numbers, higher systolic blood pressure, and increased apoptosis in 
glomeruli, interstitial cells, proximal tubule, and distal tubule cells (183). Rat 
embryonic day 13 (E13) metanephroi in embryos of mothers given a low-protein 
diet during pregnancy present increased metanephric apoptosis with a reduced 
number of progenitor cells during kidney development (184). Uteroplacental 
insufficiency, which causes IUGR, significantly diminishes nephron numbers while 
augmenting Bcl-2-associated X protein (Bax) and tumor protein 53 (p53) mRNA 
expression in IUGR kidneys (185). It has been postulated that the observed increase 
in apoptosis may be due to downregulation of anti-apoptotic factors, such as Pax2. 
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In Pax2 promoter-Bax Tg mice, loss of Pax2 anti-apoptotic activity accounts for the 
reduced ureteric bud (UB) branching seen in renal-coloboma syndrome (RCS), 
indicating that heightened UB apoptosis may be a key process responsible for a 
decreased number of nephrons (186). 
 
2.4.3.6. RAS 
All components of the RAS, expressed in the developing kidney, play an 
important role in nephrogenesis (187). RAS suppression by ACE inhibitors leads to 
renal abnormalities in both structure and function. Ang II receptor blockade also 
causes renal maldevelopment. In newborn Sprague-Dawley rat pups, administration 
of the AT1R antagonist losartan from days 1 to 12 of postnatal life reduced the 
number of nephrons and caused hypertension (188). Several animal model studies of 
fetal programming have shown that the lowered expression of RAS components 
during nephrogenesis is associated with low nephron numbers and hypertension in 
later life (166;167;189). Growth-retarded infants have small kidneys, elevated cord 
blood renin levels (190) and heightened renin gene expression in the kidneys (191), 
suggesting that the intrarenal RAS may be elevated after IUGR. In another maternal 
animal model, ewes were undernourished between days 28 and 77 of gestation, 
which resulted in increased AT1R expression in the kidneys of lambs at birth (192). 
In addition, gender may play a role in programming. Wood et al. (167;193) 
demonstrated that modest maternal dietary protein restriction in rats reduced 
nephron numbers in both males and females but hypertension developed only in 
adult male offspring. Renal renin protein and Ang II levels declined by 50-65% in 
males but not in females. 
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2.4.3.7. Glucocorticoids 
Fetal exposure to maternal glucocorticoids is associated with programming of 
hypertension in the offspring (194). In human pregnancy, glucocorticoids are used 
primarily in the management of women at risk of preterm delivery to advance fetal 
maturation and decrease neonatal morbidity and mortality (195). Ortiz et al. 
(196;197) reported that dexamethasone administration to pregnant rats during 
gestation resulted in a 17% reduction of nephron numbers in the offspring, and 
increased blood pressure in adult life.  
 
2.4.3.8. Social/Behavioral    
Excessive alcohol consumption in pregnancy may induce fetal alcohol syndrome 
(FAS) characterized by craniofacial dysmorphology, growth restriction, and 
intellectual dysfunction (198). Studies of children diagnosed with FAS have 
demonstrated that some of them have renal malformations (199). Recently, in a 
sheep model, fetal exposure to alcohol during the latter half of gestation caused a 
11% decrease of nephron numbers (200). 
 
 
 
 
 
 
 
 
 
 
  
31
CHAPTER 3: NEPHROGENESIS OR KIDNEY DEVELOPMENT 
3. Nephrogenesis or Kidney Development 
The kidneys are one of the main excretory and homeostatic organs of the body. 
These paired, bean-shaped organs regulate the composition and volume of body 
fluids, and eliminate metabolic waste products. The internal structures of the 
kidneys include an outer cortex and an inner medulla (Figure 3-1)(201). 
 
Figure 3-1. Kidney structure (201) 
 
The nephron is the basic structural and main functional unit of the kidney. There 
are approximately 300,000 to 1 million nephrons per kidney in humans, and 11,000 
nephrons per kidney in mice (202). The nephron consists of a renal tubule and a 
renal corpuscle (Figure 3-2) (203). The renal corpuscle is composed of a glomerulus 
and Bowman's capsule, which surrounds the glomerulus. The renal tubule is the 
portion of the nephron containing tubular fluid that is filtered through the 
glomerulus. After wastes pass through the renal tubule, the filtrate continues to the 
collecting duct system, which is the end of the nephron. 
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Figure 3-2. Simple diagram of the kidney nephron (203) 
 
In mammals, kidney development, also called nephrogenesis, progresses 
sequentially in 3 main stages, as seen in Figure 3-3 (204). The first 2 stages of 
rudimentary kidney development lead to the formation of transient structures, the 
pronephros and mesonephros, and the third stage results in the formation of the 
metanephric kidney, which is the permanent kidney. Compared to other organ 
systems, the excretory system develops quite late in embryogenesis. Metanephric 
kidney development occurs at E28 in humans and at E10.5 in mice. 
 
Figure 3-3. Schematic representation of kidney development (204) 
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3.1. Pronephros 
The pronephros, the most basic of the 3 excretory organs that develop in 
vertebrates, corresponds to the first stage of kidney development. It arises from the 
portion of the intermediate mesoderm at E22 in humans or at E8.0 in mice, and then 
completely degenerates through massive apoptosis (205;206). The pronephros is a 
segmented organ that consists of pronephric tubules originating from the 
nephrogenic cord and the pronephric duct. Pronephric tubules and the pronephric 
duct form at the cranial end of the intermediate mesoderm and fuse to form the 
pronephros. Early regulators have been studied during pronephros formation, 
including functionally-redundant paired-box homeotic transcription factors, such as 
Pax2 and Pax8, zinc finger transcription factor GATA-binding protein 3 (GATA3), 
which belongs to a family of transcription factors that bind to a GATA consensus 
motif (A/TGATAA/G), and the LIM class homeodomain transcription factor, LIM 
homeobox protein 1 (Lim1). Pax2 and Pax8, co-expressed in nephric duct 
precursors at E8.5 in mice, are essential for the initiation of pronephros and 
mesonephros development (207). GATA3 is expressed in nephric duct precursors, 
starting at E8.5 in mice and is a putative direct target of Pax2 and Pax8 (208). In 
mice, Lim1 is initially expressed in the intermediate mesoderm at E7.5 and becomes 
restricted to the nephric duct at E9.5 (209). Direct targets of Lim1 in the nephric 
duct are not known, and Pax2 expression is not dependent on Lim1 function (210). 
 
3.2. Mesonephros 
The mesonephros is the second type of excretory organ to develop in vertebrates. 
It is composed of the mesonephric duct (also called the Wolffian duct (WD)), 
mesonephric tubules, and associated capillary tufts. The mesonephric duct grows 
caudally, reaches the mesonephric mesenchyme (MM) and induces mesonephros 
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formation. The mesonephros is the permanent kidney in fish and amphibians, but 
atrophies in reptiles, birds, and mammals. In humans, the mesonephros begins 
development at E26. In mice, it starts degenerating at E10.5, and almost all of the 
tubules undergo apoptosis within 24 hours and disappear in a caudal to cranial 
direction (211). A number of genes, such as Pax2, Pax8, Wilms’ tumor suppressor 1 
(WT-1), Forkhead box c 1 (Foxc1), and Sine oculis homeobox homolog 1 (Six1), 
have been implicated in different aspects of mesonephric development 
(207;212;213). 
 
3.3. Metanephros 
The metanephros is the third, and permanent, excretory organ to develop in 
vertebrate embryos. The metanephric kidney begins to develop at E28 in humans or 
at E10.5 to E11 in mice. It develops from 2 major structures, UB and the MM. There 
are 2 key processes in kidney nephrogenesis: UB branching morphogenesis and 
mesenchyme-to-epithelial transformation (MET). Kidney development begins when 
the WD, which is the precursor of UB, grows caudally, and elongates to generate 
UB at its extreme caudal end. As illustrated in Figure 3-4 (214), UB grow into the 
loosely-organized mesenchyme. Through secreted signals, the MM induces the UB 
to elongate further and grow into the blastema, branching and giving rise to the 
collecting system. At the same time, the UB prompts the adjacent surrounding 
mesenchymal cells to aggregate and condense around their tips. The condensed 
mesenchyme proliferates rapidly and differentiates into early-polarized epithelial 
structures, such as renal vesicles, comma- and S-shaped bodies. Metanephric tubules 
lead to formation of the glomerulus, proximal tubule, loop of Henle, and distal 
tubule. The fusion of developing metanephric tubules to a UB branch completes 
nephron formation. 
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Figure 3-4. Reciprocal induction in mammalian kidney development (214) 
 
3.4. Gene Regulation 
At present, the Kidney Development Database website lists more than 300 genes 
known to be involved in nephrogenesis (URL address http:// 
www.ana.ed.ac.uk/anatomy/database/kidbase/kidhome.html). Although kidney 
development has been studied for more than half a century, understanding the 
molecular control of nephrogenesis is still in its infancy. Animal experiments, 
especially on Tg mouse models and explants of rodents, have identified several 
genes that are important in kidney development, but their relevance in humans 
remains to be demonstrated. For example, as shown in Table 3-1 (215), GDNF, 
rearranged during transfection proto-oncogene (Ret), Pax2, and WT-1 are all crucial 
in murine renal organogenesis. Genes of the Wnt family, including Wnt4, are also 
known to be essential in UB branching. Sal-like 1 (Sall1), a mammalian homologue 
of the Drosophila region-specific homeotic gene spalt (sal), plays an important role 
in renal development (216). In addition, members of the bone morphogenetic protein 
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(Bmp) family of secreted factors, such as Bmp4 and Bmp7, have been implicated as 
anti-apoptotic factors for the MM (217;218). So far, the Pax2/GDNF/c-Ret pathway 
has been identified as the most critical for kidney development. 
 
Table 3-1. Selection of genes in kidney development (modified from Piscione et al.: 
Differentiation) (215)   
 
 
3.4.1. Pax2/Pax8 and Lim1: Earliest Markers of Nephrogenesis 
As discussed below (see Section 3.6), Pax2 is a transcription factor that belongs 
to the family of “paired domain” proteins, and is involved in organogenesis. During 
kidney development, Pax2 is first detected in the nephrogenic cord in the 
metanephric region at E9.5 in mice and then in the MM at E10.0. Pax2 is strongly 
expressed in UB when it emerges from the WD and invades the MM. In Pax2 
mutants, the nephric duct does not reach the cloaca, Ret expression is absent, and the 
duct starts to degenerate by E12.5, resulting in the failure of UB formation and 
metanephros development (219). Pax2 is detected in early epithelial structures, the 
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comma- and S-shaped bodies, which differentiate into glomeruli and the proximal 
portions of emerging nephrons. Indeed, Pax2 is required for 
mesenchyme-to-epithelium conversion in kidney development. Kidney explant 
cultures treated with Pax2 antisense oligonucleotides fail to express some epithelial 
markers, and the tubulogenesis of mesenchymally-derived structures is blocked 
(220). Pax8 is also present during pro-, meso-, and metanephros development. Pax2 
and Pax8 together are essential for pro- and mesonephros formation. Mouse 
embryos lacking both Pax2 and Pax8 fail to form the pronephros or any later nephric 
structures and to express the early kidney-specific genes c-Ret and Lim1 (207). In 
mice, Lim1 is initially expressed in the intermediate mesoderm at E7.5 but becomes 
restricted to the nephric duct primordium by E9.5 (209). Direct targets of Lim1 in 
the nephric duct are not known, and Pax2 expression is independent of Lim1 
function (221). 
 
3.4.2. UB Outgrowth Requires Signaling: WT-1, Eyes-absent-1 (Eya1) and the 
GDNF/c-Ret Pathway  
WT-1 is one of the most investigated transcriptional regulators in the developing 
kidney. It encodes a zinc finger-containing nuclear protein that is essential for 
kidney and urogenital development. During renal development in mice, WT-1 is 
initially expressed throughout the nephrogenic cord as early as E9.0 and is also 
detected at a low level in the MM prior to UB outgrowth at E10.5 (222). WT-1 is 
upregulated when the mesenchyme begins to form epithelial condensates around UB 
tips. In WT-1 null mice, the UB fail to form and the MM, which appears to be 
morphologically normal, undergoes apoptosis at E11.0 (223). In adult kidneys, 
WT-1 expression is restricted to glomerular podocytes, which form the filtration 
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barrier within the glomerulus. WT-1 is therefore important for normal podocyte 
function (224).  
Eya1, a mammalian homologue of the Drosophila eyes-absent gene, encodes a 
transcriptional co-activator that can complex with other transcription factors to 
induce the expression of target genes (225). In developing mice kidneys, Eya1 is 
first detected in the nephrogenic cord at E8.5, and it is only expressed in the MM at 
E11.5 (226). In mice, Eya1 deficiency (Eya1-/-) results in the absence of UB 
outgrowth and the failure in the formation of a morphologically-distinct population 
of MM (227). Eya1-/- mice kidneys display an early loss of the GDNF signal in the 
nephrogenic cord, but Pax2 is present in the remaining blastema cells, indicating that 
it functions either upstream or independently of Eya1 (226). The first indication that 
the GDNF/c-Ret developmental pathway is crucial for metanephric development 
came from an analysis of c-Ret knockout mice (228). GDNF, a distant member of 
the transforming growth factor-beta (TGF-β) superfamily, is a potent neurotrophic 
factor for neurons of the central nervous system (CNS) and is essential for renal 
development (229). During kidney development in mice, GDNF is expressed in the 
nephrogenic cord at E9.5, but becomes restricted to the MM at E10.5. GDNF family 
ligands signals through a unique multicomponent receptor complex consisting of 
glycosyl-phosphatidylinositol (GPI)-anchored coreceptor (Gfrα1–4) as a ligand 
binding component and RET receptor tyrosine kinase as a signaling component 
(230). During early kidney development, Ret and Gfrα1 are expressed all along the 
WD, while GDNF is expressed only in the MM. GDNF binds to the Ret receptor, 
activates Ret and then induces UB outgrowth. GDNF signaling is important to 
induce UB outgrowth from the WD and to promote its early growth and branching. 
GDNF mutations result in renal aplasia. In humans, 5-10% of cases of renal 
agenesis are found to be linked with GDNF mutations (231). Ret encodes a 
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transmembrane receptor of the tyrosine kinase (TK) family of proteins and is 
required for kidney morphogenesis. In the developing kidney, Ret is initially 
expressed on the mesonephric duct and early UB, and later its expression is 
restricted to UB branch tips (232). Mice with a c-Ret null mutation exhibit severe 
renal dysplasia or agenesis as a result of defective UB outgrowth (228). In humans, 
30% of cases of renal agenesis are found to be associated with Ret mutations (231). 
 
3.4.3. The Wnt Pathway  
Wnts have been implicated in epithelial-mesenchymal interactions (233). The 18 
Wnt genes identified in mice encode secreted glycoproteins that bind to the cell 
surface and the extracellular matrix (ECM) (234). Wnt signaling via the canonical 
β-catenin pathway has been shown to be involved in UB branching (235). A number 
of Wnts which signal through the canonical β-catenin pathway are present in the 
developing metanephros, including Wnt6, Wnt7b, and Wnt9b in the collecting duct 
system, and Wnt4 in early nephron precursors (236). Wnt-4 plays an essential role 
in kidney development and is expressed in condensing MM cells very soon after UB 
induction, persisting in comma- and S-shaped bodies (237). Wnt-4 acts during MET 
and is required for tubulogenesis in the metanephric kidney. In Wnt4-deficient mice, 
epithelial renal vesicles fail to form, resulting in small kidneys consisting of 
undifferentiated MM interspersed with ureter branches. In addition, homozygous 
Wnt4 mutation pups die of renal failure within 24 hours of birth (237). In Wnt9b 
mutant embryos, down-regulation of Wnt-11 and GDNF expression prior to 
morphological appearance of the branching defect indicates a later requirement for 
Wnt9b in the regulation of secondary branching (238). 
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3.5. Renal Malformations 
Human renal malformations are the main causes of ESRD in children less than 5 
years of age (239). They include multiple ureters, renal agenesis (the absence of 
kidneys), renal hypoplasia (reduced kidney size), and renal dysgenesis (kidneys 
containing abnormal structures) (240;241). Developmental abnormalities of the 
kidneys are various, and mutations of genes expressed in the developing kidney 
cause congenital abnormalities in humans, as shown in Table 3-2 (242). 
 
Table 3-2. Congenital abnormalities and gene defects identified in patients (242) 
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3.5.1. Renal Agenesis 
   Renal agenesis is a medical condition in which one or both kidneys fail to 
develop in the fetus and are absent at birth. Bilateral renal agenesis, the failure of 
both kidneys to develop during gestation, has a frequency of 1 in 30,000 newborns 
(242). Unilateral renal agenesis, the absence of 1 kidney in the fetus, occurs in 1 in 
5,000 newborns (242). Children with unilateral renal agenesis have considerably 
higher chances of developing hypertension (243). Renal agenesis seems to be 
associated with a failure of GDNF-Ret signaling. GDNF activation in the MM is 
controlled by several regulators: Eya1, Six1, Six4, and Pax2. A number of recent 
studies have shown that mice deficient in Eya1, Six1, Six4, or Pax2 lack kidneys 
(212;227;244;245). Some authors suggest that nephronectin, an ECM protein, is also 
important for maintaining GDNF expression. Mice lacking nephronectin fail to 
express GDNF and to develop kidneys (246). 
    
3.5.2. Multiple Ureters   
Duplex ureters are the most common malformations of the urinary tract. In a 
normal urinary tract, each kidney is connected to 1 ureter, and drains urine into the 
bladder. Patients with a duplex collecting system have 2 ureters for 1 kidney that 
drain independently into the bladder, rather than 1 ureter for each kidney. Gene 
targeting experiments have identified several genes, including Foxc1, Slit 
homologue 2 (Slit2), and its receptor, Roundabout homologue 2 (Robo2), that are 
required to prevent ectopic UB formation. Mutations in these genes lead to 
expansion of GDNF expression and cause ectopic ureters (247;248). The receptor 
tyrosine kinase antagonist sprouty 1 (Spry1) is essential for early kidney 
development and is also important for limiting branching during kidney 
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development (249). Spry1−/− embryos have supernumerary UB, resulting in the 
development of multiple ureters and multiplex kidneys (250). 
 
3.5.3. Renal Dysgenesis 
   Renal dysgenesis, the consequence of disordered renal tissue differentiation, 
culminates in a form of dysplasia with or without cysts, hypoplasia or hypodysplasia 
(251). Renal dysplasia is characterized by the existence of primitive mesenchymal 
structures, which are remnants of the collecting duct or some other UB surrounded 
by absent or abnormally-differentiating MM (252). Pax2 or Wnt4 mutations may 
cause renal dysplasia, originating from the inhibition of mesenchymal-to-epithelial 
conversion or UB formation occurring at an ectopic site on the WD (253). 
 
3.5.4. Renal Hypoplasia 
   Renal hypoplasia is a medical condition in which an abnormally small kidney 
that is morphologically normal has either a reduced number of nephrons or smaller 
nephrons. In humans, the average number of nephrons ranges from 300,000 to 1 
million in each kidney, and there is a correlation between nephron number and the 
risk of developing hypertension (254). A defect in the rate of UB branching is the 
most common cause of renal hypoplasia. Studies have shown that RCS, a congenital 
disease characterized by optic nerve coloboma, renal hypoplasia and diminished 
nephron number, is due to heterozygous mutations of the Pax2 gene (255). Retinoic 
acid is important to maintain Ret expression in UB, so deficiency of vitamin A, a 
precursor of retinoic acid, is well known to elicit renal hypoplasia (174). In rats, 
early in utero exposure of fetuses to hyperglycemia causes a 10-35% decrease in 
nephron numbers (256). 
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3.5.5. OMN 
   Congenital OMN, characterized by a low number of nephrons, glomerular 
hypertrophy and a tendency towards glomerularsclerosis, is a model of nephron 
under-endowment (153). OMN has been reported in 2 siblings, indicating a genetic 
background (257). In addition, Salomon et al. (156) found heterozygous Pax2 
mutations in 3 patients with OMN, confirming the critical role of Pax2. 
 
3.5.6. Polycystic Kidneys 
   Polycystic kidneys are a genetic disorder that is characterized by the presence of 
multiple cysts. The cysts are numerous and fluid-filled, causing massive kidney 
enlargement. Mutations in PKD1 (polycystic kidney disease 1), PKD2, and PKHD1 
(polycystic kidney and hepatic disease 1) evoke polycystic kidneys (258). 
    
3.6. Pax2 Pathways 
   Renal malformations account for about 40% of renal failure in childhood 
(259;260). To date, most human and experimental studies have focused on the 
phenotype, with only a few investigating the mechanism(s). Pax2 was first cloned 
and characterized by Peter Gruss’s group in 1990 (261). It plays an essential role in 
nephrogenesis. Pax2 mutations cause increased apoptosis and are associated with 
renal hypoplasia (186;262). Homozygous null Pax2 (Pax2-/-) mice lack kidneys, 
ureters, and genital tracts (219). In humans and mice, heterozygous Pax2 mutations 
elicit kidney, eye, and CNS abnormalities, constituting RCS. (263). 
  
3.6.1. Pax Proteins and Gene Structure 
The murine Pax gene family was first identified on the basis of sequence 
homology with the Drosophila segmentation gene (264). Pax proteins are a family 
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of 9 proteins that contain a highly homologous 128 amino acid “paired” domain 
(265), originally identified in Drosophila paired protein (Prd) (266). Pax proteins 
can be divided into 4 groups based on a paired-box DNA-binding domain, with or 
without an octapeptide coding region and/or homeodomains, as shown in Figure 3-5 
(267). In addition to the “paired” domain, Pax genes have 2 other conserved 
sequences, the helixed homeodomain, an additional DNA binding motif, and the 8 
amino acid octapeptide motif, an additional conserved domain (267). Based on 
similarities of molecular structure, the 9 Pax genes are divided into 4 groups: Pax1 
and Pax9 belong to Group 1; Pax2, Pax5 and Pax8 comprise Group 2; Pax3 and 
Pax7 are members of Group 3; and Pax4 and Pax6 make up Group 4 (Figure 3-5) 
(267). 
Figure 3-5. The Pax protein family (modified from Mansouri et al.: Cell 
Differentiation) (267) 
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3.6.2. Pax Genes in Organogenesis 
All Pax proteins are expressed in different tissues during development. Pax1 is 
present in the thymus and a mutation of Pax1 gene causes reduced thymus size (268). 
Pax2 is expressed in the eyes, ears, and kidneys during embryonic development; 
heterozygous Pax2 expression in the mouse (Pax2+/-) is associated with kidney 
hypoplasia (255). Pax3 is found in the limb muscle, neural tube and neural crest. Its 
mutation leads to Waardenburg syndrome, a rare genetic disorder most often 
characterized by varying degrees of deafness, minor defects in structures arising 
from the neural crest, and pigmentation anomalies (269). Pax4 is a master gene for 
pancreatic development; Pax4-/- mice lack most pancreatic cells (270). Pax5 is 
expressed in the thymus and is involved in regulating B cell proliferation (271). 
Pax6, a highly conserved gene that controls eye development, is required for optic 
cup development (272). Pax7, expressed in somites and muscle, plays an important 
role in skeletal muscle formation (273;274). Pax8 is detected in the kidneys and 
thyroid; Pax8-/- mice die from a thyroid defect quickly after weaning (275). Pax9 
plays an important role in tooth development; heterozygous mutations in Pax9 have 
been shown to be associated with human tooth agenesis (276). Nine Pax genes have 
been described in humans and mice. The expression of Pax genes in many tissues 
during embryogenesis is associated with their critical roles during development. 
Mutations in 5 genes, Pax2, Pax3, Pax6, Pax8 and Pax9, cause human congenital 
abnormalities, as summarized in Table 3-3 (277). 
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Table 3-3. Abnormalities in humans and mice with heterozygous Pax gene 
mutations (277) 
 
3.6.3. Pax2 Mutations Cause Human RCS 
Pax2 is expressed in the eyes, ears, CNS, and urogenital system during 
embryogenesis. In the kidneys, Pax2 is expressed in the early stages of 
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mescenchymal to epithelial differentiation, proceeding to form the glomerulus, and 
is also detected in UB and at low levels in the collecting duct, renal pelvis and ureter. 
Pax2 mutations cause a special autosomal dominant human condition, RCS, a 
multisystem developmental disorder involving optic nerve colobomas and renal 
hypoplasia/insufficiency (278). Eight different mutations have been identified in the 
various exons of Pax2 gene. Exon 2, in the N-terminal portion of the paired box 
domain, is the most frequent site of mutation in RCS patients (263). Patients with 
Pax2 mutations often have small kidneys with reduced size of the renal pelvis and 
renal cortex. Renal disease in patients with Pax2 mutations is usually progressive. 
Renal cortical biopsies from RCS patients show mesangial fibrosis and 
glomerulosclerosis (Figure 3-6) (278). Fletcher et al. (279) reported that RCS 
patients seem to display the mild hypertension in adulthood.  
 
 
Figure 3-6. Renal cortical biopsy from a RCS patient (278) 
3.6.4. Animal Models of Pax2 Mutations  
Three different Pax2 mutant mice have been reported: Kidney and retinal defect 
(Krd) mice (280), Pax21Neu mice (281), and Pax2 knockout mice (219). The mutation 
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in Krd mice is transgene-induced with approximately 7 cM chromosomal deletion 
that includes the Pax2 locus on chromosome 19. Krd/+ mice have kidney defects, 
including aplastic, hypoplasic and cystic kidneys. Homozygosity (Krd-/-) results in 
early embryonic lethality (280). Pax21Neu mice have a single point mutation, a G 
insertion with a string of 7 G’s in exon 2, in the Pax2 gene. Heterozygous Pax21Neu 
mice present reduced kidney size, renal agenesis and cystic kidneys. Homozygous 
mutant Pax21Neu mice die at or soon after birth, and lack ureters, kidneys, and other 
parts of the genital tract (281). Pax2 knockout mice contain a neomycin cassette 
between exon 1 and exon 2, inducing the deletion of intervening DNA. Pax2 
heterozygous mice (Pax2+/-) exhibit a renal phenotype similar to that of homozygous 
mutant Pax21Neu mice, including smaller kidneys, renal agenesis, delayed ureters and 
renal cysts. Pax2 homozygous knockout (Pax2-/-) newborn mice lack kidneys, 
ureters and genital tracts (219). 
 
3.6.5. Pax2 in Kidney Development 
Experimental studies have demonstrated that Pax2, necessary for kidney 
development, is highly expressed in the UB as it undergoes branching 
morphogenesis. There was fewer UB tips and less branching in Pax21Neu+/- mutant 
mice (277). Porteous et al. (262) demonstrated that kidney hypoplasia is associated 
with increased apoptosis of UB cells, with a reduced number of UB branches in the 
fetal kidneys of Pax21Neu+/- mutant mice. Similarly, another study revealed a striking 
decrease in UB branching at E13.5 in metanephric kidneys from heterozygous Pax2 
mutant mice (Figure 3-7) (282). Taken together, these experiments indicate that 
Pax2 is essential for UB branching. 
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Figure 3-7. (A) Wild type kidney, (B) Pax21Neu+/- mutant kidney (282) 
  
Torres et al. (219) reported that during mesonephros development, Pax2 
mutations cause renal defects, not only in WD and ureter formation, but also in 
tubule formation. In contrast, in Pax2-/- embryos, metanephric development simply 
does not occur since the UB is absent. Additionally, Pax2-null mutant mice (Pax2-/-) 
fail to develop any kidneys, ureters and genital tracts (Figure 3-8 C and D), whereas 
heterozygous Pax2 mutations (Pax2+/-) produce smaller kidneys (Figure 3-8 B). 
 
Figure 3-8. Analysis of urogenital system defects in Pax2 mutant mice (A-D). 
Whole mounts of dissected complete urogenital systems at E17.5 in male (A, C) and 
female (B, D) homozygous and heterozygous mutants and wild type fetuses (219) 
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In summary, Pax2 is an essential regulator of genitourinary axis development in 
mammals. Inappropriate or dysregulated Pax2 expression is associated with a number of 
malignancies and dysplasia, indicating that Pax2 plays an important role in cell growth 
and differentiation. 
 
3.7 The GenitoUrinary Development Molecular Anatomy Project (GUDMAP ) 
The GenitoUrinary Development Molecular Anatomy Project (GUDMAP) is a 
consortium of laboratories working to provide the scientific and medical community 
with tools to facilitate research on the kidney and urogenital tract (UGT) (283). The 
GUDMAP aims to chronicle gene expressions during the development and 
maturation of the murine genitourinary tract and to create tools for the scientific 
community to examine the biological function of these genes (283). There are three 
components to the GUDMAP: (1) providing ontology of the cell types during 
urogenital tract development and the molecular hallmarks of those cells. 
Whole-mount in situ hybridization (WISH) is being used as a low-resolution 
approach to map gene expression domains and identify patterns that are diagnostic 
of specific anatomic regions or individual cell types. The WISH data also provide an 
excellent prescreen for further high-resolution section in situ hybridization (SISH) 
analysis. SISH and immunohistochemistry (IHC) provide high-resolution 
approaches that enable gene activity to be mapped at single-cell or near-signal-cell 
resolution within a tissue. (2) generating novel mouse strain. The generation of 
novel mouse strains is an important part of GUDMAP initiative. The consortium 
goal has been to identify cell-type or anatomic regions of interest within the UGT by 
the expression of a specific gene. The consortium goal is to generate 30 to 40 new 
mouse lines. (3) The Web-based GUDMAP Database. The Web-based GUDMAP 
database has been publicly accessible since April 2006. The Web-based GUDMAP 
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database includes primary WISH, SISH, IHC, microarray-based transcriptional 
profiling, mouse strain characterization data together with subsequent follow-up 
analyses of these data set, and information regarding methods, research tools, and 
community resources relevant to the UGT. The complete ontology for the 
genitourinary tract has been incorporated into the GUDMAP anatomy database 
(http://www.gudmap.org) (284). That database interface presents different views of 
the ontology according to the requirements of the user. The ontology will also be 
used in the EuReGene Renal Genomics Project (EuReGene) 
(http://www.euregene.org) and will be used to update the EMAP ontology used by 
the GXD (http://www.informatics.jax.org/mgihome/GXD/aboutGXD.shtml) (284). 
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CHAPTER 4: MATERNAL DIABETES MODULATES NEPHROGENESIS 
4. Maternal Diabetes Modulates Nephrogenesis 
Maternal diabetes has an adverse influence on intrauterine growth of the fetus, 
which is attributable to exposure of the mammalian embryo to an abnormal 
metabolic environment. When the fetus is exposed to high, sustained concentrations 
of peripheral glucose during the first 6 to 8 weeks of gestation in humans, 
widespread fetal damage may result in diabetic embryopathy, which is characterized 
by a multitude of congenital birth defects, including neural tube, heart, urogenital 
system, skeleton and alimentary tract defects and CRS (86). Also referred to as 
caudal dysplasia and sacral agenesis syndrome, CRS is a rare congenital defect 
characterized by absence of the sacrum and defects of variable portions of the lumbar 
spine in association with anomalies of different systems (285). The pathogenesis of 
RCS is unclear. It is diagnosed in only 0.1 to 0.25 of 10,000 normal pregnancies, but 
its prevalence is 200-250 times higher in diabetic pregnancies, occurring in up to 1% 
of pregnancies in diabetic women (286). Up to 22% of CRS cases in women are 
associated with either T1DM or T2DM, making it the most characteristic fetal 
abnormality of diabetic embryopathy (287). 
 
4.1. Clinical Phenotypes or Outcome 
As described in Section 1.6.2.1, 2 opposite abnormal situations regarding fetal 
growth are clinically associated with maternal diabetes (Figure 4-1). Fetal 
macrosomia is a common problem characterized by baby overgrowth, often in mild 
maternal hyperglycemia characterized by blood glucose values 20% higher than 
normal. Early pancreatic endocrine cells can be detected during the 7th and 8th weeks 
of human embryonic development. Pancreatic beta islets mature in the last quarter of 
gestation and are thus very sensitive to changes in glucose (288;289). High maternal 
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glucose levels are transmitted to the fetus by placental flow, causing fetal 
hyperinsulinemia, which, in turn, mediates accelerated fuel utilization, adipose 
tissue accumulation and excessive growth.  
In contrast, maternal diabetes with severe hyperglycemia often leads to 
microsomic babies. This phenotype is referred to as fetal restriction or IUGR. 
Severe maternal hyperglycemia during pregnancy creates a rich glucose 
environment, and fetuses are confronted by very high glucose concentrations, 
inducing fetal beta cell hypertrophy and/or hyperplasia. These cells then become 
depleted of insulin and often appear to be disorganized. The degranulated cells are 
incapable of insulin secretion, and their exhaustion results in fetal hypoinsulinemia. 
Fetal hypoinsulinemia and reduced numbers of insulin receptors on target cells 
culminate in decreased fetal glucose uptake (147). 
 
Figure 4-1. Two opposite, abnormal fetal growth situations associated with maternal 
diabetes 
 
4.2. Possible Mechanisms in Maternal Diabetes Modulating Nephrogenesis 
Diabetic mellitus is a major risk factor for congenital malformations. When the 
fetus is exposed to high, sustained ambient glucose levels, widespread fetal damage 
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may affect multiple organs, including the kidneys (diabetic embryopathy). The 
kidneys appear to be one of major organs targeted by diabetic embryopathy. 
Hyperglycemia constitutes an adverse uterine environment that dynamically and 
adversely impairs nephrogenesis, resulting in renal agenesis, dysplasia or aplasia 
(incomplete differentiation, often with cysts) and hypoplasia. However, the 
molecular mechanisms by which high, ambient glucose levels lead to renal 
dysmorphogenesis and birth defects have not yet been delineated. There is some 
experimental evidence, however, that hyperglycemia plays a significant role in this 
process (Figure 4-2) (95). 
 
Figure 4-2. Hypothetical model of diabetes-induced embryopathy (95) 
 
4.2.1. Hyperglycemia 
Diabetes mellitus is a metabolic disorder in which hyperglycemia damages 
several organ systems, including blood vessels, nerves, muscles, eyes, and kidneys 
(290). The 4 main hypotheses associated with diabetic complications caused by 
hyperglycemia were summarized by Brownlee’s group (291). They are: increased 
polyol pathway flux; augmented advanced glycation end-products (AGEs); 
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activation of protein kinase C (PKC) isoform; and heightened hexosamine pathway 
flux (Figure 4-3) (291). 
 
Figure 4-3. Potential mechanisms of hyperglycemic damage (291) 
 
4.2.1.1. Hyperglycemia and Renal Malformations    
Metabolic alterations in the diabetic mother have adverse effects on 
embryogenesis. Congenital malformations of various organs, including the kidneys, 
occur with increased frequency in the offspring of diabetic mothers (292).  
Experimental studies suggest that hyperglycemia is a major teratogen in diabetic 
pregnancies (293). Clinical investigations have demonstrated a positive correlation 
between hyperglycemia and fetal malformations (87), whereas good blood glucose 
control of diabetic mothers during this time period decreases the rate of fetal 
dysmorphogenesis (96). The mechanisms of hyperglycemia-induced renal 
malformation are not clearly defined. Amri et al. (256) postulated that 
hyperglycemia in utero impairs nephrogenesis in rats, resulting in a reduced number 
of nephrons in the kidneys of 14-day-old pups. Similarly, E13 embryos exposed to 
30 mM D-glucose for 1 week show decreased metanephric size. The UB tips are 
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swollen, their branches are deformed and thickened, and their tips blunted (Figure 
4-4) (294). 
    
   Figure 4-4. Light micrographs depicting the effect of a high glucose enviroment on 
the morphology of murine embryonic metanephros  
 
   Kanwar et al. (295) found that increased apoptosis in E13 metanephroi treated 
with 30 mmol/L D-glucose when compared to 5mmol/L D-glucose, Moreover, 
apoptosis was observed in the kidneys of newborn and 1-week-old mice pups from 
diabetic mothers. Taken together, hyperglycemia impairs kidney development in 
utero.   
 
4.2.2. ROS 
ROS include free radicals, such as superoxide (·O2−), hydroxyl (·OH-), and 
peroxyl (·R-OO-), and non-radical species, such as hydrogen peroxide (H2O2) and 
hydrochlorous acid (HOCl) (296). There are a number of enzymatic and 
non-enzymatic sources of ROS in the diabetic kidney, such as xanthine oxidase 
(XO), peroxidase, nitric oxide synthase, nicotinamide-adenine dinucleotide 
phosphate (NADPH) oxidase, AGEs and glucose auto-oxidation (297). Oxidative 
stress is increased in diabetes, and ROS overproduction is a direct consequence of 
hyperglycemia. Excessively high ROS levels lead to protein, lipid and DNA damage. 
ROS can activate transcription factors, such as nuclear factor kappa B (NF-kB) and 
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activated protein-1 (AP-1), signaling transduction cascades (PKC) and 
mitogen-activated protein kinases (MAPK), which result in ECM accumulation, 
glomerular mesangial expansion and tubulointerstitial fibrosis (298). Nam et al. (299) 
reported that stimulated ROS is significantly higher with NF-kB and AP-1 
up-regulation in diabetic patients with DN than in diabetic patients without DN. Ha 
et al. (300) demonstrated that the antioxidant taurine effectively inhibits membrane 
translocation of PKC and PKC  in STZ-induced diabetic rat glomeruli, indicating 
that ROS activate PKC in the diabetic kidney as well. These observations suggest 
that increased ROS induced by hyperglycemia act as intracellular messengers and 
integral glucose signaling molecules in DN. 
 
4.2.2.1. Hyperglycemia and ROS  
The embryo appropriates both aerobic and anaerobic metabolic pathways during 
early development (301). Embryos grow under a relatively low oxygen 
concentration at E7.5-9.5 in mice and E9-11 in rats (302), and high oxygen levels 
are toxic to them (303). Developing embryos seem to be very sensitive to high ROS 
levels, especially during early organogenesis. Maternal hyperglycemia causes 
sustained ROS generation with depletion of antioxidants (304). In diabetic 
environments or hyperglycemia, increased ROS production leads to embryonic 
dysmorphogenesis, and ROS scavenging enzymes can reduce the rate of 
abnormalities in cultured E10.5 rat embryos (305). Hyperglycemia induces 
embryonic malformations in rats because of glutathione (GSH) depletion, as GSH 
ester supplementation decreases the formation of free oxygen radical species, 
virtually normalizing growth retardation and embryonic dysmorphogenesis (306). A 
hyperglycemic environment in utero affects the embryo by increasing ROS, leading 
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to genetic variations and damage caused by oxidative stress, with excessive 
apoptosis and impaired organogenesis (307). 
  
4.2.3. Apoptosis  
Apoptosis plays an important role in the morphogenesis of various systems. Proper 
regulation of apoptosis is essential for normal nephrogenesis and to maintain normal 
renal function in adulthood (308). The kidney mesenchyme is divided into 2 types: 
the MM and the stromal mesenchyme (SM). The MM gives rise to parts of the 
nephron from Bowman’s capsule to the distal tubule, while the SM does not 
differentiate into nephrons or the collecting duct system. Most undifferentiated SMs 
differentiate into interstitial cells. Early in the developing kidney, the uninduced 
MM is programmed for apoptosis to prevent it from converting to epithelia and then 
differentiating (308). The undifferentiated SM undergoes apoptosis to free space for 
the expanding loops of Henle (309). On the other hand, an imbalance of apoptosis in 
kidney development causes abnormal kidney morphology. Bcl-2, an anti-apoptotic 
gene, is normally expressed in the UB, metanephric cap tissue, and primitive tubular 
structures at El2 in mice (310). Sorenson et al. (311) demonstrated that 
bcl-2-deficient mice develop small kidneys, contain far fewer nephrons and have 
smaller nephrogenic zones in newborns, resulting from excessive apoptosis within 
the developing metanephric kidney. Mice carrying a Pax2 (1Neu) mutation show 
exaggerated apoptosis with reduced UB branching (262). In adult kidneys, apoptosis 
is normally observed at low levels, but can increase because of hyperglycemia or 
oxidative stress due to disease.  
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4.2.3.1. Hyperglycemia and Apoptosis 
Both acute and chronic hyperglycemia cause oxidative stress and trigger tubular 
and glomerular cells into apoptosis, producing DN (296;312). Recent studies have 
demonstrated that loss of podocytes is an early feature of DN (313). For example, 
Susztak et al. (314) showed that podocyte apoptosis increases with the onset of 
hyperglycemia in Ins2Akita mice with T1DM and in Leprdb/db mice with obesity and 
T2DM. Hyperglycemia can also induce mesangial cell apoptosis, eliciting ECM 
accumulation. High glucose evokes ROS-dependent apoptosis in mesangial cells via 
Bax-mediated mitochondrial permeability and subsequent cytochrome c release 
(315). Functional and structural changes in renal proximal tubular cells (RPTCs) are 
associated with DN progression. Liu et al. (189) observed that high glucose evokes 
ROS generation and apoptosis in both rat immortalized renal proximal tubular cells 
and STZ-induced diabetic mice. Antioxidant administration to animals has 
protective effects that attenuate DN development (316). The antioxidant taurine 
inhibits high glucose-induced ROS formation and apoptosis in human renal tubule 
cells (317). 
 
4.2.4. The NF-kB Pathway 
NF-kB was first discovered as a factor bound to the k light-chain 
immunoglobulin enhancer in nuclei of B lymphoid lineage (318). Emerging 
evidence demonstrates that the NF-kB signaling pathway is important in the control 
of cell growth, differentiation, the immune response, inflammation, and the stress 
response (319). Indeed, NF-kB is a regulator of programmed cell death, either by 
apoptosis or necrosis, since it possesses both pro- and anti-apoptotic qualities (320). 
The NF-kB family has 5 proteins: RelA (p65), RelB, Rel, NF-kB1 (p50), and 
NF-kB2 (p52). Each NF-kB family member may form homo- or heterodimers. As 
  
60
depicted in Figure 4-5 (321), activated NF-kB is a heterodimer, which usually 
consists of p65 and p50 or p52 and RelB. Without specific extracellular signal 
stimulation, NF-kB is sequestered in the cytoplasm as an inactive heterodimer 
composed of subunits p50 and p65 complexed with the inhibitory protein IkB. 
Stimuli, such as hyperglycemia, elevated free fatty acids, ROS, and ultraviolet 
irradiation, trigger a cascade of serine kinase that activate IkB kinase (IKK) 
phosphorylation leading to IkBa dissociation from the NFkB heterodimers, and 
degradation in the cytoplasm. The released NF-kB heterodimer is translocated to the 
nucleus and then regulates the expression of a large number of genes (322). 
 
Figure 4-5. The NF-kB pathway (modified from Evans et al.: Endocr Rev) (321) 
 
An important role of NF-kB in epidermal homeostasis and the development of 
skin appendages has been reported recently. The crucial involvement of NF-kB in 
embryonic development was demonstrated by Beg et al. (323) in IkBa-deficient 
mice in 1996. These animals exhibit severe runting and skin defects in the first days 
after birth, with major skeletal deformities. Mice heterozygous for IKKγ have skin 
lesions with granulocyte infiltration, keratinocyte apoptosis and abnormal 
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development of teeth, eyes, and hair (324). Such results underscore the importance 
of NF-kB in both embryonic development and normal tissue growth. 
 
4.2.4.1. Hyperglycemia and the NF-kB Pathway 
   The transcription factor NF-kB is a major intracellular target of hyperglycemia 
(325). Peripheral blood mononuclear cells isolated from patients with DN show a 
positive correlation with NF-kB activation (326), which is associated with 
inflammatory processes, and an increase in NF-kB nuclear translocation has been 
documented in human DN (327). Schmid et al. (328) established that 
NF-kB-regulated genes are up-regulated in progressive DN, emphasizing the 
importance of the hyperglycemia-activated NF-kB pathway in human DN. Kuhad et 
al. (329) found that after 8 weeks of STZ-induced diabetes, rats manifest significant 
alterations in renal function, and the active p65 subunit of NF-kB can be detected in 
nuclear lysates of diabetic rat kidneys. 
 
4.2.4.2. Oxidative stress and the NF-kB Pathway 
It is well known that NF-kB is critically involved in the oxidative stress response. 
Oxidative stress is a frequent component of aging, immune disorders, inflammatory 
diseases, metabolic diseases, and cancers. When ROS are formed intracellularly, 
NF-kB is up-regulated, leading to the expression of cytokines, chemokines, cellular 
adhesion molecules, and inflammatory enzymes that activate the immune and 
inflammatory system. Increased oxidative stress and subsequent NF-kB activation 
have been linked to the development of late diabetic complications. Hofmann et al. 
(326;330) found a correlation between NF-kB activity and the severity of 
albuminuria in DN. Patients with diabetes also show significant suppression of 
NF-kB activation during treatment with the antioxidant thioctic acid (α-lipoic acid). 
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These obvervations confirm that hyperglycemia-induced diabetic complications 
result from the oxidative stress-mediated NF-kB pathway, causing cellular damage. 
In T1DM, pancreas-specific ROS production is critical in the signal transduction 
response by activating NF-kB (331;332). 
 
4.2.4.3. Apoptosis and the NF-kB Pathway  
NF-kB is a major player that coordinates innate and adaptive immunity, cellular 
proliferation, apoptosis and development (333). It has been shown that H2O2 induces 
apoptosis through NF-kB activation (334). Ang II elicits podocyte apoptosis via 
extracellular signal-regulated kinase pathway activation and subsequent NF-kB 
translocation (335). Schneider et al. (336) observed that NF-kB promotes apoptosis 
in focal cerebral ischemia. These observations suggest that NF-kB activation 
regulates apoptosis. The mechanisms associated with NF-kB-mediated apoptosis are 
not clear, and the role of p53 and c-Myc induction through NF-kB has been studied 
(337). 
 
4.2.4.4. The NF-kB and Protein 53 or Tumor Protein 53 (p53) Pathways  
Both the NF-kB and p53 pathways can be stimulated (338). As discussed above, 
hyperglycemia activates the NF-kB pathway and induces apoptosis mediated by p53. 
The mechanisms of hyperglycemia-induced apoptosis mediated by the NF-kB and 
p53 pathways are poorly defined. Studies have demonstrated that NF-kB-binding 
sites are present in the promoter regions of p53 (339), and p53 expression can be 
activated by NF-kB (340). Thus, NF-kB may play a role in p53 regulation in 
response to certain types of stress (341). Gilli et al. (342) established that NF-kB is 
an intracellular pathway triggered by glutamate and leads to apoptosis in which p53 
induction lies downstream of NF-kB activation. Nakai et al. (337) provided 
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additional support for the view that NF-kB activation contributes to p53 induction 
and subsequent apoptosis in an excitotoxic model of Huntington’s disease. 
 
4.2.5. The p53 Pathway 
Exposure to cellular stress can trigger the tumor suppressor p53, a 
sequence-specific transcription factor, to elicit cell growth arrest or apoptosis. 
p53-mediated apoptosis was first reported in 1991 by Yonish-Rouach et al. (343). In 
mammalian cells, p53 can activate both the extrinsic and intrinsic apoptotic 
pathways. The extrinsic apoptotic pathway is induced by transmembrane proteins, 
such as Fas, DR5, and p53 apoptosis effector related to PMP-22, activating caspases, 
including caspase-8 and caspase-3, which provoke apoptosis. The intrinsic apoptotic 
pathway is controlled by the Bcl-2 family of proteins, which releases cytochrome c 
from the mitochondria. p53 stimulates apoptosis through cytochrome c and 
procaspase-3 (Figure 4-6) (344). Several events can regulate p53 gene expression 
and activity, including post-translational modification and protein-protein 
interactions in cells. Phosphorylation of the amino acid serine 15 (Ser15), which 
increases p53 stability and apoptosis, is one of the important mechanisms that 
regulates p53 protein level and activity (345). Several kinases, including ataxia 
telangiectasia mutated kinase, A-T-related kinase, and dsDNA-activated protein 
kinase, initiate signaling pathways through p53 phosphorylation at Ser15 (346). 
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Figure 4-6. A model of p53-mediated apoptosis (344) 
4.2.5.1. Hyperglycemia and the p53 Pathway  
The mechanisms of apoptosis evoked by hyperglycemia have been investigated. 
Growing evidence has defined the induction of apoptosis by p53 (347). Studies 
support the idea that p53 can elicit apoptosis by directly signaling the mitochondria 
(348) and prompting cytochrome c release (349). It has been shown that p53 
provokes apoptosis under conditions of cellular stress, including hyperglycemia and 
ROS (350;351). Ortega-Camarillo et al. (352) demonstrated that hyperglycemia 
promotes apoptosis in RINm5F cells, the insulin-secreting cell line, via an increase 
in ROS production, and is associated with p53 mobilization to the mitochondria. 
Fiordaliso et al. (353) have reported that hyperglycemia induces myocyte apoptosis 
by activating p53. In addition, Keim et al. (354) showed that high glucose heightens 
p53 expression and activates Bax expression, downstream of p53, in mouse 
blastocysts.   
 
4.2.5.2. The p53 Pathway and Kidney Development  
p53 in humans is encoded by the TP53 gene and expressed during kidney 
development. Carev et al. (355) observed that p53 is neither expressed in the 
mesonephros nor in the metanephros, but can be found in the coelomic epithelium 
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during the 5th and 6th weeks of development. p53-positive cells appear in the 
mesonephros for the first time at the beginning of the 7th developmental week, 
except in the WD and Bowman’s capsule. During the 8th and 9th weeks of human 
kidney development, p53 is detected in all structures of the developing metanephros, 
indicating its importance in the morphogenesis of both the collecting system and 
nephrons (Table 4-1) (355). 
Table 4-1. Immunoreactivity to specific antibodies in the human mesonephros and 
metanephros during the 7th, 8th and 9th developmental weeks 
 
 
4.2.5.3. The p53 Pathway and Renal Malformation 
Apoptosis plays an important role in nephrogenesis, a process that requires 
structural formation and reformation. p53 is an active component of the apoptosis 
cascade and appears during kidney development (355). p53 Tg mice present 
defective differentiation of the UB and hypoplastic kidney due to increased 
apoptosis in the undifferentiated mesenchyme, resulting in smaller kidneys and 
about half the normal number of nephrons, with compensatory hypertrophy of the 
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glomeruli (356). Lichnovsky et al. (357) showed that p53 overexpression can cause 
defects in human kidney development. As IUGR influences the formation of 
nephrons, it has been suggested that apoptosis excessively clears progenitor cells 
during renal development. However, apoptosis is found to be altered by IUGR (185). 
Baserga et al. (358) demonstrated impaired renal function in the IUGR rat kidney 
that they attributed to increased p53 phosphorylation at Ser15. 
4.2.6. The Intrarenal RAS 
The RAS is well-known to play an important role in blood pressure regulation, 
renal hemodynamics, and fluid and electrolyte homeostasis (359). Angiotensinogen 
(Agt), the sole substrate and a precursor of Ang, is released from the liver and 
secreted into the circulation. Circulating plasma renin cleaves Agt to form the 
decapeptide Ang Ι, which is converted to the octapeptide Ang II by ACE, a 
membrance-bound metalloproteinase. Ang II interacts with 2 types of receptors, 
AT1R and AT2R. Most of its physiological effects are mediated through AT1R. In 
addition to classical RAS components, several new constituents have been 
discovered in recent years. ACE2, a homologue of ACE, converts Ang I to Ang 1-9 
and Ang II to Ang 1-7 (360). Mas proto-oncogene is a receptor for Ang 1-7 (361). In 
addition, (pro)renin receptors, which bind and activate renin and prorenin in tissues, 
has been discovered recently (362).  
 
Figure 4-7. The RAS (363)      
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4.2.6.1. The Intrarenal RAS and Kidney Development 
The Intrarenal RAS plays a fundamental role in kidney development. All RAS 
components are expressed in the metanephric kidney of rodents (Table 4-2) (204). 
Intrarenal RAS activity is high during fetal and neonatal life and declines during 
postnatal maturation. Schutz et al. were the first to demonstrate the presence of all 
RAS components in very early human development (364). In humans, Agt 
expression is first found in immature tubules as early as E30 and persists throughout 
embryonic life; renin mRNA expression is detected in the mesonephros and is 
confined to the juxtaglomerular (JG) apparatus in the metanephros at E25-27. ACE 
appears at nearly E30 and is expressed in proximal tubules; AT1R mRNA is 
expressed in glomeruli around E25-27, and AT2R mRNA is evident in the 
undifferentiated mesenchyme from E23-24 (364). As shown in Table 4-2, RAS 
components are expressed during metanephric kidney development in rats and in 
mice.  
 
Table 4-2. Expression of RAS components during metanephric kidney development 
(204) 
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Immunohistochemistry has demonstrated that Agt and AT1 are expressed in the 
UB and SM in mice at E12 (204). Ang II stimulates UB branching via AT1R 
activation in vitro (365). In ex vivo studies, exogenous Ang II increases UB 
branching but can be blocked by the AT1R antagonist candesartan (366). These 
findings show that Ang II stimulates UB branching morphogenesis via AT1R. 
AT2R is important in organogenesis as it is abundantly expressed in fetal tissues of 
mice (367), rats (368) and primates (369). Zhang et al. documented that Ang II 
stimulates Pax2 expression via AT2R in the metranephric kidney (370). AT2R 
mutant mice exhibit ureteral budding and duplicated collecting systems (371). Such 
observations suggest that AT2R expression may be important in embryological 
development of the urinary tract. In addition, the major Ang II fraction present in 
renal tissues, including the proximal tubules, renal interstitium, and renal lymph, is 
generated from Agt produced locally by RPTCs (372-374). Renin is secreted by JG 
cells and delivered to the renal interstitium. ACE is localized in proximal tubules, 
distal tubules, the collecting ducts and renal endothelial cells. Therefore, all 
components necessary to generate intrarenal Ang II are present along the nephron. 
Ang II is important in the regulation of renal blood flow, glomerular filtration, and 
tubular sodium reabsorption. In addition, ACE2, a new member of the RAS, express 
in the kidney on the luminal surface of tubular epithelial cells (360). Alenina et al. 
(375) reported that Mas mRNA is abundant in mouse renal cortex. The role of the 
ACE2-Ang-(1-7) –Mas axis in kidney development and UB branching 
morphogenesis remains to be determined. However, ACE2 homology collectrin is 
expressed in the UB branches as early as E13 in the mouse (376). 
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4.2.6.2. The Intrarenal RAS and Renal Malformation 
The genetic interruption of RAS components in mice causes a series of 
abnormalities in development of the ureters, renal pelvis and papilla (377-382). Agt, 
renin, ACE or AT1R deficiency in mice results in vascular thickening, interstitial 
fibrosis, reduced ability to concentrate urine and specific UB/collecting system 
changes, including atrophy of the papilla and medulla with hydronephrosis (Table 
4-3) (204). In addition, AT2R gene deletion in mice causes congenital abnormalities 
of the kidney and urinary tract (371). Chen et al. (383) studied the effect of AT2R 
deficiency on renal malformations and showed that a lack of AT2R alters the 
expression of Pax-2 and N-Myc genes during nephrogenesis.   
Table 4-3. Effect of genetic RAS inactivation in mice on renal collecting system 
development (204) 
 
 
The RAS has been reported to be associated with abnormal kidneys and 
decreased nephron numbers in experimental studies. Woods et al. (167) showed that 
suppression of RAS components, such as renin and Ang II, in the developing 
fetus/newborn leads to impaired renal development and lower nephron numbers at 
birth, culminating in adult hypertension in a maternal protein restriction model. 
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4.2.6.3. Hyperglycemia and the Intrarenal RAS  
There is evidence of an association between the development of diabetes and 
RAS activation. However, clinical and experimental studies have demonstrated that 
ACE inhibitors and AT1R blockade may have potent beneficial effects by delaying 
cardiac disease in diabetes mellitus (384-387). Increased renin expression has been 
found in proximal tubules from STZ-induced diabetic rats, and renin expression 
after insulin treatment completely regressed to control values, suggesting intrarenal 
RAS activation by hyperglycemia (388). Liu et al. (189) have shown that apoptosis 
in proximal tubules in DN is exacerbated by Agt overexpression. Yoo et al. (389) 
noted that high glucose induces Agt mRNA and protein expression in cultured 
podocytes via the PKC pathway, and increased Agt and AT1R expression is also 
seen in podocytes of diabetic glomeruli. It has been established that the effect of 
maternal diabetes is associated with consequent hyperglycemia and impaired 
cardiovascular function in the offspring (390). Wichi et al. (391) determined that 
hyperglycemia during pregnancy produces long-lasting hypertension in male 
offspring with enhanced tissue ACE activity.  
  
71
CHAPTER 5: EXPERIMENTAL APPROACHES 
5.1 In Vitro Studies 
5.1.1 cell line 
MK4 cells representing late embryonic MM undergoing epithelial conversion 
were created from Tg mice with Simian Virus 40 T-antigen gene driven by the Hoxa 
11 promoter (392). As illustrated in Figure 6-1 (392), MK4 cells are smaller, more 
polygonal or epithelial in shape with a cobblestone-like appearance at confluence. 
Morphologically, they represent a later stage of nephrogenesis when mesenchymal 
cells are converting to epithelia. MK4 cells express several gene characteristics of 
MM cells undergoing epithelial conversion, including E-cadherin, Wnt4, Pax8, Pax2, 
Cadherin-6, collagen IV, and LFB3 (392). In the present studies, mouse MK4 cells 
were tested as in vitro models and cultured in normal glucose or high glucose either 
with or without inhibitors of signaling pathways. They were obtained from Dr. 
Steven Potter (Children’s Hospital Medical Center, Cincinnati, OH, USA).  
 
Figure 5-1 MK4 cell morphology (392) 
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5.1.2 Brief description of different glucose analogues 
We have employed the four glucose analogs including D-glucose, L-glucose, 
D-Mannitol and 2-Deoxy-D-glucose in our studies in vitro and ex vivo. 
Figure 5-2 The structure of D-gluocse, L-glucose, D-Mannitol and 
2-Deoxy-D-glucose 
(1) D-glucose is the right-handed form of glucose (C6H12O6) and plays a major role 
in biologically active and function as a source of energy and metabolic intermediates. 
D-glucose is synthesized in the liver and kidneys from non-carbohydrate 
intermediates, such as pyruvate and glycerol, by a process known as 
gluconeogenesis;  Through glycolysis and later in the reactions of the citric acid 
cycle (TCAC), glucose is oxidized to eventually form CO2 and water, yielding 
energy sources, mostly in the form of ATP. In our studies, we have demonstrated 
that high D-glucose (25mM) as compared normal glucose (5mM) specifically 
induced Pax2 gene expression in MK4 cells. 
(2) L-glucose is an enantiomer of D-glucose with mirror-image form. It does not 
occur naturally in higher living organisms and cannot be metabolized in the 
biochemical process known as glycolysis. In our studies, we have observed that 
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there is no any stimulatory effect of L-glucose on Pax2 gene expression indicating 
that the stimulatory effect of D-(+) glucose on Pax2 expression in MK4 is specific. 
(3) D-Mannitol: D-Mannitol is a sugar alcohol and derived by reduction of 
d-fructose or of d-mannose. D-Mannitol is widely used in the food and 
pharmaceutical industries because of its unique functional properties. D-Mannitol is 
non-cariogenic and has a low caloric content and often used as a sweetner or 
laxative. D-mannitol is used as an osmotic diuretic agent because that it could be 
filtered in the glomerulus, but cannot be reabsorbed. Their presence leads to an 
increase in the osmolarity of the filtrate. In our studies, we have added the 
supplement of D-mannitol (20 mM) into 5 mM glucose DMEM to maintain constant 
isotonicity or osmolality as in 25mM glucose DMEM. Our data indicates that the 
stimulatory effect of high glucose level on Pax2 expression in MK4 is via the 
specific D-glucose effect, not the osmolality stress effect. 
(4) 2-Deoxy-D-glucose: 2-Deoxy-D-glucose is a glucose molecule which has the 
2-hydroxyl group replaced by hydrogen, so that it cannot undergo further glycolysis. 
2- Deoxy-D-glucose is uptaken by the glucose transporters of the cell. Therefore, 
cells with higher glucose uptake have also a higher uptake of 2- Deoxy-D-glucose. 
In our studies, we have observed that there is no any stimulatory effect of 
2-Deoxy-D-glucose on Pax2 gene expression. 
 
5.2. Ex Vivo Studies  
5.2.1. Animals 
Hoxb7-GFP mice specifically express GFP in UB driven by the Hoxb7 promoter 
(393). This model is interesting in that real-time observation of UB development is 
possible under fluorescence microscopy because GFP permits direct study of the 
branching process. As seen in Figure 6-2 (393), GFP is expressed throughout the 
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WD and each branch of the UB, but not in the surrounding MM or its epithelial 
derivatives throughout kidney development. As GFP can be easily visualized in 
living tissue, we can follow the dynamic pattern of UB growth and branching 
morphogenesis in organ culture to directly investigate the UB branching 
morphogenesis pattern under nondiabetic and diabetic conditions ex vivo. In the 
present studies, murine Hoxb7-GFP mice served as an in vitro model. They were 
obtained from Dr. Frank Costantini (Department of Genetics and Development, 
Columbia University Medical Center, New York, NY, USA).  
 
Figure 5-3. GFP expression in UB derivatives of Tg fetuses at E12.5 through E16.5 
(393) 
 
5.2.2. Metanephric Organ Culture 
Kidney explants (E12 to E18) were microdissected from timed-pregnant mice. 
GFP-positive metanephroi were photographed immediately after isolation (time 0) 
and were individually cultured in normal glucose or high glucose either with or 
without inhibitors of signal pathways at different time points.    
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5.3. In Vivo Studies  
5.3.1. Animals 
In our in vivo experiments, we investigated 2 Tg mice lines: Hoxb7-GFP mice 
(as described above) and Nephrin-CFP mice. Nephrin-CFP mice were obtained from 
Dr. Susan Quaggin (University of Toronto, Toronto, ON). As shown in Figure 6-3, 
Nephrin-CFP mice specifically express Cyan fluorescent protein (CFP) in glomeruli 
driven by the podocyte-specific nephrin promoter. Nephrin-CFP mice allow us to 
follow the glomerular morphogenesis pattern during nephrogenesis under 
nondiabetic and diabetic conditions ex vivo.  
 
Figure 5-4. Glomerular isolation under dissecting microscopy. EDG: early 
developing glomeruli (late S shape/early capillary loop); CLG: capillary loop 
glomeruli; MG, mature glomeruli 
 
5.3.2. Maternal Diabetes Animal Models 
5.3.2.1. STZ Injection  
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STZ has been generally administered to induce T1DM, based on its efficiency in 
selectively destroying pancreatic beta cells (394). This method has been employed 
to elucidate the effect of maternal diabetes on fetal growth and development. The 
phenotype of the offspring is associated with the STZ dose given during pregnancy 
(395). Low-dose STZ results in mid-maternal diabetes, and fetal macrosomia (396). 
On the other hand, high-dose STZ induces insulin deficiency diabetes and fetal 
microsomia (397). 
 
5.3.2.2. BioBreeding (BB) Diabetes-prone Rats  
The BB rat is a model of spontaneous T1DM development. Experimental study 
of spontaneous autoimmune T1DM in BB rats has shown that the effects of severe 
hyperglycemia on the BB rat pancreas and fetal growth in utero are similar to the 
metabolic conditions induced by STZ injection to create a severely hyperglycemic 
environment (398). Eriksson et al. (399) demonstrated that the offspring of 
spontaneously diabetic BB/E rats had smaller kidneys than those of non-diabetic 
controls. 
 
5.3.2.3. Ins2 Akita Mice 
The Ins2 Akita mouse is an autosomal dominant mutant T1DM model. 
Experimental studies in Ins2 Akita mice have shown that maternal T1DM does not 
cause cardiac hypertrophy or triglyceride accumulation in the fetal heart, possibly 
because genes controlling fatty acid uptake are down-regulated (400). 
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5.3.2.4. Non-obese Diabetic (NOD) Mice 
The NOD mouse, with spontaneous development of beta cell failure, may also 
serve as a model of maternal diabetes with fetal hyperinsulinemia and macrosomia 
(401;402). 
 
5.3.2.5. Heterozygous Leprdb/+ Mice 
The db/db mouse is one of the models of T2DM. Heterozygous leptin 
receptor-deficient (Leprddb/+) mice develop spontaneous glucose intolerance during 
pregnancy, and the offspring of these mothers heterozygous for the leptin receptor 
(Leprdb/+) are macrosomic (403). The offspring of heterozygous Leprdb/+ mothers 
have HBW compared to the controls, as depicted in Table 6-1 (404). Heterozygous 
Leprdb/+ mice are a good model to study the fundamental role of maternal diabetes in 
HBW and modulation of renal morphogenesis in their offspring. 
 
Table 5-1. Average fetal birth weight and litter size of wild type (+/+) and 
heterozygous db/+ mothers (404).  
 
 
5.3.2.6. Rich Diet-induced Rats 
A rich diet (cafeteria type with 33% standard food for rats, 33% sweetened 
condensed milk, 7% sucrose and 27% water) primes the Wistar rat to develop GDM. 
Rich diet-induced rats are another experimental model used to demonstrate glucose 
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intolerance in mothers during pregnancy, emphasizing that obesity is one of the 
most important risk factors for GDM. 
 
5.3.3. Our Maternal Diabetes Animal Models 
In our laboratory, we generate maternal diabetes animal models by a single 
intraperitioneal (IP) STZ injection at a dosage of 150 mg/kg at E13 in Hoxb7-GFP 
mice. Compared to low-dose STZ, a single high-dose STZ creates a severely high 
glucose environment in utero, resulting in fetal microsomia (146;294). On the other 
hand, our model of severe maternal diabetes does not represent the phenotypes 
commonly found in humans in industrialized countries, or gestational diabetes with 
mild hyperglycemia control and fetal macrosomia. 
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CHAPTER 6: OBJECTIVES OF THE PRESENT STUDIES 
Rationale: Diabetes mellitus is a major risk factor for congenital malformations. 
When the fetus is exposed to high, sustained, ambient glucose levels, widespread 
fetal damage may affect multiple organs, including the kidneys. Infants born to 
women with both PGDM and GDM have a relatively high risk of congenital 
malformations. Renal malformations account for 40% of childhood renal failure. 
Hyperglycemia constitutes an adverse in utero environment that dynamically 
impairs nephrogenesis, resulting in absent kidneys, small kidneys, or too few 
nephrons. Experimental studies have demonstrated that hyperglycemia in diabetic 
women triggers ROS production which causes oxidative stress. Oxidative stress 
somehow increases apoptosis and activates the apoptosis-inducing signaling 
pathway. However, the molecular mechanisms by which high ambient glucose 
levels lead to renal dysmorphogenesis and birth defects have not yet been delineated. 
Therefore, the objectives of the present studies are:   
   
(1) To investigate whether high glucose alters Pax2 gene expression in the mouse 
embryonic MM (MK4 cells in vitro) 
(2) To demonstrate the influence of a high-glucose milieu on UB branching 
morphogenesis (ex vivo) 
(3) To dissect the fundamental role of maternal diabetes in renal morphogenesis 
impairment in offspring (in vivo) 
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CHAPTER 7 : ARTICLE 1 
Reactive Oxygen Species (ROS) and NF-kB Pathway Mediate High Glucose- 
Induced Pax-2 Gene Expression in Mouse Embryonic Mesenchymal Epithelial Cells 
and Kidney Explants 
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7.1 Abstract  
Diabetic mellitus confers a major risk of congenital malformations, and is 
associated with diabetic embryopathy, affecting multiple organs including the 
kidney. The DNA paired box-2 (Pax-2) gene is essential in nephrogenesis. We 
investigated whether high glucose alters Pax-2 gene expression and aimed to 
delineate its underlying mechanism(s) of action using both in vitro (mouse 
metanephric mesenchymal cells (MK4) and ex vivo (kidney explant from 
Hoxb7-GFP mice) approaches. Pax-2 gene expression was determined by RT-PCR, 
Western blotting, and immunofluorescent staining. A fusion gene containing the 
full-length 5’-flanking region of the human Pax-2 promoter linked to a luciferase 
reporter gene, pGL-2/hPax-2, was transfected into MK4 cells with or without 
dominant negative IκBα (DN IκBα) co-transfection. Fusion gene expression level 
was quantified by cellular luciferase activity. Reactive oxygen species (ROS) 
generation was measured by lucigenin assay. Embryonic kidneys from Hoxb7-GFP 
mice were cultured ex vivo. High D(+) glucose (25 mM), compared to normal 
glucose (5 mM), specifically induced Pax-2 gene expression in MK4 cells and 
kidney explants. High glucose-induced Pax-2 gene expression is mediated, at least 
in part, via ROS generation and activation of the NF-kB signaling pathway, but not 
via PKC, p38 mitogen activated protein kinase (MAPK) and p44/42 MAPK 
signaling. 
 
7.2 Introduction 
Diabetic mellitus confers a major risk factor for congenital malformations. When 
the fetus is exposed to sustained high ambient glucose, widespread fetal damage 
may affect multiple organs including kidney (diabetic embryopathy)[1;2].  Infants 
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born to women with pre-gestational insulin-dependent diabetes mellitus have a 
10-fold relative risk of congenital malformations, and those born to women with 
gestational diabetes have a five-fold relative risk. Both the diabetic mother and her 
fetus are at risk for significant morbidity and mortality, even in the 21st century 
[3;4].  
Renal malformations account for approximately 40 percent of childhood renal 
failure [5;6]. During kidney development, two major events, ureteric bud (UB) 
branching and mesenchymal-to-epithelial transformation control the main thrust of 
renal morphogenesis. When the normal pattern of nephrogenesis is interrupted, 
kidney abnormalities, such as renal agenesis, renal dysplasia or aplasia, may ensue 
[6-8]. 
Kanwar et al. [9] recently reviewed the mechanisms that appear to be involved 
in diabetic embryopathy, pointing out that high glucose increases damage to DNA 
and the extracellular matrix (ECM) via reactive oxygen species (ROS); high glucose 
inhibits COX-2, resulting in PGE2 deficiency; and high glucose may induce 
transcription factors and proto-oncogenes. Kanwar et al. also demonstrated that 
renal-specific oxidoreductase is closely linked to renal morphogenesis in a high 
glucose milieu [10]. However, the molecular mechanisms by which high ambient 
glucose levels lead to renal dysmorphogenesis and birth defects have not yet been 
delineated [9-11]. 
ROS have been proposed as a major factor in the pathogenesis of diabetic 
nephropathy [12;13]. Increased ROS generation by high glucose directly damages 
DNA and also alters the expression of ECM glycoproteins [14-16]. Additionally, 
kidney related key proto-oncogenes and transcription factors such as GDNF, cRet 
and Pax-2 may be altered in diabetic embryopathy [9], although clear experimental 
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evidence is presently lacking. The paired-box 2 (Pax-2) gene is a “kidney-specific” 
master gene that is expressed in both UB and mesenchymal cell lineages, normally 
optimizing UB branching and mesenchymal-to-epithelial transformation in kidney 
development [17-19]. Mutations in the Pax-2 gene cause increased apoptosis 
[20-22], associated with renal hypoplasia [20;23;24]. For instance, homozygous null 
Pax-2 mice fail to form any kidneys, ureters and genital tracts [25]. In humans and 
mice, heterozygous Pax-2 mutations cause kidney, eye, and central nervous system 
abnormalities, constituting a syndrome called renal-coloboma syndrome (RCS) 
[26;27]. The mechanism by which reduced Pax-2 expression leads to decreased UB 
branching and subsequently to a reduced number of nephrons in patients with RCS 
seems to be highly related to UB lineage apoptosis [28]. It appears that regulation of 
UB cell survival by activation of Pax-2 regulated factors such as Naip (neuronal 
apoptosis inhibitory protein) and Wnt-4 will be powerful determinants of congenital 
nephron endowment [28-31]. 
The transcription factor nuclear factor kappa B (NF-kB) is a major intracellular 
target in hyperglycemia and oxidative stress [32;33]. NF-kB plays a critical role in 
mediating immune and inflammatory responses and apoptosis. It is also associated 
with a number of chronic diseases including diabetes and atherosclerosis [34;35]. 
In the present study, we investigated whether there is a link between 
hyperglycemia and Pax-2 gene expression that might influence kidney development. 
We employed in vitro and ex vivo approaches and observed that high glucose (25 
mM D-glucose) as compared to normal glucose (5 mM D-glucose) specifically 
induced Pax-2 gene expression in MK4 cells and kidney explants, with ROS 
generation and the NF-kB pathway certainly being involved as underlying 
mechanisms.  
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7.3 Materials and Methods 
Reagents  
Normal glucose (5 mM D-glucose Dulbecco’s modified Eagle’s medium 
(DMEM) (Cat. #12320) was purchased from Invitrogen Inc. (Burlington, Ontario, 
Canada). D(+)-Glucose, L-glucose, D-mannitol, 2-deoxy-d-glucose, diphenylene 
iodinium (DPI), rotenone, GF109203X, PDTC,  xanthine oxidase (XO) and 
hypoxanthine were purchased from Sigma-Aldrich Canada Ltd. (Oakville, ON, 
Canada). SB203580, PD98059 were obtained from CalBiochem (San Diego, CA, 
USA). Mouse anti-β-actin monoclonal antibody (clone AC-15) and rabbit polyclonal 
anti-Pax-2 antibody were purchased from Sigma-Aldrich Canada Ltd. (Oakville, ON, 
Canada) and Covance (Richmond, CA, USA), respectively. The luciferase activity 
assay kit was purchased from Promega (Fisher Scientific, Montreal, QC, Canada). 
Hoxb7-GFP mice were obtained from Dr. Frank Costatini (Department of Genetics 
and Development, Columbia University Medical Center, NY, NY, USA) [36;37], 
and the 4.2-kb ApaI/NcoI fragment of the human PAX2 promoter (AF515729)  was 
a generous gift from Dr. Michael Eccles (Department of Pathology, University of 
Otago, Dunedin, New Zealand) [20;38]. MK4 cells were from Dr. S. Steven Potter 
(Division of Developmental Biology, Children's Hospital Medical Center, 
Cincinnati, OH, USA) [39]. Dominant negative IκBα (DN IκBα) plasmid 
(pcDNA3.1/DN IkBa) from Dr. John S.D. Chan (CHUM-Hôtel-Dieu, Montreal, QC, 
Canada), was produced by PCR-based site-directed mutagenesis in Serines 32 and 
36 in the N terminal regulatory domain of IκBα (NM_010907) to resist 
phosphorylation. DN IκBα can bind the p50 and p65 subunits complexed in an 
inactive form, preventing p50 and p65 from translocating to the nucleus for further 
action. 
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Depleted fetal bovine serum (dFBS, depleted of endogenous steroid and thyroid 
hormones) was prepared by incubation with 1% activated charcoal and 1% AG 1 X 
8 ion-exchange resin (Bio-Rad Laboratories, Inc., Richmond, CA, USA) for 16 to 
24 hous at room temperature, as described previously [40;41]. Though endogenous 
steroid and thyroid hormones have been removed from FBS, the purpose of adding 
1% dFBS into either 5mM glucose or 25 mM DMEM after rendering them 
quiescent with serum free medium is to support the cells during the additional 24 
hour experimental period until harvested, as demonstrated previously [40;41]. 
 
Culture of MK4 Cells 
The MK4 cell line is representative of late embryonic mesenchymal 
mesenchyme (MM) as it undergoes mesenchymal to epithelial conversion [39]. 
MK4 cells are relatively polygonal or epithelial in shape and express genes typical 
of late mesenchyme, including Pax-2, Pax-8, Wnt-4, Cadherin-6, Collagen IV, and 
LFB3 (REF) [39]. In the present study, MK4 cells were cultured in normal glucose 
DMEM (pH 7.45), supplemented with 5% FBS, 100 U/ml of penicillin and 100 
µg/ml of streptomycin in 95% air and 5% CO2 at 37ºC.  
 
Ex vivo Embryonic Kidney Culture 
Embryonic kidneys were isolated from timed pregnant HoxB7-GFP mice at 
embryonic stage E16 [36;37] under sterile conditions and cultured either in normal 
glucose or high glucose DMEM supplied with 1% dFBS. These mice specifically 
express the green fluorescence protein (GFP) in the UB driven by the Hoxb7 
promoter. Each kidney explant was cultured in 1 ml of medium in a separate well of 
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a 24-well plate for up to 24 hours in the presence or absence of DPI (10-6 M), 
rotenone (10-6 M) and H2O2 (10-5 M).    
 
Immunofluorescence Studies 
MK4 cells were grown to 70 to 80% confluence in two-chamber slides, and then 
synchronized with overnight serum-free medium. After culture in either normal 
glucose or high glucose DMEM for 24 hours, cells were processed for 
immunofluorescence investigation as reported previously [40;41]. 
Immunofluorescence images were recorded with a Olympus 1X71 Microscope 
(CARSEN, ON, CA).  The images are presented at 400 X magnification.  
 
Western Blotting  
Western blots were performed as in previous studies [40;41]. Briefly, small 
aliquots (20-50 μl) of homogenized cell sample were subjected to 10% SDS-PAGE 
and then transferred onto a PVDF membrane (Hybond-P, Amersham Pharmacia 
Biotech, Canada). The membrane was first blotted for anti-Pax-2 and then re-blotted 
for β-actin. The relative densities of the Pax-2 vs β-actin bands were measured by 
computerized laser densitometry.  
 
ROS Generation 
ROS production was quantified by the lucigenin method [42;43]. After 
overnight culture in serum-free medium to render them quiescent, cells were 
incubated in either normal  glucose or high glucose DMEM containing 1% 
depleted FBS for periods of 15 mins to 2 hours. Cells were then  trypsinized, 
collected by centrifugation, and the pellet washed in modified Krebs buffer 
containing NaCl (130 mM), KCl (5 mM), MgCl2 (1 mM), CaCl2 (1.5 mM), K2HPO4 
  
87
(1 mM) and Hepes (20 mM), pH 7.4. After washing, the cells were resuspended in 
Krebs buffer with 1 mg/ml bovine serum albumin (BSA), and cell concentration was 
adjusted to 1×107 in 900μl buffer. To measure ROS production, the cell suspension 
was transferred to plastic tubes and assessed in a luminometer (LB 9507, Berthold, 
Wildbad, Germany). The final value, RLU (related light unit) of ROS generation 
was normalized by protein concentration of the samples. 
 
RT-PCR for Pax-2 mRNA  
Total RNA was prepared from cultured cells according to the manufacturer’s 
protocol using TRIZOL (Invitrogen Inc.) [40;41]. First strand cDNA was 
synthesized with the Super-Script preamplification system (Invitrogen Inc.). We 
employed the following forward and reverse primers: forward primer 5' TTT GTG 
AAC GGC CGG CCC CTA 3', and the reverse primer 5' CAT TGT CAC AGA 
TGC CCT CGG 3'; these correspond to the nucleotide sequences N+622 to N+642 
and N+902 to N+922 of Pax-2 cDNA [40;41]. For internal control, we deployed 
primers specific for mouse β-actin [44] (forward and reverse primers 5' ATG CCA 
TCC TGC GTC TGG ACC TGG C 3' and 5' AGC ATT TGC GGT GCA CGA 
TGG AGG G 3', corresponding to nucleotide sequences N+600 to N+622 and 
N+1179 to N+1203 of mouse β-actin cDNA (X03672)). 
 
Real Time-Polymerase Chain Reaction (qRT-PCR) 
qRT-PCR were performed as in previous studies [40]. In brief, first-strand 
cDNA was produced from 2 ug of random hexamer primed total RNA using 
Super-Script pre-amplification system (Invitrogen). Relative quantitation by 
real-time PCR was carried out using iQTM SYBR@ Green Supermix Kit (Bio-Rad 
Laboratories, Mississauga, ON, Canada) and MiniOpticonTM Real-Time PCR  
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Detection System (Bio-Rad), following the protocol described by the supplier. PCR 
reactions in triplicate underwent 40 cycles of 95 oC for 20 s, 60 oC for 20 s, 72 oC for 
20 s, and 79 oC for 5 s in the thermal cycler. The parameter CT (threshold cycle) 
value was measured to determine starting copy number of target genes using the 
standard curve. Lower value of CT indicates higher amount of PCR products. We 
employed the following forward and reverse primers for Pax-2: forward primer 5' 
ACA TCA AAT CAG AAC AGG GGA AC 3', and the reverse primer 5' CAT GTC 
ACG ACC AGT CAC AAC 3'; these correspond to the nucleotide sequences 
N+1319 to N+1341 and N+1453 to N+1473 of Pax-2 cDNA (NM_003990). For 
internal control, we deployed primers specific for mouse β-actin (forward and 
reverse primers 5' CGT GCG TGA CAT CAA AGA GAA 3' and 5' GCT CGT TGC 
CAA TAG TGA TGA 3', corresponding to nucleotide sequences N+704 to N+724 
and N+820 to N+840 of mouse β-actin cDNA [NM_007393]) [40].  
 
Luciferase Assay for High Glucose Effect on Pax-2 Gene Promoter Activity  
We have constructed a fusion gene, pGL-2/hPax-2, containing a full length 
5’-promoter of 4.2-kb ApaI/NcoI fragment of the human PAX2 promoter 
(AF515729) [20;38] inserted into luciferase reporter pGL-2 basic vector (Promega), 
and performed transient transfection of this fusion gene into MK4 cells  by 
Lipofectamine 2000 (Invitrogen Inc.), while pGL-2 basic vector serving as control. 
IκBα is an inhibitor of   NF-κB. To study the effect of DN IκBα on high glucose 
induced Pax-2 promoter activity, we transiently cotransfected both plasmids: 
pGL-2/hPax-2 and pcDNA3.1/DN IkBa, into MK4 cells, while both pGL-2 and 
pcDNA3.1 basic vector served as controls. MK4 cells grown in 12-well plates were 
transfected with 1.5 μg of each plasmid. After a 24 hours stimulation with high 
glucose medium with or without ROS inhibitors, cells were harvested and the 
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luciferase activity was quantified by Luciferase assay kit (Promega) according to the 
protocol from the supplier with renilla luciferase as an internal control.  
 
Statistical Analysis 
Statistical significance between experimental groups was analyzed initially by 
student’s t test or by 1-way ANOVA followed by the Bonferroni test as appropriate.  
Three to four separate experiments were performed for each protocol. Data are 
expressed as means ± SD. A probability level of P  0.05 was considered 
statistically significant.  
 
7.4 Results 
High Glucose Stimulates Pax-2 Expression in MK4 cells 
MK4 cells were incubated in media containing 1% dFBS and 25 mM different 
glucose analogues such as D-Glucose, D-Mannitol, L-glucose or 
2-Deoxy-D-Glucose. After incubation for 24hours, cells were harvested and 
analyzed for Pax-2 mRNA (RT-PCR) and protein (Western blotting) levels. As 
shown in Figure 1, high glucose stimulated the Pax-2 mRNA expression (Figure 1A, 
RT-PCR) and protein (Figure 1B: Western blotting) in a dose-dependent manner 
from 5mM to 25mM with a maximal effect at 25mM D-glucose. To maintain 
constant isotonicity or osmolality, 5-mM glucose media was supplemented with 
D-mannitol (20 mM) (final concentration) in additional studies. Figure 2 indicates 
that high glucose as compared to normal glucose specifically induced Pax-2 gene 
expression, while other glucose analogs such as D-Mannitol, L-glucose or 
2-Deoxy-D-Glucose in MK4 cells had no effect, suggesting that the effect of high 
D(+)-glucose medium is specific (Figure 2A: RT-PCR; Figure 2B: Western Blot). 
Moreover, Pax-2 immunostaining with intranuclear appearance was induced by high 
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glucose, consistent with the fact that Pax-2 is a nuclear transcription factor (Figure 3) 
[40;41;45]. Pax-2 expression was normalized by β-actin. The 24-hour incubation 
period was used for all subsequent studies.  
 
p38 MAPK, p44/42 MEK and PKC Inhibitors Fail to Block the High Glucose Effect 
on  Pax-2 Gene Expression  in  MK4 Cells 
Figure 4A and 4B reveal that inhibitors of p38 MAPK (SB203580), P44/42 
MEK (PD98059) and PKC (GFX) could not block the stimulatory effect of high 
glucose on Pax-2   mRNA and protein expression in MK4 cells, suggesting that 
p38 MAPK, p44/42 MEK and PKC signaling are not involved in mediating the 
stimulatory influence of high glucose on Pax-2 gene expression. 
 
ROS Generation and Pax-2 Gene Expression in MK4 Cells 
 We observed that MK4 cells after 15 minutes incubation in high 
glucose medium, ROS generation began to increase in MK4 cells, and 
this elevation lasted 60 minutes (Figure 5A). These data indicate that 
high glucose induced ROS generation in MK4 cells. In order to confirm 
that ROS directly regulate Pax-2 gene expression, we performed studies 
involving the xanthine oxidase (XO) system. Superoxide generated from 
the XO system directly stimulates Pax-2 gene expression in MK4 cells 
in a dose-dependent manner (Figure 5C, 5D and 5E).  
 
Inhibitors of NADPH Oxidase, Mitochondrial Electron Transport Chain Complex I, 
and NF-kB Pathway Block the Stimulatory Effect of High Glucose on  Pax-2 Gene 
Expression  in  MK4 Cell. 
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 The stimulatory effect of high glucose on ROS generation was inhibited in the 
presence of DPI and rotenone, but not PDTC (Figure 5B). Figure 6 shows that 
inhibitors of NADPH oxidase (DPI), mitochondrial electron transport chain complex 
I (rotenone), and NF-kB pathway (PDTC) block the stimulatory action of high 
glucose on Pax-2 expression in MK4 cells. These data suggest that the stimulatory 
effect of high glucose on Pax-2 gene expression is mediated via ROS generation and 
the activation of NF-kB signaling pathway in MK4 cells. 
 
High Glucose Effect on Pax-2 Gene Expression in Kidney Explants from 
Hoxb7-GFP mice 
In order to confirm our in vitro observation, we adapted an ex vivo   model 
using embryonic kidney explants. Embryonic kidneys at E16 gestation from 
Hoxb7-GFP mice were isolated and cultured ex vivo as shown in Figure 7A. After 
culturing the explants for 24 hours in either normal glucose (5mM) or high glucose 
(25mM) DMEM with or without ROS inhibitors, high glucose stimulated Pax-2 
mRNA and protein expression. The high glucose effect was blocked by ROS 
inhibitors, as illustrated in Figure 7B and 7C. We have also tested H2O2, an 
important source of O2•−, and observed that exogenous H2O2 at 10-5 M stimulates 
Pax-2 gene expression modestly; however, in combination with high glucose, the 
H2O2 stimulatory effect is enhanced substantially as shown in Figure 7 E (qRT-PCR) 
and 7F (Western blot). 
 
High Glucose Effect on Pax-2 Gene Promoter Activity 
 Transient transfection of pGL-2/hPax-2 in MK4 cells followed by culturing in 
high glucose medium stimulated Pax-2 gene promoter activity, compared to 
culturing the cells in normal glucose medium. The stimulatory effect of high glucose 
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was inhibited in the presence of inhibitors of ROS and NF-kB signaling pathway 
(Figure 8A). Moreover, after co-transfection with pcDNA3.1/DN IκBα, high 
glucose-induced Pax-2 promoter activity was abolished, which suggests that NF-κB 
is involved in Pax-2 transcription stimulated by high glucose (Figure 8B). These 
data demonstrate that the stimulatory effect of high glucose on Pax-2 gene 
expression occurs at the transcriptional level via ROS activation of the NF-kB 
signaling pathway. 
 
7.5 Discussion 
 The present studies demonstrate that high glucose stimulates Pax-2 gene 
expression in mouse embryonic metanephric mesenchymal (MM) cells and 
embryonic kidney explants. The stimulatory effect of high glucose on Pax-2 gene 
expression is mediated, at least in part, via ROS generation and activation of NF-kB 
signaling pathway. 
During embryogenesis, embryonic stem cells must proliferate dynamically and 
precisely in order to form functional organs. Additionally, apoptosis and 
proliferation is involved.  Any interruption or error caused by the surrounding 
environment or misleading signals involved in gene regulation can elicit aberrant 
organogenesis and may even be lethal. For example, in renal morphogenesis, certain 
undifferentiated MM must undergo apoptosis to make room for UB branching [7;8]. 
Diabetes constitutes an adverse in utero environment that may impair nephrogenesis. 
For example, a high glucose milieu can result in an abnormal pattern of UB 
branching evoking duplex ureters or cystic kidneys; reduced populations of nascent 
nephrons, resulting in hypoplasia; increased apoptosis in mesenchyme and UB 
epithelium, resulting in renal agenesis, aplasia or dysplasia [46-49]. Nielsen et al. 
reported that the prevalence of renal malformations such as renal agenesis and 
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congenital abnormalities of kidney and urinary tract (CAKUT) have a strong 
association with pre-gestational maternal diabetes, more than cardiovascular 
congenital abnormalities or multiple congenital abnormalities [50].  
Renal-specific genes are also clearly important for accurate nephrogenesis.  
The “kidney-specific” master gene Pax-2 is necessary for initial signaling of the 
Wolffian duct (WD) to optimize UB branching and mesenchymal-to-epithelial 
transformation [19;26]. Pax-2-null mice fail to form any kidneys, ureters and genital 
tracts [25]. In humans and mice, heterozygous Pax-2 mutations cause kidney, eye, 
and central nervous system abnormalities, constituting a syndrome called 
renal-coloboma syndrome (RCS) [26;27].  
To the best of our knowledge, high ambient glucose has not been reported 
previously to regulate Pax-2 gene expression and its underlying mechanism(s) of 
action in embryonic kidney cells.  In the present study, we employed both in vitro 
(MK4 cells) and ex vivo (kidney explants) approaches to explore this potential 
interaction.  As our data indicate, high D(+) glucose (25mM) specifically and 
dose-dependently stimulated Pax-2 gene expression in MK4 cells, while other 
glucose analogs such as D-mannitol, L-glucose and 2-deoxy-D- glucose had no 
effect.  A similar stimulatory action of high glucose was also observed in our 
kidney explant system. Additionally, high glucose ambience increases ROS 
generation in MK4 cells, and this was blocked by ROS inhibitors, not by NF-kB 
inhibitors. These data are consistent with our previous observation that high glucose 
induces ROS generation in immortalized renal proximal tubular cells [42;43]. In 
order to confirm that ROS directly regulate Pax-2 gene expression, we examined the 
effect of the xanthine oxidase (XO) system.  Indeed, superoxide generated from the 
XO system directly stimulates Pax-2 gene expression in MK4 cells in 
dose-dependent manner; another important source of O2•−, H2O2 at 10-5 M stimulates 
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Pax-2 gene expression modestly; however, in combination with high glucose, the 
H2O2 stimulatory effect is enhanced substantially in E16 kidney explants. 
Brownlee [12;13] has suggested that the underlying mechanisms regarding high 
glucose as an inducer of kidney damage, indicating that excessive ROS generation 
and then subsequent PKC and NF-kB activation are the key elements in tissue injury. 
Other studies have revealed that both p38 MAPK and p44/42 MAPK signaling 
pathways may also be involved in hyperglycemia-induced ROS generation in 
proximal tubular cells [42;43] and mesangial cells [51;52]. To determine whether 
p38 MAPK, p44/42 MAPK and PKC signaling is involved in mediating the high 
glucose effect on Pax-2 gene expression, inhibitors of these signaling pathways were 
tested. Our data disclosed that SB203580, PD98059 or GFX could not blocked the 
high glucose action on Pax-2 gene expressions at both protein and mRNA levels, 
suggesting that both p38 MAPK, p44/42 MAPK and PKC signaling pathways are 
not involved. In contrast, we observed that the stimulatory effect of high glucose on 
Pax-2 gene expression was blocked in the presence of DPI, rotenone and PDTC in 
both in vitro and ex vivo studies, indicating that high glucose on Pax-2 gene 
expression is mediated, at least in part, via ROS generation and activation of the 
NF-kB signaling pathway.  
 NF-kB is one of the major intracellular targets of hyperglycemia [13;35]. It is 
present in the cytoplasm as an inactive heterodimer, consisting of the p50 and p65 
subunits complexed with IkB and it is activated through a common pathway, which 
involves the phosphorylation-induced proteasome-mediated degradation of the 
inhibitory subunit, IkB. Upon stimulation, a serine kinase cascade is activated 
leading to the phosphorylation of IkB and dissociating from the NF-κB heterodimer. 
This event primes IkB as a substrate for ubiquitination and subsequent degradation 
in the cytoplasm. The NF-kB heterodimer is then translocated to the nucleus and 
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regulates the expression of a large number of genes including growth factors (e.g., 
vascular endothelial growth factor (VEGF)), pro-inflammatory cytokines 
(e.g.,TNF-α and IL-1β), RAGE, adhesion molecules (e.g., vascular cell adhesion 
molecule-1) [34;35]. The enzyme that phosphorylates IκB is IκB kinase (IKK), a 
heterotrimeric complex consisting of two catalytic subunits, IKKα (also called IKK1) 
and IKKβ (also called IKK2), and a regulatory subunit, IKKγ [53;54].  In order to 
further understand the underlying mechanisms of the NF-kB pathway involved in 
high glucose induced Pax-2 gene expression, we tested DN IκBα which can bind the 
p50 and p65 subunits complexed in an inactive form, preventing p50 and p65 from 
translocating to the nucleus. Our data in MK4 cells demonstrate that high glucose 
stimulates Pax-2 promoter activity at a transcriptional level, which may be blocked 
by both ROS and NF-kB inhibitors. After cotransfection with DN IκBα, Pax-2 
promoter activity induced by high glucose is abolished, suggesting that NF-κB is 
involved in glucose-induced stimulation of Pax-2 transcription. Using the sequence 
searching software AliBaba2.1 (www.gene-regulation.com), we have now identified 
several NF-κB binding motifs including 6 of GGrmwkyCCC and 2 of 
GGGGmyTyy located in a full length of 5’-promoter region of Pax-2 (AF515729). 
Additional studies are ongoing to address the underlying molecular mechanisms.  
 Taken together, these data demonstrate that the stimulatory effect of high 
glucose on Pax-2 gene expression is mediated, at least in part, via ROS generation 
and activation of the NF-κB signaling pathway, but not via the PKC, p38MAPK and 
p44/42 MAPK signaling pathways. This indicates that modifying these pathways 
might be important in further understanding diabetic embryopathy. 
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7.8 Legends and Figures 
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Figure 7-1 High glucose dose-dependent effect. High D(+) glucose up-regulates 
Pax-2 gene expression in a dose-dependent manner in MK4 cells analyzed by 
RT-PCR (A) and Western blot (B). After synchronized with serum free medium 
overnight, the quiescent cells were incubated in DMEM with 1% dFBS containing 
final glucose concentration from 5mM to 25mM for 24 hours, whereas D-mannitol 
was supplemented to maintain constant isotonicity or osmolality; (C) Relative 
densities of Pax-2 were normalized to ß-actin. The normalized Pax-2 level in cells 
incubated in 5 mM glucose was considered to be the control (100%).  Each point 
represents the mean ± SD of 3 independent experiments. *, P 0.05; **, P 0.01; 
***, P 0.005.  
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Figure 7-2 High glucose specifical effect. Pax-2 gene expression is specifically 
stimulated by high D(+) glucose (25mM), not by other glucose analogs such as 
L-Glucose, D(+)-Mannitol or 2-Deoxy-D-Glucose in MK4 cells analyzed by 
RT-PCR (A) and Western blot (B). The quiescent cells were incubated in DMEM 
with 1% dFBS containing different glucose analogs in 25mM as final concentration 
for 24 hours; (C) The relative densities of Pax-2 were normalized to ß-actin. The 
normalized Pax-2 level in cells incubated in 5 mM glucose was considered the 
control (100%).  Each point represents the mean ± SD of 3 independent 
experiments. *, P 0.05; **, P 0.01; ***, P 0.005.  
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Figure 7-3 Pax-2 immunofluorescence staining. High glucose up-regulatPax-2 
expression in MK4 cells as shown by immunofluorescence staining (A) (original 
magnification x 400). Quiescent cells were incubated in either 5 mM or 25mM 
D-glucose DMEM containing 1% dFBS for 24 hours; (C) The normalized Pax-2 
level in cells incubated in 5 mM glucose was considered the control (100%). Each 
point represents the mean ± SD of three independent experiments. *, P 0.05; **, P 
0.01; ***, P 0.005. 
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Figure 7-4 p38 MAPK, p44/42 MAPK, and PKC inhibitor effect. Effect of 
SB203580, PD98059 and GFX on Pax-2 gene expression stimulated by high glucose 
in MK4 cells as analyzed by RT-PCR (A) and western blot (B); Quiescent cells 
were incubated in either 5 mM or 25mM D-glucose DMEM containing 1% dFBS 
for 24 hours with or without inhibitors; (C) The relative densities of the Pax-2 were 
normalized to the ß-actin. The normalized Pax-2 level in cells incubated in 5 mM 
glucose was considered as the control (100%).  Each point represents the mean ± 
SD of 3 independent experiments. *, P 0.05; **, P 0.01; ***, P 0.005.  
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Figure 7-5 High glucose induced ROS on pax-2 gene expression. High glucose 
time dependently stimulates ROS generation in MK4 cells (A), that is blocked by 
ROS inhibitors, but not NF-kB inhibitors (B) analyzed by lucigenin assay. Moreover, 
superoxide generated from xanthine oxidase (XO) system (Figure 5C) directly 
stimulates Pax-2 gene expression in MK4 cells in a dose-dependent manner, shown 
here as  analyzed by real-time PCR (Figure 5D) and western blot (Figure 5E); (A) 
Quiescent cells were incubated in either 5 mM glucose DMEM or 25 mM 
containing 1% dFBS for periods of 15 mins to 2 hours, then trypsinized and assayed. 
The final value of ROS generation was normalized by the protein concentration of 
sample. At the 15-min incubation point, basal ROS generation was, RLU/ug/ul : 
1817 ± 84.35 vs 2250.85 ± 90.40 in 5mM and 25 mM glucose medium, respectively; 
(B) Quiescent cells were incubated in either 5 mM glucose DMEM or 25 mM 
containing 1% dFBS with or with inhibitors for periods of 30 min, then trypsinized 
and assayed. The normalized ROS generation in cells incubated in 5 mM glucose 
was considered the control (100%); (C) superoxide generated from the xanthine 
oxidase (XO) system was detected by lucigenin assay; (D+E) Quiescent cells were 
incubated in 5 mM glucose DMEM containing 1% dFBS with or with XO system 
for 24 hours. Each point represents the mean ± SD of three independent experiments. 
*, P 0.05; **, P 0.01; ***, P 0.005. 
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Figure 7-6 Inhibitory effect of ROS and NF-kB inhibitors. The inhibitory effect 
of PDTC, DPI and rotenone on Pax-2 gene expression upregulated by high glucose 
in MK4 cells analyzed by RT-PCR (A) and Western Blot (B); Quiescent cells were 
incubated in either 5 mM or 25mM D-glucose DMEM containing 1% dFBS for 24 
hours with or without inhibitors; (C) The relative densities of Pax-2 were compared 
with ß-actin. The normalized Pax-2 level in cells incubated in 5 mM glucose was 
considered the control (100%).  Each point represents the mean ± SD of 3 
independent experiments. *, P 0.05; **, P 0.01; ***, P 0.005. 
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Figure 7-7 High glucose effect on Pax-2 gene expression ex vivo. Ex vivo study. 
Kidney explant isolated from Hoxb7-GFP mice on embryonic day 16 (A); The 
inhibitory effect of DPI and rotenone on Pax-2 gene expression was upregulated by 
high glucose in renal explant analyzed by RT-PCR (B) and Western Blot (C), 
respectively; (D) The relative densities of Pax-2 were compared with ß-actin. The 
normalized Pax-2 level in cells incubated in 5 mM glucose was considered the 
control (100%); H2O2 effect on Pax-2 gene expression analyzed by qRT-PCR (E) 
and Western blot (F), respectively.  Each point represents the mean ± SD of 3 
independent experiments. *, P 0.05; **, P 0.01; ***, P 0.005. 
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Figure 7-8 High glucose effect on the full length of 5’-franking region of Pax-2 
promoter activity in MK4 cells. High glucose effect on the full length of 
5’-franking region of Pax-2 promoter activity in MK4 cells. MK4 cells grown in 
12-well plates were transiently transfected with 1.5 μg of pGL-2/hPax-2 plasmid by 
Lipofectamine 2000, with pGL-2 basic vector serving as control (A); DN IKBa 
effect on high glucose induced Pax-2 promoter activity. MK4 cells were transiently 
co-transfected with 1.5 μg of each pGL-2/hPax-2 and pcDNA3.1/DNIKBa plasmid 
by Lipofectamine 2000, while pcDNA3.1 plasmid serving as the control (B).  
Promoter activity was measured by luciferase assay kit with renilla luciferase as an 
internal control after 24 hours stimulation by high glucose with or without inhibitors. 
The final value of Pax-2 promoter activity was normalized by the protein 
concentration of sample. Normalized Pax-2 promoter activity in cells incubated in 5 
mM glucose was considered the control (100%). Each point represents the mean ± 
SD of 3 independent experiments. *, P 0.05; **, P 0.01; ***, P 0.005. 
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8.1 Abstract 
Renal malformations are a major cause of childhood renal failure. During the 
development of the kidney, ureteric bud (UB) branching morphogenesis is critical 
for normal nephrogenesis. In the present studies, we investigated whether renal UB 
branching morphogenesis is altered by a high ambient glucose environment and 
studied underlying mechanism(s). Kidney explants isolated from different periods of 
gestation (E12 to E18) from Hoxb7- green fluorescent protein (GFP) mice were 
cultured for 24 hours in either normal D-glucose (5mM) or high D-glucose (25mM) 
medium with or without various inhibitors. Alterations in renal morphogenesis were 
assessed by fluorescence microscopy.  Paired-homeobox 2 (Pax-2) gene expression 
was determined by real time-quantitative polymerase chain reaction (RT-qPCR), 
western blotting and immunohistology. Our results revealed that high D-glucose 
(25mM) specifically stimulates UB branching morphogenesis via Pax-2 gene 
expression, while other glucose analogs such as D-mannitol, L-glucose or 
2-Deoxy-D-glucose had no effect. The stimulatory effect of high glucose on UB 
branching was blocked in the presence of catalase and inhibitors of  NADPH 
oxidase, mitochondrial electron transport chain complex I, and Akt signaling. 
Moreover, in in vivo studies, it appears that high glucose induces, via Pax-2 (mainly 
localized in UB), acceleration of UB branching but not nephron formation. Taken 
together, our data demonstrate that high glucose alters ureteric bud branching 
morphogenesis.  This occurs, at least in part, via ROS generation, activation of Akt 
signaling, and upregulation of Pax-2 gene expression. 
 
8.2 Introduction 
Maternal diabetes mellitus (DM) constitutes a major risk factor for congenital 
malformations in the offspring. When the fetus is exposed to sustained levels of high 
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ambient glucose, widespread fetal damage may develop, affecting multiple systems, 
including cardiovascular, nervous, skeletal and urogenital systems-- a condition 
called diabetic embryopathy.1;2 Infants born to women with pre-gestational diabetes 
have a 10-fold risk of congenital malformations, and those born to women with 
gestational diabetes have a 5-fold relative risk of congenital malformations. Both the 
diabetic mother and her fetus are at risk for significant morbidity and mortality, even 
in the 21st Century.3;4 Of those congenital malformations seen in offspring of 
pre-gestational maternal diabetes, renal malformations such as renal agenesis and 
congenital abnormalities of kidney and urinary tract (CAKUT) are most prevalent.5  
Renal morphogenesis involves complex events in which many genes interact to 
coordinate the formation of the final kidney. Abnormalities occur when the normal 
pattern of nephrogenesis is interrupted. In humans, the fetal kidneys begin to 
develop at 5 weeks gestation; renal glomeruli, at 8-9 weeks; and tubular function, 
after the 14th week. The full complement of nephrons (between 200,000 and well 
over 1 million) has formed by approximately 36 weeks of gestation; no further 
nephrons are formed after this time. 6;7 However, rodents, which have a gestation 
period in the range of 19-21-days, continue nephrogenesis postnatally-- until ~10 
days after birth. DM constitutes an adverse in utero environment that may impair 
nephrogenesis in both human and experimental animal models, resulting in renal 
agenesis, dysplasia or aplasia and hypoplasia.8-11 We have initiated investigations 
concerning the interaction between high glucose and paired-homeobox 2 (Pax-2) 
gene expression in renal development. As a “kidney-specific” master gene, Pax-2 is 
expressed in both UB and metanephric mesenchyme (MM) lineages, normally 
optimizing UB branching and mesenchymal-to-epithelial transformation in kidney 
development. 12-14 Mutations in the Pax-2 gene cause increased apoptosis, 15-17 
associated with renal hypoplasia. 15;18;19  We recently reported that high D(+) 
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glucose (25mM), as compared to normal glucose (5mM), specifically induced Pax-2 
gene expression in both in vitro (mouse metanephric mesenchymal cells (MK4) and 
ex vivo (kidney explant from Hoxb7-GFP (green fluorescent protein) mice) 
models.20;21 High glucose-induced Pax-2 gene expression is mediated, at least in part, 
via reactive oxygen species (ROS) generation and activation of the NF-kB signaling 
pathway, but not via protein kinase C (PKC), p38 mitogen activated protein kinase 
(MAPK) and p44/42 MAPK signaling. 22 
The present work is designed to demonstrate the influence of a high glucose 
milieu on UB branching morphogenesis and its underlying mechanism(s) using real 
time in an ex vivo model. Additional in vivo studies that complement the ex vivo studies 
are also included. Our results indicate that high glucose stimulates UB branching via 
ROS generation and Pax-2 gene expression. We conclude that the stimulatory effect 
of high glucose is mediated, at least to some extent, via activation of NADPH 
oxidase and mitochondrial oxidative metabolism and stimulation of Akt signaling 
pathway.   
 
8.3 Results 
High D-Glucose Stimulates UB Branching in Time-Dependent Manner 
Kidney explants isolated from timed-pregnant mice at E13 were cultured either 
in normal (5 mM) D-glucose DMEM plus 20 mM D-mannitol (left kidney) or high 
(25mM) D-Glucose DMEM (right kidney) supplemented with 1% dFBS up to 96 
hours with fresh medium changed every 24 hours. As seen in fluorescent 
microscopic sequential images, as comparing to 5 mM Glucose (Figure 1A (A2-A6) 
and 1B (B2-B6)), 25 mM D-Glucose (Figure 1C (C2-C6) and 1D (D2-D6)) 
stimulates UB branching morphogenesis in time-dependent manner. Since a 
stimulatory effect of high glucose is present after 24 hours of incubation, we used 24 
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hours of stimulation for subsequent studies. By carefully measuring the diameter of 
metanephroi cultured from 0 to 96 hours (Figure 1E), we have found that high 
glucose reduced the size of metanephroi in a time-dependent manner. 
 
High D-Glucose Specificity on UB Branching Morphogenesis  
E13-kidney explants were incubated in media containing 1% dFBS and 25 mM 
different glucose analogues such as D-Mannitol, L-glucose, 2-Deoxy-D-glucose or 
D-glucose. After incubation for 24hours, high D-glucose (Figure 2A-a) specifically 
stimulates UB branching morphogenesis by fluorescent microscopy, while other 
glucose analogs such as D-Mannitol (Figure 2A-b), L-glucose (Figure 2A-c) or 
2-Deoxy-D-glucose (Figure 2A-d) had no effect. Moreover, high D-glucose 
stimulates UB branching in a dose-dependent manner (Figure 2B). To maintain 
constant isotonicity or osmolality, 5-mM glucose media was supplemented with 
D-mannitol (20 mM final concentration) in additional studies. High glucose 
stimulated a greater than 2-fold increase of UB tip numbers as compared to normal 
glucose (Figure 3A+B). This increase in UB branching is induced by high 
D-glucose (25mM), but not by other glucose analogs.  
 
High Glucose Stimulated Pax-2 Gene Expression 
 High glucose increased Pax-2 gene and protein expression-- mRNA (RT-qPCR, 
Figure 4A) and protein (Western Blot, Figure 4B)-- as compared to normal glucose 
in E18-kidney explants. Immunohistological staining indicated that the upregulation 
of Pax-2 is localized mainly to the UB (Figure 4C). These data indicate that high 
glucose stimulation of UB branching morphogenesis is mediated via Pax-2 gene 
expression. 
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Inhibitors of NADPH Oxidase and Mitochondrial Electron Transport Chain 
Complex I Block the Stimulatory Effect of High Glucose on  Pax-2 Gene 
Expression and UB Branching ex vivo 
 It is apparent that inhibitors of NADPH oxidase (DPI, 10-6 M) and 
mitochondrial electron transport chain complex I (rotenone, 10-6 M) block the 
stimulatory action of high glucose on Pax-2 expression (Figure 5) and UB branching 
morphogenesis (Figure 6) in E14-kidney explants. These data indicate that the 
stimulatory effect of high glucose is mediated, at least in part, via NADPH oxidase 
activation and ROS generation,  
 
High Glucose-induced ROS Generation on UB Branching and Pax-2 Gene 
Expression 
 We have previously reported that H2O2 modestly increases Pax-2 gene 
expression. However, this stimulatory effect of H2O2 was significantly enhanced in 
the presence of high glucose in E16-kidney explants. 22 The question has been raised 
about whether H2O2 also directly modulates UB branching. Indeed, exogenous H2O2 
at 10-5 M could trigger UB branching morphogenesis, particularly in the presence of 
high glucose in E13-kidney explants (Figure 7 A-E). Our data also indicate that high 
glucose activates the total ROS generation in E18 Kidney explants (Figure 7F). 
Moreover, high glucose induced UB branching in E12-kidney explants could be 
partially blocked by catalase (250 U) and completely abolished by Akt Inhibitor IV 
(a cell-permeable benzimidazole compound that inhibits Akt 
phosphorylation/activation by targeting the ATP binding site of a kinase upstream of 
Akt, but downstream of PI3K) at concentration of 10-6 M (Figure 8). Similar results 
were also found in Pax-2 mRNA and protein expression (Figure 9). These data 
indicate that high glucose evokes ROS generation and upregulates Pax-2 gene 
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expression via Akt signaling, and subsequently stimulates UB branching 
morphogenesis. 
 
The Effect of Gestational Diabetes on Offspring Neonatal Kidney 
We have employed STZ to induce gestational diabetes in the pregnant mother at 
E13.23-29 Figure 10A shows our experimental protocol in detail. As may be seen the 
newborn offspring of STZ-diabetic dams remained significantly smaller and lighter 
(average 20% less body weight (g)) as compared to offspring of control dams 
[Figure 10B (control vs STZ (g): 1.414 ± 0.11 vs 1.03 ± 0.07)]. Most impressively, 
kidneys of the diabetic offspring were significantly smaller and growth retarded as 
compared to the kidneys of control offspring (Figure 10C). 
 
Pax-2 Expression in Neonatal Kidney in Vivo  
We have evaluated the Pax-2 gene expression analyzed by immunohistological 
staining (Figure 11A and B), qRT-PCR (Figure 11C) and western blot (Figure 11D) 
in neonatal kidney of both control and diabetic dams.  Our data indicated that 
maternal hyperglycemia via Pax-2 (mainly localized in UB) appears to accelerate 
UB branching but not nephron formation in neonatal kidney of diabetic dams.  
 
8.4 Discussion 
In the present study, we observed that high glucose alters UB branching 
morphogenesis via Pax2 gene expression. The high glucose effect appears to be 
mediated, at least in part, via ROS generation and activation of the PI3K-AKT 
pathway.  
Maternal diabetes creates a high-risk intrauterine environment that has been 
directly linked to the development of congenital renal abnormalities, including 
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caudal regression syndrome, which is highly associated with renal agenesis and 
abnormalities of the kidney and urinary tract.8-11 These anomalies have been noted 
as either isolated events or as part of multiple malformation syndromes that are more 
common in offspring of maternal diabetes. The incidence appears to be proportional 
to the degree of maternal hyperglycemia.  For example, in the human, a high 
glucose ambient environment throughout pregnancy (pregestational diabetes) is 
present prior to embryonic development, which may result in a fetus with markedly 
teratogenic features that may include the caudal regression syndrome. In 
experimental animal, Hoxb7-GFP mice in our hand, if the pregnant dams are 
exposed to STZ before the budding process, in which the wolffian duct becomes UB, 
the dams are barely able to deliver. We have observed the same consequences- 
teratogenic embryos including caudal regression syndrome with renal agenesis 
under those conditions. Based on the timing found in the literature 26;27 and our own 
experiences, we induced gestational diabetes by STZ injection at E13, and we have 
successfully managed to obtain small litters of offspring from diabetic dams. Since 
the budding process is already completed prior to E13, from day E13 to birth, it 
seems likely that the high glucose ambient environment may impair the 
nephrogenesis. 
To date, most human and experimental studies on gestational diabetes have 
focused on the phenotype, but only in a few instances, on the mechanism(s). Most 
maternal diabetes-related kidney explant studies, however,  based on long culture 
time (average 4 to 6 days) revealed that hyperglycemia dose-dependently reduces 
the size of the metanephros, UB branching dymorphogenesis and the population of 
nascent nephrons.26;27;30 This observation has been questioned, since the ideal 
observation time of the recognized architectural “pattern” of UB tree is between 
18-48 hours.31 In the current project, studies were designed to resolve potential 
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ambiguities arising from specific protocols or to examine UB morphogenesis under 
conditions that allow direct comparison to previous studies. 32;33 
In order to understand the effect of high glucose per se on renal UB 
development and its underlying molecular mechanisms, we used Hoxb7-GFP-Tg 
mice 20;21 as a model with which we would be able to monitor UB branching under 
normal or high glucose condition ex vivo. By employing sequential images, we have 
observed that E13-kidney explant cultured in high D(+) glucose (25mM) condition 
display more UB branching as compared to normal glucose medium (5 mM). A 
stimulatory effect was obvious at 24 hours post-exposure. Moreover, high D(+) 
glucose specifically triggers UB branching morphogenesis and increased UB tip 
numbers in a dose-dependent manner,  while other glucose analogs such as 
D-mannitol, L-glucose and 2-deoxy-D- glucose had no effect.  We previously 
reported that high glucose specifically induces Pax-2 gene expression via ROS 
generation in E16 kidney explants from Hoxb7-GFP mice. 22 In the current study, 
we have observed that high glucose elevated total ROS generation and triggered UB 
branching morphogenesis. It appears that the stimulatory effect of high glucose 
could be blocked by ROS inhibitors such as DPI and rotenone. Although the Pax-2 
gene is expressed in both UB and MM lineages,12;34-39 our immunohistological 
staining data have clearly revealed that the greatest upregulation of Pax-2 by high 
glucose is in the area of the UB. Meanwhile, in order to clarify the direct functional 
impact of ROS on UB branching morphogenesis, we have also tested H2O2, an 
important source of superoxide (O2•−), and observed that exogenous H2O2 at 10-5 M 
stimulates UB branching morphogenesis; however, in combination with high 
glucose, the H2O2 stimulatory effect is enhanced substantially, the similar response 
pattern as Pax-2 gene expression. 22 Taken together, our data suggest that high 
glucose induced ROS generation has a functional impact on UB lineage ex vivo. 
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Evidence indicates that the high glucose-ROS-PI3K/Akt-NF-κB pathway 
appears to be a major signaling pathway that almost covers all major renal cell 
types.40-45 This scenario has been postulated as that by which high glucose leads to 
kidney damage.40-45  Indeed, a study 46 suggests that down-regulation of Pax-2 
expression correlates with a decreased Akt phosphorylation and an enhanced 
sensitivity to renal endothelial cell apoptosis both in vivo and in vitro, suggesting 
that Pax-2 promotes angiogenesis, likely via survival, proliferation, invasion, and 
cell organization via the PI3K/Akt-dependent pathway. Thus, we hypothesize that 
the pathway, high glucoseÆROSÆAktÆNF-κBÆPax-2 is involved in impairment 
in the UB lineage induced by high glucose. Indeed, our data suggest that high 
glucose action on UB branching morphogenesis as well as on Pax-2 gene expression 
could be completely abolished by Akt inhibitors, but partially blocked by catalase. 
The reason for this partial blocking effect may be due to the fact that catalase could 
only convert H2O2 into H2O, but has no effect on other species such peroxynitrites, 
hydroxyl radicals, etc. Indeed, more studies are needed to elucidate the action of 
other ROS.  
We used STZ to induce gestational diabetes in an in vivo model to generate a 
high ambient glucose environment during pregnancy. We observed that this 
impaired UB branching morphogenesis in E13 pregnant Hoxb7-GFP mice. This in 
vivo strategy avoids the limitations imposed by using ex vivo studies. Our data 
indicate that the body weight (in grams) of neonate offspring from diabetic mother 
remained significantly lower and smaller (average 20% less) than control animals. 
Renal morphology revealed that kidneys of diabetic offspring showed growth 
retardation. However, it appears that high glucose via Pax-2 (mainly localized in UB) 
could accelerate UB branching but not nephron formation, but at the same time, high 
glucose also triggers cell apoptosis in both UB and nephron, which we believe is the 
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major mechanism by which renal function is ultimately affected in diabetic offspring 
over time (our long time follow-up study). 
In summary, our data demonstrate that high glucose alters UB branching 
morphogenesis via Pax-2 gene and protein expression. The stimulatory effect of 
high glucose appears to be mediated via ROS generation and activation of the Akt 
signaling pathway.  
 
8.5 Concise methods 
Reagents  
Normal glucose medium (5 mM D-glucose Dulbecco’s modified Eagle’s 
medium (DMEM; Cat. #12320)) was purchased from Invitrogen Inc. (Burlington, 
Ontario, Canada). D(+)-Glucose, L-glucose, D-mannitol, 2-deoxy-d-glucose, 
diphenylene iodinium (DPI), rotenone, H2O2, catalase and 
5-(2-Benzothiazolyl)-3-ethyl-2-[2-(methylphenylamino)ethenyl]-1-phenyl-1H-benzi
midazolium iodide (Akt Inhibitor IV), were purchased from Sigma-Aldrich Canada 
Ltd. (Oakville, ON, Canada). Mouse anti-β-actin monoclonal antibody (clone 
AC-15) and rabbit polyclonal anti-Pax-2 antibody were purchased from 
Sigma-Aldrich Canada Ltd. (Oakville, ON, Canada) and Covance (Richmond, CA, 
USA), respectively.  
Animals 
We used the murine Hoxb7-GFP model 20;21 [obtained from Dr. Frank Costantini 
(Department of Genetics and Development, Columbia University Medical Center, 
NY, NY, USA) ], which is useful for studying alterations in UB branching 
morphogenesis, as the GFP permits direct observation of the branching process.  
This is especially useful for studying adverse in utero development as in diabetic 
mellitus. Hoxb7-GFP mice express GFP driven by the Hoxb7 promoter throughout 
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the Wolffian duct (WD) and UB epithelium but not in the surrounding MM or its 
epithelial derivatives, allowing UB branching morphogenesis to be visualized in real 
time during growth of the kidney, either in organ culture or in fixed tissue.20;21  We 
used these features for the direct study of UB branching morphogenesis pattern under 
non-diabetic and diabetic conditions ex vivo. 
Animal care in these experiments met the standards set forth by the Canadian 
Council on Animal Care, and the procedures utilized were approved by Institutional 
Animal Care Committee of the CHUM. Hoxb7-GFP mice were housed under 
standard humidity and lighting conditions (12 hour light-dark cycles), and were 
allowed free access to standard mouse chow and water ad libitum. Timed-pregnant 
mice aged 8-10 weeks were used in all experiments. Vaginal wet mounts were made 
to determine the estrous cycles of the mice. On the evening before estrus, female 
mice were housed overnight with male mice; the presence of spermatozoa in a 
vaginal smear the next morning was defined as day 1 of pregnancy.  
 
Metanephric Organ Culture 
Embryos (E12 to E18) were dissected aseptically from timed-pregnant mice, and 
the metanephroi were isolated under sterile conditions.22 GFP-positive metanephroi 
were photographed immediately after isolation (time 0) and were individually 
cultured either in 1 ml of normal glucose (5mM glucose) or high glucose (25mM 
glucose) DMEM supplied with 1% dFBS, 100 U/ml of penicillin and 100 µg/ml of 
streptomycin in 95% air and 5% CO2 at 37ºC in separate wells of a 24-well plate for 
different time periods, depending on the experiment. For example, we constantly 
monitored and recorded every 8 hours the sequential images of UB branching in 
metanephroi cultured either in normal glucose or high glucose DMEM supplied with 
1% dFBS condition up to 96 hours with fresh medium changed every 24 hours. 
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Based on initial results a 24-hour incubation period was subsequently used for the 
rest of our experiments. The surface area of cultured metanephroi either in 5mM or 
25mM glucose DMEM from time 0 to time 96 hours was measured by QCapture 
Pro 5.1 image analysis program provided in Olympus 1X71 Microscope (CARSEN, 
ON, CA). 
To address the variability in embryonic kidney size and in UB branching 
patterns among conceptuses, the effect of different treatments on UB branching was 
studied in  kidneys  from the same fetus; for example, the left kidney was 
incubated with normal glucose and the right kidney, with high D-glucose or 
L-glucose; or the left kidney was incubated with high D-Glucose and right kidney, 
with high D-Glucose in the presence or absence of DPI (10-6 M), rotenone (10-6 M), 
catalase (250 U) and Akt inhibitor (10-6 M).    
 Sequential images of branching UB were recorded with a Olympus 1X71 
Microscope (CARSEN, ON, CA). Quantitative assessment of UB branching in each 
treatment group was performed by manually counting the number of UB tips at time 
0 and at 24 hours.  
Western Blotting  
 
Western blots were performed as in previous studies. 22;47;48 Briefly, small 
aliquots (20-50 μl) of homogenized kidney explant sample were subjected to 10% 
SDS-PAGE and then transferred onto a PVDF membrane (Hybond-P, Amersham 
Pharmacia Biotech, Canada). The membrane was first blotted for anti-Pax-2 and 
then re-blotted for β-actin. The relative densities of the Pax-2 vs β-actin bands 
were measured by computerized laser densitometry.  
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Real-Time -Quantitative Polymerase Chain Reaction (RT-qPCR) 
RT-qPCR was performed as reported previously. 22;47 In brief, first-strand cDNA 
was produced from 2 g of random hexamer primed total RNA using Super　 -Script 
preamplification system (Invitrogen). Relative quantitation by real-time PCR was 
carried out using iQTM SYBR@ Green Supermix Kit (Bio-Rad Laboratories, 
Mississauga, ON, Canada) and MiniOpticonTM Real-Time PCR  Detection System 
(Bio-Rad), following the protocol described by the supplier. PCR reactions in 
triplicate underwent 40 cycles of 95 oC for 20 s, 60 oC for 20 s, 72 oC for 20 s, and 
79 oC for 5 s in the thermal cycler. The parameter CT (threshold cycle) value was 
measured to determine starting copy number of target genes using the standard 
curve. Lower value of CT indicates a higher amount of PCR products.  We 
employed the following forward and reverse primers: forward primer 5' 
ACATCAAATCAGAACAGGGGAAC 3', and the reverse primer 5' 
CATGTCACGACCAGTCACAAC 3'; these correspond to the nucleotide sequences 
N+1319 to N+1341 and N+1453 to N+1473 of Pax-2 cDNA (NM_003990). For 
internal control, we deployed primers specific for mouse β-actin (forward and 
reverse primers 5' CGTGCGTGACATCAAAGAGAA 3' and 5' 
GCTCGTTGCCAATAGTGATGA 3', corresponding to nucleotide sequences 
N+704 to N+724 and N+820 to N+840 of mouse β-actin cDNA (NM_007393)). 47   
 
Immunohistochemistry 
Kidney explants were fixed in 4% paraformaldehyde in phosphate-buffered 
saline (PBS) (Fisher Scientific, Nepean, ON, Canada) after 24 hours in culture and 
then paraffin-embedded. Kidney sections of 5 µm were deparaffinized in xylene and 
rehydrated. Immunohistochemical examination was performed by the standard 
avidin–biotin–peroxidase complex method (ABC Staining System, Santa Cruz 
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Biotechnologies, Santa Cruz, CA, USA). Endogenous peroxidase was inhibited in 
1% hydrogen peroxide–methanol for 10 min at room temperature and followed by 
trypsin treatment for 10 min in a moist chamber at 37°C. After serum blocking, the 
sections were incubated with primary anti-Pax-2 polyclonal antibody diluted 1:100 
overnight at 4°C humidity chamber; then, biotinylated secondary antibody was 
added, followed by the addition of preformed ABC reagents supplied by the ABC 
kit. The Pax-2 protein was visualized by color development with 3, 
3'-diaminobenzidine tetrahydrochloride. All sections were counterstained with 
hematoxylin, dehydrated, and covered with glass coverslips.  
 
ROS Generation 
ROS production was monitored by the lucigenin method with minor 
modifications. 22;49;50 ROS generated in E18 kidney explant were normalized with 
protein concentration and expressed as relative light units (RLU) per mg protein. 
 
In vivo Study 
We induced gestational diabetes in pregnant Hoxb7-GFP mice with an 
intraperitoneal injection of streptozotocin (STZ,150 mg/kg body weight (BW)) at 
E13.23-29 Maternal glucose concentration (mM) was carefully monitored by 
Accu-Chek Compact Plus Blood Glucose Meter (Roche Diagnostics, Laval, QC, 
Canada) (Figure 10 A). Newborn birth weight (BW) was carefully recorded, as 
shown in Figure 10B. Hematoxylin/eosin (H/E) staining was used to review renal 
morphology, whereas Dolichos Biflorus Agglutinin-FITC (DBA-FITC, Vector 
Laboratories) staining for UB identification 15 in 5 µm of paraformaldehyde 
(4%)-fixed-paraffin-embedded kidney sections under a light microscope (Figure 
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10C). Pax-2 expression was analyzed by immunohistological staining, qRT-PCR 
and western blot as mentioned above (Figure 11). 
Statistical Analysis 
Statistical significance between experimental groups was analyzed initially by 
Student’s t test or by 1-way ANOVA followed by the Bonferroni test as appropriate.  
Three to four separate experiments were performed for each protocol. Data are 
expressed as means ± SD.  A probability level of P  0.05 was considered 
statistically significant.  
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ABBREVIATIONS: CAKUT, congenital abnormality of kidney and urinary tract; 
DMEM, Dulbecco’s modified Eagle’s medium; dFBS, depleted fetal bovine serum; 
DPI, diphenylene iodinium, an inhibitor of NADPH oxidase; FBS, fetal bovine 
serum; GFP, green florescent protein; MAPK, mitogen activated protein kinase; 
MK4, mouse late embryonic mesenchymal epithelial cells; MM, metanephric 
mesenchyme; NF-kB, nuclear factor kappa B; Pax, paired homeobox gene; PKC, 
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protein kinase C; PI3K, phosphatidylinositol 3-kinase; ROS, reactive oxygen species; 
UB, ureteric bud; WD, Wolffian duct. 
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8.8 Legends and Figures 
 
 
 
 
Figure 8-1 High D-Glucose Stimulates UB Branching in Time-Dependent 
Manner. Kidney explants isolated from time-pregnant mice at E13 stage were 
cultured either in normal (5mM) D-glucose DMEM (left kidney) or high (25mM) 
D-Glucose DMEM (right kidney) supplied with 1% dFBS up to 96 hours with fresh 
medium changed every 24 hours. The UB branching morphogenesis sequential 
images were recorded by fluorescent microscope.  A(1-6) (2X magnification) and 
B (1-6) (10 magnification)  representative the kidney explant were cultured in 
5mM Glucose supplemented with 20 mM D-mannitol DMEM to maintain constant 
isotonicity or osmolality, whereas C (1-6) (2X magnification) and D (1-6) (10 
magnification) in 25mM Glucose DMEM. The sequential images were recorded by 
every 24 hours. E shows that high ambient glucose reduced the surface area of 
cultured metanephroi in a time-dependent manner. 
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Figure 8-2   High D-Glucose on UB Branching Morphogenesis. Figure 2A 
shows the specificity of the effect of glucose analogs on UB branching. E13 kidney 
explants were incubated in media containing 1% dFBS and 25 mM different glucose 
analogues such as D-Glucose (a), D-Mannitol (b), L-glucose (c) or 
2-Deoxy-D-Glucose (d) for 24 hours. The images were recorded by fluorescent 
microscope (2X and 10X magnification); Figure 2B shows the D-glucose 
dose-dependent effect on UB branching from 5mM to 30mM in E13 kidney explant 
(2X magnification). 
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Figure 8-3 High D-Glucose stimulates UB Branching Morphogenesis. (A) 
E13 kidney explants were incubated either in 5mM glucose (left kidney) or 25 mM 
glucose DMEM (right kidney) containing 1% dFBS for 24 hours. The images were 
recorded by fluorescent microscope (2X, 4X and 10X magnifications). (B) 
Quantification of UB numbers. Kidney explants incubated in 5 mM glucose were 
considered the control (100%). Each point represents the mean ± SD of three 
independent experiments. *, P 0.05; **, P 0.01; ***, P 0.005. 
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Figure 8-4  High glucose up-regulates Pax-2 expression in E18 kidney explant 
analyzed by (A) RT-qPCR; (B) western blot; and (C) immunohistological staining 
(20X and 32X magnification). The normalized Pax-2 level in explant incubated in 5 
mM glucose was considered the control (100%). Each point represents the mean ± 
SD of three independent experiments. *, P 0.05; **, P 0.01; ***, P 0.005. 
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Figure 8-5 The inhibitory effect of DPI and rotenone on Pax-2 gene 
expression in E16 kidney explants. E16 kidney explants were cultured in either 5 
mM glucose or 25 mM glucose DMEM with or without DPI (10-6 M) and rotenone 
(10-6 M) for 24 hours. The Pax-2 gene expression was analyzed either by (A) 
RT-qPCR or (B) western blot, respectively. The relative densities of Pax-2 were 
compared with ß-actin. The normalized Pax-2 level in kidney explants incubated in 
5 mM glucose was considered the control (100%); Each point represents the mean ± 
SD of 3 independent experiments. *, P 0.05; **, P 0.01; ***, P 0.005. 
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Figure 8-6 The inhibitory effect of DPI and rotenone on UB branching 
morphogenesis stimulated by high glucose.  E14 kidney explants were incubated 
either in 5mM glucose (A) or 25 mM glucose DMEM (B) in the absent or present of 
DPI (10-6 M) (C) and rotenone (10-6 M) (D) for 24 hours. The images were recorded 
by fluorescent microscope (2X and 10X magnifications). (E) Quantification of UB 
numbers. Kidney explants incubated in 5 mM glucose were considered to be 
controls (100%). Each point represents the mean ± SD of three independent 
experiments. *, P 0.05; **, P 0.01; ***, P 0.005. 
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Figure 8-7   H2O2 effect on UB branching morphogenesis in E13 kidney 
explants. E13 kidney explants were incubated either in 5mM glucose (A and B) or 
25 mM glucose DMEM (C and D) with or without H2O2 (10-5 M) for 24 hours. The 
images were recorded by fluorescent microscope (10X magnifications). (E) 
Quantification of UB numbers. Kidney explants incubated in 5 mM glucose were 
considered as controls (100%). (F) ROS generation was assessed by lucigenin 
method, and the final value of ROS generation was normalized by the protein 
concentration of sample. The normalized ROS generation in cells incubated in 5 
mM glucose was considered as the control (100%). Each point represents the mean 
± SD of three independent experiments. *, P 0.05; **, P 0.01; ***, P 0.005. 
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Figure 8-8.  The inhibitory effect of catalase and AKT inhibitor on UB 
branching morphogenesis in E12 kidney explants. E12 kidney explants were 
incubated either in 5mM glucose (A) or 25 mM glucose DMEM (B) in the absent or 
present of Catalase (250 U) (C) and AKT inhibitor (10-6 M) (D) for 24 hours. The 
images were recorded by fluorescent microscope (2X and 10X magnifications). (E) 
Quantification of UB numbers. Kidney explants incubated in 5 mM glucose was 
considered the control (100%). Each point represents the mean ± SD of three 
independent experiments. *, P 0.05; **, P 0.01; ***, P 0.005. 
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Figure 8-9. The inhibitory effect of catalase and AKT inhibitor on Pax-2 gene 
expression in E17 kidney explants. E17 kidney explants were cultured in either 5 
mM glucose or 25 mM glucose DMEM with or without Catalase (250 U) and AKT 
inhibitor (10-6 M) for 24 hours. The Pax-2 gene expression was analyzed either by 
(A) RT-qPCR or (B) western blot, respectively. The relative densities of Pax-2 were 
compared with ß-actin. The normalized Pax-2 level in kidney explants incubated in 
5 mM glucose was considered the control (100%); Each point represents the mean ± 
SD of 3 independent experiments. *, P 0.05; **, P 0.01; ***, P 0.005. 
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Figure 8-10. In vivo studies on the effect of maternal diabetes on the neonatal 
kidney of the offspring. Figure 10 A shows a representative mouse in our 
experimental protocol in detail. Diabetic-STZ newborn offspring remained 
significantly smaller and lighter (average 20% less (g)) as compared to control 
animals, as shown in Figure 10B (control vs STZ (g): 1.414 ± 0.11 vs 1.03 ± 0.07). 
Kidney of diabetic offspring was significantly smaller and growth retarded (H&E 
staining and DBA staining) compared to control (Figure 10C). 
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Figure 8-11. In vivo Pax-2 expression in neonate kidneys. Pax-2 
immunohistological staining in newborn kidney of offspring: Control (A, 2X and 
10X magnification) and STZ (B, 2X and 10X magnification). Pax-2 gene expression 
in neonatal kidney was analyzed by qRT-PCR (C) and western blotting (D). The 
normalized Pax-2 level in control-neonate-kidney was considered as 100%; each 
point represents the mean ± SD of 3 independent experiments. *, P 0.05; **, P 
0.01; ***, P 0.005. 
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9.1 Abstract 
 Maternal diabetes leads to an adverse in utero environment but whether 
maternal diabetes impairs nephrogenesis is unknown. Diabetes was induced with 
streptozotocin in   pregnant diabetic Hoxb7-green fluorescent protein mice   at 
embryonic day 13, and the offspring were euthanized at several time points after 
birth. Compared with offspring of non-diabetic controls, offspring had lower body 
weight, body size and kidney weight, and nephron number.  The observed renal 
dysmorphogenesis may be the result of increased apoptosis, because 
immunohistochemical analysis revealed significantly more apoptotic podocytes, as 
well as increased active caspase-3 immunostaining in the renal tubules compared 
with control mice. Regarding potential mediators of these differences, offspring of 
diabetic mice had increased expression of intrerenal angiotensinogen and renin 
mRNA, upregulation of NF-kB isoforms p50 and p65 and activation of the NF-kB   
pathway. In conclusion, maternal diabetes impairs nephrogenesis, possibly via 
enhanced intrarenal RAS activation and NF-kB signaling.   
 
9.2 Introduction 
Diseases such as maternal diabetes create an adverse in utero environment that 
may impair the process of embryogenesis, thus predisposing infants of low birth 
weight (LBW) to subsequent increased risk of future disease 1-5. The developing 
kidney appears particularly sensitive to a high glucose milieu, exposure to which 
may result in congenital renal malformations, i.e., renal agenesis, dysplasia or 
hypoplasia. 6-9  
Intrauterine growth retardation, defined as birth weight below the 10th percentile 
for gestational age, is associated with a reduction in nephron number. 10 Although 
the so-called "thrifty phenotype" hypothesis suggesting that LBW is linked to 
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perinatal programming, 10;11 the underlying mechanisms whereby nephron number 
may be affected and/or nephron function altered, are not yet completely delineated.  
The NF-kB pathway has been reported to be a major intracellular target in 
hyperglycemia and oxidative stress, 12;13 and its two functional pathways 
(canonical-classical and noncanonical) have been studied in the diabetic kidney. 14-16 
Five members of the NF-kB family have been identified: NF-kB1 (p50/p105), 
NF-kB2 (p52/p100), RelA (p65), RelB, and c-Rel. It appears that RelA (p65) and 
p50, in particular, can contribute to p53-, tumor necrosis factor-a (TNF-a)- and 
reactive oxygen species (ROS)-mediated cell apoptosis 17-21 There is a growing 
consensus that a high glucose milieu and diabetes-induced activation of the NF-kB 
pathway has a functional impact on the course of diabetic nephropathy. 15;16;22;23 
However, the underlying mechanisms of NF-kB signaling in impairing renal 
morphogenesis are not well understood.  
Deficiency, mutation or abnormal expression of genes of the intrarenal renin 
angiotensin system (RAS) during organogenesis in experimental animal models 
often leads to abnormal kidneys, 12;24-28 with a decrease in ultimate nephron numbers. 
29-36 Studies including ours have demonstrated that intrarenal RAS activation plays a 
key role in the development of hypertension and renal injury in diabetes. 37-40 In a 
model of experimental diabetes in the rat Lee et al reported a functional interaction 
between NF-kB (in particular, the p65 subunit) and the Ang II type I receptor 
(AT1-R).23 Given these data, we hypothesize that, in diabetes, enhanced intrarenal 
RAS activation and NF-kB signaling are two key elements intimately involved in 
the process of apoptosis in nascent nephrons, ultimately leading to nephron 
deficiency.  
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9.3 Results 
Neonatal Offspring from Control- and Diabetic -Hoxb7-GFP-Tg Mothers 
The body length of neonatal offspring of STZ-induced diabetic mothers was 
significantly smaller as compared to those from control mothers (control vs diabetic 
neonate offspring in length (cm): 2.54  0.27 vs 2.03  0.25), as shown in Figure 
1(A+B). 
 
Biological Parameters  
 Offspring from diabetic mice remained significantly smaller and lighter 
(average 20% less) than control offspring during the entire suckling period. Figure 
2A shows body weight (BW) for control vs STZ offspring (1.414 ± 0.11 vs 
1.03 0.07 g (p≤ 0.001) in neonate; 3.744 0.90 vs 3.00 1.01 g (p≤ 0.05) in 1 week; 
6.93 1.32 vs 5.71 1.11 (p≤ 0.001)  2 week old; 12.12 1.16 vs 9.79 2.07 (p≤ 
0.001)  3 week old animals), and Figure 2B indicates the ratio of kidney weight 
(KW) to BW, suggesting that kidneys of diabetic offspring are relatively large for 
their BW.  
 
Renal Morphology, Nephron Number and Glomerular Volume in Neonatal Kidneys   
  H&E stained sections of whole-mount neonatal kidneys indicated that 
offspring from diabetic pregnant mice had smaller kidneys with smaller glomeruli 
size as compared to the kidneys of control offspring (Figure 3A). Meanwhile, we 
have found that the glomerular volume (VG) of young diabetic offspring from 
neonate to 2 week-old is persistently less than one of control animals (Figure 3B).  
By carefully counting the number of nephrons, we have observed that neonatal 
nephron number in diabetic offspring is significantly lower than in control animals 
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(average 40% less) [control vs diabetic neonate offspring in number: 3,038 ± 175.52 
(N=6) vs 1,862 ± 128.74 (N=5) (p≤ 0.001)] (Figure 3C).. 
 
STZ Toxicity Effect 
STZ is an unstable product with a biological half-life in cell culture medium of 
approximately 19 minutes (www.sigmaaldrich.com). Since STZ administration does 
not induce diabetes 100% of the time, we had the opportunity to examine 
nephrogenesis in fetuses of STZ-exposed animals with or without diabetes. We 
performed additional experiments to determine whether STZ could affect 
nephrogenesis in Nephrin-CFP-Tg mice in vivo. We have observed that renal 
damage (kidney size and number of glomeruli forming) appeared to be dependent on 
the level of maternal hyperglycemia (Figure 4A) but independent of STZ 
administration (Figure 4B) or the length of exposure to STZ (from 0 to 5 days 
(Figure 4C)). Thus, we feel that it is unlikely that a small amount of STZ (if it 
crosses the placenta) exerts toxicity in the fetus in utero in our model. 
 
Apoptosis in Kidneys of Diabetic Offspring 
 TUNEL assay revealed that apoptotic cells appear to be increased in the 
collapsed nephron region in neonates and 1 week-old offspring of diabetic mothers 
as compared to control offspring at the same ages (Figure 5A). Double 
immunostaining with anti-Wilms tumor-1 (WT-1) and anti-active cleaved caspase-3 
antibody indicates that glomerular podocytes undergo apoptosis, which ultimately 
results in nephron collapse (Figure 5B). Similarly, we have observed augmented 
cleaved caspase-3 immunostaining in renal tubule of offspring of diabetic mothers 
from neonate to 3-weeks of age as shown in Figure 6. Taken together, these data 
suggest that high glucose milieu creates an adverse in utero environment that 
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dynamically triggers nascent nephron apoptosis during nephrogenesis, consequently 
resulting in dysmorphogenesis with small kidneys. 
Activation of the Intrarenal RAS and NF-kB pathways in Diabetic Offspring 
RT-qPCR assays revealed that high glucose milieu in utero is capable of 
affecting intrarenal RAS gene expression in kidneys of offspring of diabetic dams; 
in particular, ANG and renin mRNA expression was persistently upregulated from 
the neonatal period to 3 weeks of age (Figure 7). Immunohistochemical examination 
of renal sections confirmed that augmented ANG protein expression is generally 
localized to the proximal tubule region in kidneys of offspring of diabetic mother 
(Figure 8), whereas cells positive for renin appear in a glomerular or tubular position 
in offspring of diabetic mothers rather than in the juxtaglomerular apparatus as in 
normal offspring (Figure 9). Moreover, we have observed that the p50 and p65 
subunits of NF- B were up-regulated and translocated from the cytosol to the 
nucleus in the proximal tubules of offspring from diabetic mother (Figure 10A).  In 
gel mobility shift assays (GMSA), we have found that NF-kB activation is more 
elevated in the neonatal kidneys of offspring from diabetic mothers compared to the 
offspring of control dams (Figure 10B). Taken together, our data indicate that a 
hyperglycemic environment in utero reduces kidney size and triggers apoptosis of 
nascent nephrons, possibly via the activation of the intrarenal RAS and NF-kB 
pathways. 
 
9.4 Discussion 
In the present work we aimed to delineate the functional role of maternal 
diabetes in modulating renal morphogenesis in their offspring and to study their 
underlying mechanisms. Our data indicate that a hyperglycemic environment in 
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utero reduces kidney size and triggers nascent nephron apoptosis via intrarenal RAS 
activation and NF-Kβ signaling. 
Maternal diabetes presents an environmental challenge in utero and may 
fundamentally and dynamically impair the process of embryogenesis, thus 
predisposing to low birth weight (LBW). 1-5 By comparing the global phenotypes 
displayed in young offspring of control and diabetic mothers, we have observed that 
LBW pups with small kidneys are frequent in the offspring of diabetic dams. In the 
kidneys, we observed that glomeruli are smaller and that there are a relatively low 
number of nephrons; there is evidence of nephron collapse in these kidneys.  These 
findings may constitute the genesis of low glomerular endowment. 
In the 1980s Brenner and associates hypothesized that “low glomerular 
endowment” or “fewer numbers of nephrons” are a risk factor for hypertension and 
ESRD in adulthood. 41-44 In principle, decreased nephron number leads to renal 
hyperfiltration (higher filtration pressure and an increased glomerular filtration rate 
(GFR) per glomerulus). Consequently, later in life, pressure natriuresis curves shift, 
leading to increase in blood pressure (BP), thereby enhancing the risk of injury due 
to hypertension and ESRD. Although outcomes such as LBW, small kidneys, fewer 
nephron numbers resulting from an adverse intrauterine environment that might 
predispose to future hypertension are known, the mechanisms by which this occurs 
remain incompletely delineated. 
Increased apoptosis in the blastocyst, and later, in embryonic kidnesy, has been 
reported in rodent embryos developing in diabetic dams.45-50 We would suggest  
that apoptosis, in particular differential apoptosis of specific renal lineages during 
nephrogenesis, induced by a high glucose milieu, is the major mechanism by which 
renal function is ultimately affected in diabetic offspring over time. The activation 
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of intrarenal RAS and NF-kB pathways are two key mechanisms that appear critical 
in the apoptosis induced by an intrauterine high glucose milieu.  
In normal nephrogenesis, apoptotic events occur normally throughout renal 
organogenesis until the formation of the final kidney is complete. For example, the 
undifferentiated stromal mesenchyme either becomes interstitial cells or is destined 
undergo apoptosis to make space for the expanding loops of Henle; in contrast the 
differentiated metanephric mesenchyme (MM) normally undergoes epithelialization 
as a result of mesenchymal-to-epithelial transformation and becomes the proximal 
portion of the nephron 51;52. However, under certain circumstances, for example, in 
maternal diabetes, if the resultant high glucose milieu triggers apoptotic events in 
cells that do not normally undergo apoptosis (e.g., differentiated mesenchymal 
mesenchyme), nephron formation may be altered and result in nephron collapse. 
Indeed, our data suggest that a high glucose milieu in utero retards renal 
morphogenesis by inducing a significantly higher number of apoptotic podocytes in 
the developing glomeruli and inducing a high level of capase-3 activity in the renal 
tubule, perhaps via activation of NF-kB pathways and the intrarenal RAS.   
Based on our observations and those of others, we propose that high 
glucose-induced cell apoptosis resulting in nephron collapse in diabetic offspring 
may be due to several factors. First, although the NF-kB pathway has been reported 
as a major intracellular target in hyperglycemia and oxidative stress, 12;13;53 the 
expression pattern of NF-kB in the kidneys of diabetic adults  is still controversial, 
14-16 Regarding the offspring of diabetic mothers, the functional impact of NF-kB 
pathways on apoptosis is unknown. We observed that NF-kB pathway is 
upregulated in kidneys of diabetic offspring.  Further, p50 and p65 subunits of 
NF- B were markedly upregulated, and these subunits were translocated from the 
cytosol to the nucleus in proximal tubular cells of diabetic offspring. Linking this 
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observation to apoptosis, a first possibility might be that NF-kB activation evokes 
several pro- and anti-apoptotic genes including Fas (CD95), TRAIL receptors (DR4, 
5 and 6), the death-inducing ligands FasL, TNFa and TRAIL, tumor suppressor p53, 
Bcl-xL and Bcl-xS, 17;19 which could lead to apoptosis  of proximal tubular cells, 
consequently resulting in nephron collapse and, ultimately, in nephron deficiency.  
Secondly, the intrarenal RAS, which has been extensively linked to 
diabetes-induced apoptosis in both human 54 and experimental animal models, 55 
may play a role.  ANG and renin are major contributors to the production of Ang II, 
the most physiologically active peptide of the RAS. We have observed that the 
expression of ANG and renin are dramatically activated and correlate with apoptotic 
events in kidneys of offspring of diabetic mother. Additionally, the cells that express 
renin, mainly in the renal juxtaglomerular apparatus 56-58 in the kidneys of the 
normal offspring, are found in the  glomerular or tubular region in kidneys of 
offspring from diabetic mother.  This shift in renin expression together with 
increased mANG expression might be capable of stimulating increased local Ang II 
formation, which  could contribute to the observed increase in glomerular or 
tubular apoptosis;  Finally, the cross-talk between NF-kB pathways and the 
intrarenal RAS 23;59 may be fundamentally associated with nephron deficiency. 
In conclusion, our present results demonstrate that maternal diabetes impairs 
renal development and induces nascent nephron cell apoptosis via enhanced 
intrarenal RAS activation and NF-κB signaling 
 
9.5 Material and Methods 
Animals  
For these present in vivo studies we employed two fertile transgenic mouse (Tg) 
lines that have normal phenotype: Hoxb7- green fluorescent protein (GFP)-Tg 
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(Hoxb7-GFP-Tg) and Nephrin- cyan fluorescent protein (CFP)-Tg 
(Nephrin-CFP-Tg). Hoxb7-GFP-Tg mice were kindly provided by Dr. Frank 
Costantini (Columbia University Medical Center, NY, NY, USA), 60;61 which have 
been used to study ureteral bud branching in nephrogenesis. 53 Nephrin-CFP-Tg mice, 
which have CFP expression driven by the podocyte-specific nephrin promoter in 
glomeruli, were obtained from Dr. Susan Quaggin (University of Toronto, Toronto, 
ON, Canada). 62; these mice permit us to follow glomerular development during 
nephrogenesis.  
Animal care in this set of studies met the standards set forth by the Canadian 
Council on Animal Care, and the procedures utilized were approved by the 
Institutional Animal Care Committee of the CHUM. Mice were housed under 
standard humidity and lighting conditions (12 hour light-dark cycles) and were 
allowed free access to standard mouse chow and water ad libitum. Timed-pregnant 
hoxb7-GFP mice aged 8-10 weeks were used in all experiments. Vaginal wet 
mounts were made to determine the estrous cycles of the mice. On the evening 
before estrus, female mice were housed overnight with male mice; the presence of 
spermatozoa in a vaginal smear the next morning was defined as day 1 of 
pregnancy.  
 
Animal Model and Experimental Design  
Based on our previous report 63 as well as those of others, 64-70 maternal diabetes 
was induced by a single intraperitoneal injection of streptozotocin (STZ, Sigma) at a 
dose of 150 mg/kg of body weight (BW) at E13 gestation age in Hoxb7-GFP mice. 
Meanwhile, we have performed pilot studies regarding STZ potential toxicity effect 
on nephron formation in Nephrin-CFP mice. 
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Offspring from diabetic Hoxb7-GFP pregnant mice were euthanized at 4 time 
periods after birth (N=24 at each time point): neonates, 1-week, 2-weeks and 
3-weeks; Offspring from non-diabetic pregnant mice at same time point were used 
as controls.  
 
Isolation of Metanephroi 
Post-STZ embryos were micro-dissected aseptically from timed-pregnant 
Nephrin-CFP mice (E16 and E18), and the metanephroi were isolated under sterile 
conditions as previous report.53;63  Glomerular images and quantification in 
nephrin-CFP-Tg were analyzed by fluorescence microscopy (Nikon Eclipse TE 
2000-S Microscope, Montreal, QC, CA). 
 
Biological Parameters, Renal Morphology Review & Renal Endowment 
Measurement (Mean Glomerular Volume (VG) and N:  
Biological parameters such as kidney weight, body weight and body length were 
carefully monitored during the entire suckling period. Hematoxylin/eosin (H/E) 
staining was used to review renal morphology; 63 We measured glomerular size 
using an estimate of mean glomerular volume (VG) and also quantitated nephron 
number. VG was determined by the method of Weibel and Gomez 71 with the aid of 
an image analysis software system (Motics Images Plus 2.0, Motic, Richmond, BC, 
Canada). The VG was estimated by the mean glomerular tuft area (AT) derived from 
the light microscopic measurement of 30 random sectional profiles of glomeruli 
from each group (n=6 animals per group) using the formula: Vg =β/k x AT1.5, where 
β = 1.382 (shape coefficient for spheres) and k = 1.1 (size distribution coefficient). 
Quantification of nephron number was adapted from J.F. Bertram’s method using 
serial sections. 72  
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Real-Time -Quantitative Polymerase Chain Reaction (RT-qPCR) 
RT-qPCR [iQTM SYBR@ Green Supermix Kit and MiniOpticonTM Real-Time 
PCR machine (Bio-Rad Laboratories, Mississauga, ON, Canada)] was performed as 
reported previously 36;53.  The forward and reverse primers corresponding to mouse 
(m) angiotensinogen (mANG), mouse renin (mRen) and β-actin cDNA  36;53 in 
RT-qPCR assays were as follows: mANG forward primer (5’- CCA CGC TCT CTG 
GAT TTA TC-3’) and reverse primer (5’- ACA GAC ACC GAG ATG CTG TT-3’) 
(NM_007428); mRen forward primer (5’- CTG GCC AAG TTT GAC GGT GTT-3’) 
and reverse primer (5’- GTG TCC ACC ACT ACC GCA CAG -3’) (BC061053); 
β-actin forward primer (5’- CGT GCG TGA CAT CAA AGA GAA -3’) and reverse 
primer (5’- GCT CGT TGC CAA TAG TGA TGA -3’) (NM_007393).  
 
Terminal Transferase-Mediated Deoxyuridine Triphosphate (dUTP) Nick 
End-labeling (TUNEL) Assay 
Paraffin-embedded kidney sections (5 µm) fixed in 4% paraformaldehyde were 
deparaffinized in xylene and rehydrated. Apoptosis quantified with a TUNEL kit 
(La Roche Biochemicals, Laval, QC, Canada) according to the supplier’s 
instructions. 
 
Immunohistochemistry and Immunofluorescent staining 
 Paraffin-embedded kidney sections (5 µm) fixed in 4% paraformaldehyde were 
deparaffinized in xylene and rehydrated. Immunohistochemical examination for 
ANG, renin, caspase-3 and NF-kB pathway (p50 and p65) was performed by the 
standard avidin-biotin-peroxidase complex method (ABC Staining System, Santa 
Cruz Biotechnologies, CA, USA).39;73 The primary antibodies used include a 
polyclonal anti-ANG antibody 39;73 (gift from Dr. John S.D. Chan, CHUM-Hôtel 
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Dieu Hospital, Montreal, QC, Canada) in a 1:100 dilution; anti-Wilms tumor-1 
(WT-1) (clone 6F-H2, Dako Cytomation, Carpinteria, CA, USA) in 1:100 dilution; 
anti-cleaved caspase-3 polyclonal antibody (Cell Signaling, USA) in a 1:100 
dilution; a polyclonal NF-kB pathway antibody (p50/p65, Santa Cruz 
Biotechnologies, CA, USA) in 1:100 dilution; and a polyclonal anti-renin antibody 
(Cat.#: RDI-rtreninabm) (Research Diagnostics Inc., Concord, MA, USA) in a 1:500 
dilution. 
 
Gel Mobility Shift Assay (GMSA)  
Nuclear protein extracts were prepared from neonatal kidneys of control and 
diabetic offspring. GMSAs were performed as described previously, 74;75 employing  
32P-labeled NF-κB  probes [NF-κB consensus oligonucleotide: C1 (5' – AGT TGA 
GGG GAC TTT CCC AGG C – 3') and C2 (5' –GCC TGG GAA AGT CCC CTC 
AAC T– 3'); NF-κB mutant oligonucleotide: M1 (5' – AGT TGA GGC GAC TTT 
CCC AGG C – 3') and M2 (5' –GCC TGG GAA AGT CGC CTC AAC T– 3')] 
(Cat.# SC-2505 and SC-2511, Santa Cruz Biotechnologies, CA, USA). 
 
Statistical Analysis 
Statistical significance between experimental groups was analyzed initially by 
Student’s t test or by 1-way ANOVA followed by the Bonferroni test as appropriate.  
Three to four separate experiments were performed for each protocol. Data are 
expressed as means ± SD.  A probability level of P  0.05 was considered 
statistically significant.  
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9.8 Legends and Figures 
 
 
 
Figure 9-1 Image of representative newborn Hoxb7-GFP mice from 
non-diabetic and diabetic mother.  The offspring of diabetic mother are 
significantly smaller than one of non-diabetic mother (control). 
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Figure 9-2 Physical parameters in offspring of Hoxb7-GFP-Tg Mice. Offspring 
from diabetic mother had significantly lower body weight (20% less on average) 
than control offspring during the entire suckling period (Neonate to 3 weeks of age) 
(A); The ratios of kidney weight (KW) to BW in offspring from diabetic mother 
were also significantly higher than control offspring (B).  (Blue bar: control 
offspring; purple bar: offspring from diabetic mother). *, P 0.05; **, P 0.01.  
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Figure 9-3 Renal Morphology and VG Measurement. (A) Hematoxylin & Eosin 
(HE) staining indicates that kidney and glomerular size of neonatal offspring from 
diabetic mother are apparently smaller as compared control offspring. (control 
neonate in blue frame; neonate from diabetic mother in red frame; Magnification, 
20X and 60X). (B) Quantification of VG value in control and diabetic offspring from 
neonate to 3 week-old. The y axis shows the percentage of VG value compared to 
control animal (100%). [Blue bar: control offspring (Neonate: N=9; 1week-old: 
N=12; 2 week-old: N=9; 3week-old: N=8); Red bar: Diabetic offspring (Neonate: 
N=8; 1week-old: N=8; 2 week-old: N=7; 3week-old: N=8)]. **, P 0.01; (C) 
Quantification of neonatal nephron number. The y axis shows the percentage of 
nephron number compared to control animal (100%). [Blue bar: control offspring 
(Neonate: N=6); Red bar: Diabetic offspring (Neonate: N=5). ***, p≤ 0.001)]. 
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Figure 9-4 STZ toxicity studies in Nephrin-CFP-Tg mice. Figure 3A show that 
E16 embryonic kidney isolated from pregnant mice with three different maternal 
hyperglycemic levels: normal (6.0 mmol), mild (14.3 mmol) and severe (24.9 mmol) 
after 3 days of STZ administration (150 mg/kg, ip, at E13). Figure 4B depicts E16 
embryonic kidneys isolated from pregnant mice in normal maternal glucose range 
with or without administration of STZ at E13.  Figure 4C shows E16 and E18 
embryonic kidneys isolated from pregnant mice in normal maternal glucose level 
with STZ administration at E13 (Magnification, 2X and 4X).  
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Figure 9-5 Apoptotic assay (TUNEL, Figure 5A) in kidneys of offspring from 
non-diabetic and diabetic mothers. Neonate (C0 and D0); offspring at 1-week old 
(C1 and D1); offspring at 2-weeks old (C2 and D2); and offspring at 3 week-old (C3 
and D3) (Magnification 60X); Figure 5B shows the double immunostaining of 
WT-1 (a) and active caspase-3 expression (b) as well as a merged image (c) in 
neonatal kidneys of offspring from non-diabetic and diabetic mothers. 
(Magnification 60X). 
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Figure 9-6 Active caspase-3 expression in kidneys of offspring from 
non-diabetic (control) and diabetic mothers: neonate (C0 and D0); offspring at 
1-week old (C1 and D1); offspring at 2-weeks old (C2 and D2); and offspring at 3 
week-old (C3 and D3) (Magnification 60X). 
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Figure 9-7 Mouse ANG and renin  mRNA expression assayed by RT-qPCR.  
Figure 7A and Figure 7B show that the expression levels of ANG and renin mRNA 
mRNA, respectively, in kidneys of offspring from non-diabetic and diabetic mothers 
aged from neonate to 3 week-old. **, P 0.01; ***, P 0.001. 
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Figure 9-8 ANG protein expression in kidneys of offspring from non-diabetic 
(control) and diabetic mothers: neonate (C0 and D0); offspring at 1-week old (C1 
and D1); offspring at 2-weeks old (C2 and D2); and offspring at 3 week-old (C3 and 
D3) (Magnification 60X) 
 
 
 
 
 
 
 
 
 
  
180
 
 
Figure 9-9  Renin protein expression in kidneys of offspring from 
non-diabetic (control) and diabetic mothers: neonate (C0 and D0); offspring at 
1-week old (C1 and D1); offspring at 2-weeks old (C2 and D2); and offspring at 3 
week-old (C3 and D3) (Magnification 60X). 
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Figure 9-10 NF-kB expression and localization as well as activation in neonate 
kidneys from control and diabetic mothers. (A) Expression and localization of 
two isoforms of NF-kB, p50 and p65, were displayed by immunostaining 
(Magnification 60X); (B) GMSA assay. The labeled DNA probe (0.1 pmol) was 
incubated without (lane 1) or with BSA (10 μg) (lane 2) or renal nuclear protein(s) 
(N.P., 10 μg each) of neonatal kidney (lanes 3-8) in the presence of 0.3 units of poly 
dI-dC.  Renal N.P. from neonatal control (line 3, 5 and 7) and diabetic offspring 
(line 4, 6, 8) is incubated with consensus NF-κB DNA cold probe (line 3 and 4), 
consensus NF-κB DNA probe (line 5 and 6) and mutant NF-κB DNA probe (line 7 
and 8), respectively. 
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CHAPTER 10: DISCUSSION 
Maternal diabetes creates a high-risk intrauterine environment that has direct 
implications in congenital malformations, including congenital renal abnormalities. 
Hyperglycemia constitutes an adverse in utero environment that dynamically 
impairs nephrogenesis, resulting in an abnormal pattern of UB branching and 
reduced nephron numbers. As a “kidney-specific” master gene, Pax2 is absolutely 
required for initial signaling of the WD to optimize UB branching and 
mesenchymal-to-epithelial transformation. Pax-2-null mice fail to form any kidneys, 
ureters and genital tracts. In humans and mice, heterozygous Pax2 mutations cause 
kidney, eye, and CNS abnormalities constituting RCS. During my PhD studies, I 
have focused on the influence of hyperglycemia on nephrogenesis and delineated the 
fundamental role of maternal diabetes in modulating renal morphogenesis and gene 
expression in the offspring. 
In studies in virto, our data demonstrated that high glucose induced Pax2 gene 
and protein expression in MK4 cells. The stimulatory effect of high glucose on Pax2 
expression is mediated, at least in part, via ROS generation and activation of the 
NF-kB signal pathway, but not via the PKC, p38MAPK, and p44/42 MAPK 
signaling pathway,  
In studies ex vivo, our data indicated that high glucose alters UB branching 
morphogenesis via Pax2 gene and protein expression. The stimulatory effect of high 
glucose seems to be mediated via ROS generation and activation of the Akt signal 
pathway. 
In studies in vivo, our data indicated that the offspring of diabetic dams had 
lower body weight, body size, kidney weight, nephron number and smaller size of 
glomerular volume as compared with the offspring of nondiabetic controls. Our 
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results demonstrate that maternal diabetes impairs renal development and induces 
nascent nephron cell apoptosis via enhanced intrarenal RAS activation and NFkB 
signaling.   
   
 
10.1. To Investigate Whether High Glucose Alters Pax2 Gene Expression in the 
Mouse Embryonic MM (MK4 Cells) 
Our laboratory is particularly interested in Pax2, a transcription factor that acts 
as a “kidney-specific” master gene. As noted in Section 3.6, Pax2 is essential for 
kidney development. Mice deficient in Pax2 fail to develop an urogenital system 
(219), whereas Tg mice overexpressing Pax2 develop multicystic dysplastic kidneys 
(405). In the present studies, we investigated whether high glucose alters Pax2 gene 
expression and aimed to delineate its mechanism of action in mouse embryonic 
mesenchymal epithelial cells (in vitro) and kidney explants from Hoxb7-GFP mice 
(ex vivo).    
 
10.1.1. Hyperglycemia Induces Pax2 Gene Expression 
To the best of our knowledge, high glucose has not been demonstrated to 
regulate Pax2 gene expression and its underlying mechanism in embryonic kidney 
cells. In the present studies, we employed both MK4 cells and kidney explants to 
examine the effect of high glucose on Pax2 gene expression. MK4 cells were 
incubated for 24 hours in medium that contained 25 mM of different glucose 
analogues, such as D-mannitol, L-glucose, 2-deoxy-glucose and D-glucose. As our 
data indicated, high D-glucose (25 mM) specifically and dose-dependently 
stimulated Pax2 gene expression in MK4 cells (Figure 7-1, page 104) but other 
glucose analogs, such as D-mannitol, L-glucose and 2-deoxy-glucose, had no effect 
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(Figure 7-2, page 105), suggesting that the action of high D-glucose (25 mM) is 
specific. Moreover, immunofluorescence staining showed that high glucose induces 
Pax2 gene expression, consistent with the fact that Pax2 is a nuclear transcription 
factor (Figure 7-3, page 106). To confirm our in vitro data, we adopted an ex vivo 
model using embryonic kidney explants from Hoxb7-GFP mice. We observed a 
similar stimulatory effect of high glucose on Pax2 gene expression in our kidney 
explant system (Figure 7-7, page 110).  
 
10.1.2. High D-glucose Induces ROS Generation in MK4 Cells 
Although detailed mechanism(s) by which high D-glucose regulates Pax2 gene 
expression are far from clear, we hypothesize that it does so via ROS generation. As 
a result, high D-glucose induces ROS generation in MK4 cells (Figure 7-5A, page 
108). These outcomes were suppressed by ROS blockers, such as inhibitors of 
NADPH oxidase (DPI) and mitochondrial electron transport chain complex I 
(rotenone), but not by NF-kB inhibitors (PDTC) (Figure 7-5B, page 108). It is 
unclear whether ROS directly regulate Pax2 gene expression. XO, a form of 
xanthine oxidoreductase that generates ROS, is an enzyme that catalyzes the 
oxidation of hypoxanthine to xanthine and can further catalyze the oxidation of 
xanthine to uric acid (406). We employed XO (Figure 7-5C, page 107) to examine 
the effect of ROS generation on Pax2 gene expression. Indeed, superoxide generated 
from the XO system directly stimulated Pax2 gene expression in MK4 cells (Figure 
7-5D and -5E, page 108). To confirm our in vitro data, E16 kidney explants were 
isolated and cultured for 24 hours in either normal glucose or high glucose with or 
without H2O2. Our results showed that H2O2 directly stimulated Pax2 gene 
expression in E16 kidney explants (Figure 7-7E and -7F, page 110). In diabetic 
environments or hyperglycemia, increased ROS generation leads to embryonic 
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dysmorphogenesis. Our findings prompted us to ask an interesting question: does 
high D-glucose regulate Pax2 gene expression via ROS generation? The data 
revealed that ROS inhibitors, such as DPI and rotenone, can block the stimulatory 
effect of high glucose on Pax2 expression in MK4 cells (Figure 7-6, page 109). To 
confirm our in vitro results, we adopted an ex vivo model of embryonic kidney 
explants from Hoxb7-GFP mice. We noted that the ROS inhibitors DPI and 
rotenone blocked the similar stimulatory effect of high glucose on Pax2 gene 
expression in our kidney explant system (Figure 7-7, page 110). Our observations 
also demonstrated that high glucose stimulated Pax2 promoter activity at the 
transcriptional level, which could be blocked by ROS inhibitors (Figure 7-8A, page 
111). Taken together, they disclosed that the stimulatory effect of high glucose on 
Pax2 gene expression was suppressed by ROS inhibitors in both in vitro and ex vivo 
studies, indicating that high glucose regulated Pax2 gene expression via ROS 
generation.     
10.1.3 High D-glucose Induces Pax2 Gene Expression via Activation of the 
NF-kB Pathway  
According to Brownlee’s hypothesis, the mechanisms underlying 
hyperglycemia-induced kidney damage include excessive ROS generation with 
subsequent PKC and NF-kB activation (291;312). Other investigations have 
demonstrated that both the p38 MAPK and p44/22 MAPK signaling pathways may 
be involved in hyperglycemia-induced ROS generation in RPTCs (407;408) and 
mesangial cells (409;410). To determine if the p38 MAPK, p44/22 MAPK and PKC 
signaling pathways are involved in the stimulatory effect of high glucose on Pax2 
expression, inhibitors of p38 MAPK (SB203580), p44/22 MAPK (PD98059) and 
PKC (GFX) were tested. Our data showed that p38 MAPK, p44/42 MAPK and PKC 
inhibitors could not block the stimulatory action of high glucose on Pax2 mRNA 
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and protein expression in MK4 cells (Figure 7-6, page 108), suggesting that the p38 
MAPK, p44/42 MAPK and PKC signaling pathways are not involved in the effect 
of high glucose on Pax2 gene expression. NF-kB, one of the major intracellular 
targets of hyperglycemia, can be stimulated by hyperglycemia and activate the 
expression of downstream genes. In the present studies, we observed that a NF-kB 
inhibitor (PDTC) could block the stimulatory effect of high glucose on Pax2 
expression in MK4 cells (Figure 7-6, page 108). We identified several 
NF-kB-binding motifs, including 6 of GGrmwkyCCC and 2 of GGGGmyTyy 
located in a full length 5’-promoter region of Pax2 (AF515729), using Alibaba2.1 
sequence searching software (www.gene-regulation.com). We transiently 
transfected a human PAX2 promoter into MK4 cells. Our data demonstrated that 
high glucose stimulated Pax2 promoter activity at the transcriptional level, which 
could be blocked by NF-kB inhibition (Figure 7-8A, page 111). To further 
understand the mechanisms underlying the NF-kB pathway involved in high 
glucose-induced Pax2 gene expression, we tested DNIκBα  which binds the 
subunits p50 and p65 complexed in an inactive form, preventing them from 
translocating to the nucleus. After co-transfection with DNIκBα into MK4 cells, 
Pax2 promoter activity induced by high glucose was decreased (Figure 7-8B, page 
111), suggesting that NF-κB is involved in high glucose-induced stimulation of 
Pax2 transcription activity. Taken together, our findings confirmed that high 
D-glucose evokes Pax2 gene expression via activation of the NF-kB pathway, but 
not via the p38 MAPK, p44/42 MAPK and PKC signaling pathways 
 
10.1.4. Conclusion 
The stimulatory influence of high glucose on Pax-2 gene expression is mediated, at 
least in part, via ROS generation and activation of the NF-κB signaling pathway, but 
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not via the PKC, p38 MAPK and p44/42 MAPK signaling pathways, as shown in 
Figure 10-1. 
  
Figure 10-1 In vitro working diagram 
 
10.2. To Demonstrate the Influence of a High-glucose Milieu on UB Branching 
Morphogenesis 
The mechanisms of hyperglycemia-induced renal malformation are not clearly 
understood. Kanwar et al. (411) reported that E13 embryos exposed to 30 mM 
glucose showed reduced metanephroi size, suggesting that hyperglycemia alters 
nephrogenesis. In our in vitro studies, we demonstrated that the stimulatory effect of 
high glucose on Pax2 gene expression is mediated, at least in part, via ROS 
generation and activation of the NF-κB signaling pathway, but not via the PKC, p38 
MAPK and p44/42 MAPK signaling pathways. Our ex vivo experiments were 
designed to examine the influence of a high-glucose milieu on UB branching 
morphogenesis and its underlying mechanism in Hoxb7-GFP-Tg mice as a model 
with which we would be able to observe UB development under fluorescence 
microscopy, as described in Section 5.2.1. 
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10.2.1. High D-glucose Stimulates UB Branching in a Time-dependent Manner 
Kidney explants were isolated from time-pregnant mice at E13, and then 
cultured in either normal or high D-glucose for up to 96 hours with fresh medium 
changed every 24 hours. As seen in sequential fluorescence microscopic images, 
high D-glucose stimulated UB branching in a time-dependent manner in comparison 
to normal D-glucose (Figure 8-1A, -1B, -1C, and -1D, page 136). We also carefully 
measured metanephroi diameter and found that high glucose reduced it, also in a 
time-dependent manner (Figure 8-1E, page 136), indicating that high glucose 
diminished metanephroi size by apoptosis. Other maternal diabetes-related kidney 
explant studies also demonstrated that hyperglycemia decreased metanephros size, 
induced UB branching dysmorphogenesis and diminished the population of nascent 
nephrons (256;294;295). 
 
10.2.2. High D-glucose Specifically Stimulates UB Branching 
Growth and branching of the epithelial ureteric tree are critical for metanephros 
development. Current methods of UB branching analysis are mostly qualitative. 
Cullen-McEwen et al. (412) noted that the ideal observation time of the recognized 
architectural “pattern” of the UB tree is between 18 and 48 hours. Based on our 
results (Figure 8-1, page 136), the stimulatory effect of high glucose occurs after 24 
hours of incubation; hence, we undertook 24 hours of stimulation in subsequent 
studies. E13 kidney explants were incubated for 24 hours in medium that contained 
25 mM of different glucose analogues, such as D-mannitol, L-glucose, 
2-deoxy-glucose and D-glucose. High D-glucose (25 mM) specifically and 
dose-dependently stimulated UB branching and increased UB tip numbers (Figure 
8-3, page 138), but other glucose analogues, such as D-mannitol, L-glucose and 
2-deoxy-glucose, had no impact (Figure 8-2, page 137). 
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10.2.3. Stimulatory Effect of High D-glucose on UB Branching Morphogenesis is 
Mediated via Pax2 Gene Expression 
We noted increased Pax2 gene expression in MK4 cells and kidney explants, 
indicating an effect of high D-glucose. Although Pax2 was detected in both UB and 
MM lineages, immunohistological staining pointed to Pax2 up-regulation by high 
D-glucose in the area of the UB (Figure 8-4C, page 139). To prove that 
hyperglycemia in utero triggers Pax2 gene expression, we injected STZ to induce 
gestational diabetes in an in vivo model to generate a high-glucose environment 
during pregnancy. Our data revealed increased Pax2 expression mainly localized in 
UB in diabetic neonate kidneys compared to the controls (Figure 8-11, page 146). 
Taken together, these findings suggest that high-glucose stimulation of UB 
branching morphogenesis is mediated via Pax2 gene expression.  
  
10.2.4. ROS-induced UB Branching Morphogenesis 
We reported that high glucose specifically prompts Pax2 gene expression via 
ROS generation in MK4 cells and E16 kidney explants from Hoxb7-GFP mice. We 
then attempted to clarify the direct functional impact of ROS on UB branching. We 
found that H2O2 directly increased UB branching in E13 kidney explants (Figure 8-7, 
page 142). Our results raised an interesting question: does high glucose induce UB 
branching morphogenesis via ROS generation? In E14 kidney explants, high 
D-glucose elicited UB branching, and inhibitors of NADPH oxidase (DPI) and 
mitochondrial electron transport chain complex I (rotenone) blocked the stimulatory 
effect of high glucose on UB branching morphogenesis (Figure 8-6, page 141). 
Catalase is a common enzyme found in nearly all living organisms exposed to 
oxygen, where it catalyzes the decomposition of H2O2 to water and oxygen (2 H2O2 
→ 2 H2O + O2) (413). Morever, high glucose-induced UB branching in E12 kidney 
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explants could be partially blocked by catalase (Figure 8-8C, page 143). To prove 
that hyperglycemia in utero evokes ROS production, we administered STZ to 
produce gestational diabetes in an in vivo model to generate a high-glucose 
environment during pregnancy. We isolated E19 kidney explants from the offspring 
of normal and diabetic mothers, and then measured ROS production. According to 
our unpublished data on E19 kidney explants from a gestational diabetes model, 
ROS levels were increased in diabetic compared to control kidneys (Figure 12-1, 
page 206). Taken together, our results indicate that a hyperglycemic environment in 
utero affects UB branching morphogenesis by an increment in ROS production.  
 
10.2.5. High Glucose Stimulates UB Branching via AKT Signaling 
Evidence shows that PI3K/AKT pathway activation plays a crucial role in 
intracellular signaling leading to hyperglycemia-induced endothelial cell apoptosis 
(414;415). Indeed, Fonsato et al. (416) demonstrated that down-regulation of Pax2 
expression correlated with decreased AKT phosphorylation, suggesting that Pax2 is 
involved in renal tumor angiogenesis via the PI3K/AKT pathway. Therefore, we 
pose the interesting question: is high D-glucose-regulated Pax2 gene expression via 
the PI3K/AKT pathway involved in impairment of the UB lineage? As our results 
show, high glucose-induced UB branching in E12 kidney explants could be blocked 
by AKT inhibitor IV (Figure 8-8D, page 143). AKT inhibitor IV suppressed the 
stimulatory effect of high glucose on Pax2 expression in E17 kidney explants 
(Figure 8-9, page 144). Indeed, our data indicate that the stimulatory action of high 
glucose on UB branching and Pax2 gene expression is completely abolished by 
AKT inhibitor, suggesting that high D-glucose-regulated Pax2 gene expression via 
the PI3K/AKT pathway is involved in impairment of the UB lineage. 
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10.2.6. Conclusion 
Our findings demonstrated that high glucose alters UB branching morphogenesis 
via Pax2 gene and protein expression. The stimulatory impact of high glucose seems 
to be mediated via ROS generation and activation of AKT signaling pathway, as 
illustrated in Figure 10-2.  
  
Figure 10-2 ex vivo working diagram 
 
10.3. To Delineate the Fundamental Role of Maternal Diabetes in Modulating 
Renal Morphogenesis in the Offspring 
Diabetes is associated with a high rate of congenital malformations, including 
urogenital abnormalities (417;418). These congenital malformations result from 
developmental defects in early organogenesis. Our in vitro and ex vivo studies have 
demonstrated that high glucose alters Pax2 gene expression and UB branching 
morphogenesis. Furthermore, our data showed that high glucose reduced 
metanephroi size in a time-dependent manner. A study in E13 kidney explants 
exposed to high glucose for 1 week confirmed our results (294). Moreover, Kanwar 
et al. (295) reported that apoptosis was increased in E13 metanephroi incubated in 
high glucose for 4 days. On the basis of our observations and those of others, we 
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suggested that high glucose induced UB branching dysmorphogenesis, and at the 
same time, it also triggered cell apoptosis in both UB and nephrons, causing their 
collapse. We hypothesized that apoptosis is the major mechanism by which renal 
function is ultimately affected in ODMs over time (our in vivo follow-up study). In 
our in vivo short-term experiments, we aimed to dissect the fundamental role of 
maternal diabetes in modulating renal morphogenesis in the offspring and to 
investigate their underlying mechanisms. 
 
10.3.1. STZ-induced Gestational Diabetes Model and STZ Toxicity  
In our in vivo study, we created a high-glucose in utero environment in pregnant 
dams by IP STZ injection (150 mg/kg) at E13, as shown in Figure 9-3. After 2 days 
of treatment, we implanted insulin minipills in diabetic pregnant dams to normalize 
blood glucose. We, therefore, had 3 groups: the offspring of non-diabetic pregnant 
mice serving as controls, the offspring of diabetic pregnant mice, i.e., diabetic 
offspring, and the offspring of insulin-treated pregnant mice, i.e. treated offspring. 
Offspring kidneys were harvested at 4 time points after birth: neonatally, at 1 week, 
2 weeks and 3 weeks of age. We followed-up by looking at kidney morphology, 
nephron number, gene expression, and apoptotic events in control and diabetic 
offspring in this short-term postnatal study. One of our ongoing experiments will 
examine the fundamental role of maternal diabetes in modulating renal 
morphogenesis in the offspring of insulin-treated, pregnant mice.    
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Figure 10-3. Experimental design of short-term in vivo study 
 
STZ-induced diabetes has been employed to elucidate the effect of maternal 
diabetes on fetal growth and development. It has been demonstrated that exposure to 
intrauterine diabetes may be an important cause of both impaired renal function and 
hypertension in the offspring (419;420). In these experiments, diabetes was induced 
before pregnancy, avoiding the possible effect of STZ on the embryos. On the other 
hand, our diabetic animals were induced during pregnancy. In fact, Tay et al. (421) 
demonstrated that even with careful optimization of STZ dosing, acute tubular 
necrosis was superimposed. To determine whether STZ could affect nephrogenesis, 
we performed additional experiments in Nephrin-CFP mice. We injected STZ IP 
(150 mg/kg) at E13 in our Nephrin-CFP mice. We followed-up by examining 
kidney size and nephron number by fluorescence microscopy in E16 kidneys 
isolated from pregnant mice with 3 different maternal hyperglycemic levels after 3 
days of STZ administration. We observed that kidney size and glomeruli number 
seemed to depend on the level of maternal hyperglycemia (Figure 9-4A, page 175). 
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Furthermore, we also isolated E16 kidneys from pregnant mice in normal maternal 
glucose with or without STZ administration at E13. Our data showed that STZ had 
no toxic effect on the kidney embryos (Figure 9-4B, page 175). Since STZ did not 
induce hyperglycemia in 100% of our cases, we isolated E16 and E18 kidneys from 
pregnant mice with normal maternal glucose levels and STZ administration at E13. 
Our data disclosed that kidney size and the number of glomeruli formed seemed to 
be independent of STZ administration or the length of exposure to STZ (Figure 
9-4C, page 175). Taken together, we believe it is unlikely that a small amount of 
STZ exerts toxicity in fetuses in utero in our model. 
 
10.3.2. LBW is Associated with Maternal Diabetes 
As described above, clinically, 2 opposite abnormal situations of fetal growth are 
associated with maternal diabetes, as illustrated in Figure 10-4. In our studies, we 
adapted an experimental model of severe maternal diabetes, which provides a 
hyperglycemic environment in utero. We are focusing on a model of fetal restriction 
because LBW is often accompanied by fewer glomeruli and perinatal programming 
in adulthood. A study of STZ-induced diabetes rat models also showed that the 
mean body weights of offspring from STZ mothers were decreased by about 10% 
compared to the controls (422). Microsomic babies were found among the offspring 
of diabetic mothers (Figure 9-1, page 172), which could be explained by IUGR. 
Severely diabetic dams displayed dehydration, and severe hyperglycemia in the 
mothers actually decreased uterine blood flow, which greatly affected the transport 
of nutrients to the fetus. Our severely diabetic dams presented dehydration and 
sickness, resulting in maternal undernutrition. Fetal IUGR can occur in response to 
maternal undernutrition (423). From birth to weaning (3 weeks), the offspring of 
diabetic mothers manifested significantly reduced body weight in comparison to 
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control offspring (Figure 9-2, page 173). Our data indicated that severe maternal 
hyperglycemia and decreased uteroplacental blood flow caused fetal malnutrition 
and delayed fetal growth. 
 
Figure 10-4. Maternal diabetes working model 
 
The relationship between LBW and nephron number has been well-documented. 
Manalich et al. (151) counted glomeruli in coronal sections of the renal cortex in 35 
neonates and found fewer nephrons in the kidneys of newborns with LBW. Next, we 
were interested in evaluating nephron endowment in our in vivo model. 
 
10.3.3. Hyperglycemia Delays Renal Formation   
Sustained exposure of the fetus to high glucose concentrations may result in 
diabetic embryopathy characterized by a multitude of congenital birth defects, 
including renal system anomalies (86). Kanwar et al. (411) have demonstrated that 
exposure to hyperglycemia in utero impairs nephrogenesis in mice, leading to 
reduced kidney size. Another study in STZ-induced diabetes rat models showed that 
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the kidneys from STZ fetuses were slightly smaller than those of their normal 
counterparts (422). To confirm that hyperglycemia impairs nephrogenesis, 
hematoxylin/eosin (HE) staining was used to view renal morphology, and Dolichos 
Biflorus Agglutinin-FITC staining was undertaken for UB identification. Less UB 
branching and a smaller cortex zone with small size glomeruli were observed in the 
kidneys of ODMs (Figure 8-10C, page 145). We also noted that the offspring of 
diabetic dams had smaller kidneys with reduced average glomerular volume (Figure 
9-3A, page 174) and 40% fewer nephrons on average (Figure 9-3C, page 174) 
compared to control offspring. We found that glomerular volume (VG) was 
persistently lower in ODMs from birth until the age of 2 weeks (Figure 9-3B, page 
174) compared to control animals. The glomerular volume (VG) in 3 week-old 
offspring from diabetic mice was not significantly different as compared to that 
from nondiabetic mice (Figure 9-3B, page 174). Neverthless, the trend to catch up 
glomerular volume at the age of 3 weeks indicated adaptation to a greater GFR per 
glomerulus (hyperfiltration), resulting from reduced nephron endowment. 
Glomerular enlargement seems to be associated with compensatory hypertrophy in 
the face of nephron deficit. Lower birthweights or intrauterine growth retardation 
undoubtedly contributes to lower nephron number. Reduction in kidney mass with 
increasing age suggests that many missing nephrons have been lost over life. 
Although, we did not demonstrate any data on the nephron number at age of 3 
week-old, we believe it is impossible that the nephron number are recovered at age 
of 3 week-old. Several studies have demonstrated that exposure to high glucose in 
utero increases the synthesis of ECM components in developing kidneys (422;424). 
Although we did not report any results on glomerular hypertrophy in ODMs, we 
believe that glomerular assessment in the offspring may show hypertrophy. Taken 
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together, our data indicate that exposure to hyperglycemia in utero delays or retards 
renal formation. 
 
10.3.4. Nascent Nephron Hypoplasia is Due to Apoptosis 
More than a decade ago, Brenner et al. (124) proposed the hypothesis that a low 
nephron number at birth is associated with essential hypertension and a tendency to 
progressive loss of renal function after renal injury. Apart from genetic factors, 
maternal hyperglycemia or maternal diabetes during pregnancy seems to play an 
important role in the pathogenesis of fewer nephrons (425). In experimental animals, 
STZ-induced diabetes during pregnancy leads to a highly significant reduction of 
nephron numbers in ODMs (117;256). This nephron deficit may be a risk factor for 
the development of chronic renal disease and hypertension in adulthood. Our results 
showed that the neonatal kidneys of ODMs had 40% fewer nephrons on average 
compared to the controls (Figure 9-3C, page 174). Furthermore, in the study Amri et 
al. (256), nephrons were counted by glomeruli isolation, whereas in our experiments, 
we adapted Bertram’s protocol, which necessitates cutting whole kidneys into serial 
sections each of 7 microns. We stained each slide with HE and took pictures of 
every 10th section. After carefully counting the glomeruli on each section, we could 
mathematically extrapolate the total number of nephrons in the kidneys. We 
postulated that nascent nephron hypoplasia is due to rapid apoptosis, resulting from 
maternal hyperglycemia observed in glomerular cells. Studies have demonstrated 
that a high-glucose milieu triggers increased apoptosis in diabetic embryopathy 
(426;427). In our investigations, apoptosis was detected by more than one method, 
such as TUNEL assay and active caspase-3 staining. The most important finding 
was increased apoptosis in embryonic kidneys in diabetic pregnant dams, indicating 
augmented apoptosis in embryos exposed to a diabetic milieu. In normal 
  
198
nephrogenesis, apoptosis is normal and necessary during kidney development in 
association with cell proliferation and differentiation. We observed more apoptotic 
cells in already-differentiated MM, specifically in the collapsed nephron region in 
neonatal and 1-week-old kidneys (Figure 9-5C, page 176). Furthermore, we found 
increased activation of caspase-3 in the kidneys of ODMs compared to control 
animals (Figure 9-6, page 177). We noted significantly increased active caspase-3 in 
renal tubules, possibly proximal tubules. During normal nephrogenesis, formation of 
the rodent kidney is complete by 2 weeks after birth. In the newborn kidney, the 
tubules are still differentiating, so that augmented active caspase-3 may localize in 
either collecting tubules or UB. Different cell types play different functional roles in 
the glomerulus. Excessive apoptosis of any cell type can lead to abnormal renal 
function in the diabetic condition. Studies have demonstrated that early loss of 
podocytes underlies filtration barrier deterioration in DN (428), and suggested that 
podocyte apoptosis represents a novel, early mechanism leading to DN (314). We 
also used double fluorescent staining for WT-1 and active caspase-3 antibodies to 
show that glomerular podocytes undergo apoptosis under hyperglycemia in 
developing glomeruli (Figure 9-5B, page 176). Our data indicate that exposure to 
hyperglycemia in utero triggers podocyte apoptosis during nephrogenesis, resulting 
in a low nephron number at the time of birth. 
 
10.3.5. Effect of Hyperglycemia and Intrarenal RAS Activation on Renal Damage 
The intrarenal RAS plays a fundamental role in nephrogenesis. All components 
of the RAS are expressed in the metanephric kidney in rodents during kidney 
development. As noted in Section 4.2.6.2, genetic interruption of RAS components 
in mice elicits a series of renal malformations. Evidence suggests activation of the 
intrarenal RAS in DN. Both clinical and animal studies have demonstrated that 
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activation of the intrarenal RAS contributes to tubular apoptosis in DN (316;429). 
We wanted to show that the RAS in hyperglycemia in utero triggers increased renal 
damage by apoptosis. We observed that Agt and renin, 2 major contributors to Ang 
II production, are up-regulated in the kidneys of ODMs (Figures 9-7, 9-8 and 9-9, 
page 178-180). Cells in the JG apparatus are responsible for secreting renal renin in 
the normal kidney, but cells positive for renin staining appear to be localized in the 
glomeruli or tubular region in the kidneys of ODMs. Specifically, this shift in renin 
expression with increased Agt expression might be capable of stimulating local Ang 
II formation, contributing to heightened RAS activation. Our data revealed that 
cleaved active caspase-3 immunostaining is increased in the proximal tubules of 
ODMs with strong staining density of Agt mostly in the proximal tubule portion of 
the diabetic offspring kidney. There was a strong correlation between apoptosis and 
RAS activation in the same cells, suggesting that RAS activation is associated with 
apoptotic events causing renal damage.  
 
10.3.6. Effect of Hyperglycemia and NF-kB Activation on Renal Damage 
The NF-kB pathway has been reported to be a major intracellular target in 
hyperglycemia and oxidative stress (325;430). Since we demonstrated that high 
glucose induced Pax2 gene expression through the NF-kB pathway, we wanted to 
investigate if NF-kB involvement in hyperglycemia in utero triggers increased 
apoptosis and renal damage. The mechanisms associated with NF-kB-mediated 
apoptosis are not clear. However, there is evidence that NF-kB activation regulates 
apoptosis (431). Up-regluation of subunits p50 and p65 has been reported in tubular 
epithelial cells of proteinuric kidneys (327). By immunohistochemistry, we 
demonstrated up-regulation of subunits p50 and p65 in the kidneys of offspring born 
to diabetic mothers, and these subunits were translocated from the cytosol to the 
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nucleus in the RPTCs of ODMs (Figure 9-10A, page 181). We believe that the 
NF-kB pathway regulates apoptosis in proximal tubules. By gel motility shift assay, 
we showed that NF-kB activation was greater in the neonatal kidneys of ODMs 
compared to their controls (Figure 9-10B, page 181). Our data indicated that a high 
glucose environment in utero triggers the apoptosis of nascent nephrons, possibly 
via activation of the NF-kB pathway.    
 
10.3.7 Conclusion 
Our findings demonstrated that maternal diabetes impairs renal development and 
induces nascent nephron cell apoptosus via intrarenal RAS and NF-kB signaling, as 
shown in Figure 10-5.  
 
Figure 10-5. In vivo working diagram 
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In summary, the adverse environment created in utero by maternal 
hyperglycemia obstructs kidney development in the offspring and increases 
vulnerability of the kidneys exposed to different pathological processes in adult life. 
Our results have shown that high D-glucose elevates Pax2 gene expression and 
apoptosis in MK4 cells; high D-glucose alters UB branching morphogenesis; 
glomerular podocytes undergo apoptosis and components of the intrarenal RAS are 
overexpressed in the kidneys of ODMs. 
In utero exposure to diabetes could cause lower nephron number and induced 
hypertension and renal disease in adult offspring. The offspring of diabetic rats 
displayed elevated systolic blood pressure and renal failure. Our ongoing long-term 
in vivo research will study if nephron underendowment induced by maternal 
diabetes is a major mechanism of the perinatal programming of hypertension as 
illustrated in Figure 10-6 as our working model. 
  
 
Figure 10-6 Our working model. 
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CHAPTER 11: RESEARCH PERSPECTIVES 
11.1 MATERNAL DIABETES AND PERINATAL PROGRAMMING 
11.1.1. Maternal Diabetes and Perinatal Programming 
Gestational diabetes or hyperglycemia occurring during pregnancy is linked with 
an increased risk of complications not only in mothers but also in their offspring. 
Accumulating evidence, from both animal studies and epidemiological data, 
indicates that fetal beta cell hyperplasia and hyperinsulinemia induce irreversible 
changes leading to heightened risk of T2DM, obesity, cardiovascular disease and 
hypertension in adulthood (432). 
 
11.1.2. Maternal Diabetes Related to the Development of Obesity 
Excessive growth has been reported in the offspring of women with diabetes 
during pregnancy, including both GDM and PGDM (433). The offspring of Pima 
Indian women with pre-existent T2DM and GDM presented fetal macrosomia, and 
were larger and heavier at every age compared to the offspring of non-diabetic 
women (434). Weiss et al. (435) showed that the offspring of women with T1DM 
had significantly higher BMI by age 5-15 years compared to those of control women. 
The Growing Up Today Study in 9- to 14-year-old white, non-Hispanic children 
disclosed that among 465 subjects whose mothers had GDM, 17.1% were at risk of 
being overweight and 9.7% were overweight in early adolescence (436). The 
mechanisms by which intrauterine exposure to maternal diabetes increases the risk 
of offspring obesity are not entirely understood. At age 5-9 years, the offspring of 
Pima women with diabetes or impaired glucose tolerance during pregnancy have 
higher fasting insulin concentrations than those of women with better glucose 
tolerance during pregnancy, indicating that relative hyperinsulinemia may be a 
precursor of childhood obesity (437). Also, leptin, a hormone secreted by adipocytes 
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and the placenta, seems to be a potential mechanism for later development of 
obesity in offspring exposed to diabetes in utero (438). These findings suggest that 
exposure to a diabetic environment in utero increases the risk of obesity in 
childhood and early adulthood. 
 
11.1.3. Maternal Diabetes Induces Impaired Glucose Tolerance, Insulin 
Resistance and T2DM in the Offspring  
Several clinical studies have disclosed that exposure to maternal diabetes in 
utero raises the risk of metabolic syndrome, including glucose intolerance, insulin 
resistance, and T2DM in the offspring in later life (439). Impaired glucose tolerance 
is one of the long-term complications in ODMs (107). In a study in Germany, the 
prevalence of impaired glucose tolerance was increased in the offspring of mothers 
with pre-existent T1DM and GDM (440). Dabelea et al. (441) reported that among 
Pima Indians, there was significantly more T2DM in the 5-34-year-old offspring of 
diabetic women than in those of nondiabetic women. In populations with a high 
prevalence of diabetes in pregnancy, such as North American Pima Indians, a 
U-shaped curve has been found, with high rates of diabetes also occurring in those 
who had HBW ( 4,500 g) (72). Wei et al. (442) confirmed a U-shaped correlation 
between birth weight and the risk of T2DM, which also afflicated those who 
weighed 4,500 g at birth in Taiwan. Segar et al. (443) showed that exposure to a 
hyperglycemic milieu during the last third of gestation results in insulin resistance in 
the offspring of STZ-induced diabetic rats. The ODMs of STZ-induced diabetic rats 
had impaired glucose tolerance compared to their controls (420). These findings 
indicate that exposure to an intrauterine diabetic environment heightens the risk of 
metabolic syndrome, including glucose intolerance, insulin resistance, and T2DM in 
the offspring in later life.      
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11.1.4. Maternal Diabetes Related to the Development of Hypertension and 
Renal Disease 
Associations between exposure to maternal diabetes and offspring blood 
pressure have been examined (444). In utero exposure to diabetes can cause lower 
body weight and induce cardiovascular abnormalities in adult offspring (390). A 
study in Chicago showed that the offspring of diabetic mothers had significantly 
higher systolic and mean arterial blood pressure than those of nondiabetic controls 
(433). Another investigation, in 42 Pima Indians aged 7-11 years, established that 
intrauterine exposure to diabetes is a significant determinant of high systolic blood 
pressure during childhood (445). Project Viva, a recent cohort study in 1,238 
mother-child pairs, revealed that children with intrauterine exposure to GDM had 
higher systolic arterial blood pressure at age 3 years than the controls (446). In Pima 
Indians, the offspring of mother who had diabetes during pregnancy were at higher 
increased risk of elevated albuminuria (447). Amri et al. (256) demonstrated that 
fetuses exposed in utero to hyperglycemia had a 13% decline in birth body weight 
and a 10-35% decrease in nephron numbers. The ODMs of STZ-induced diabetic 
rats had elevated systolic blood pressure, increased glomerular area, and reduction in 
the GFR and renal plasma flow (RPF) compared to the offspring of nondiabetic 
mothers (448). Magaton et al.(420) showed that ODMs had increased systolic blood 
pressure, glomerular hypertrophy, a decreased GFR from age 2 months, and a 
diminution of Ang 1-7 concentration, indicating early functional kidney impairment. 
Rocha et al. noted that, in comparison to control groups, ODMs had hypertension 
from 8 weeks onwards, glomerular hypertrophy from 3 months, a significantly 
decreased GFR and RPF from 3 months, and a reduction in glomeruli number in 
12-month-olds (419). These findings suggest that exposure to a hyperglycemic 
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environment in utero increases the risk of renal disease and hypertension in later 
life. 
 
11.1.5. Possible Mechanism(s) of Maternal Diabetes in Perinatal Programming 
of Hypertension  
Exposure to maternal diabetes in utero may induce irreversible changes leading to 
an heightened risk of T2DM, obesity, cardiovascular disease and hypertension in 
adult life. One of the best known renal mechanisms involved in perinatal 
programming of hypertension may be the reduction of nephron numbers in patients 
and animals models as a function of birth weight or IUGR (141;449). Diabetes is 
associated with a high frequency of congenital malformations, including urogenital 
abnormalities. These congenital malformations result from developmental defects 
occurring in early organogenesis. Studies have demonstrated that maternal diabetes 
is a novel risk factor for inborn nephron deficits. Congenital nephron deficiency is a 
risk factor for chronic renal disease and hypertension progression in adulthood. 
Multiple mechanisms are involved in maternal diabetes impacting nephron 
deficiency, such as hyperglycemia, ROS, apoptosis, and NF-kB. As described in 
Section 4.2, hyperglycemia in utero impairs nephrogenesis, culminating in a 
reduced number of nephrons. Furthermore, the crucial role of high glucose-induced 
apoptosis in experimental DN has been demonstrated. Kanwar et al. (295) have 
reported that in vitro exposure of metanephroi to high glucose concentration 
increases apoptosis. The intrarenal RAS is another important candidate. As 
described in Section 4.2.6, deficiency, mutation or the abnormal expression of 
intrarenal RAS genes during organogenesis in experimental models often results in 
abnormal kidneys, with a reduction in nephron numbers. It has been demonstrated 
that intrarenal RAS activation plays a key role in the development of hypertension 
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in diabetes (450). A study of maternal low-protein diets showed that renal AT1R 
expression was increased after IUGR in rats (451). Animal experiments have 
documented heightened renal renin expression in experimental DN, suggesting that 
hyperglycemia activates the intrarenal RAS (388). In rats, hyperglycemia in utero 
produces long-lasting hypertension in the male offspring with enhanced tissue ACE 
activity (391).  
    
 11.1.6. Effects of Perinatal Programming by Hyperglycemia in Adult 
Offspring of Diabetic Mothers (Age 20 Weeks) 
Population studies reporting the multiple long-term consequences of maternal 
hyperglycemia explain the concept of perinatal programming. Rasch et al. (452) 
established a link between the RAS and perinatal programming and adult 
cardiovascular diseases, such as hypertension. However, the mechanisms of 
programming remain unclear. The long-term part of our project will investigate the 
effects of perinatal programming by hyperglycemia in utero on diabetic adult 
offspring (age 20 weeks), as shown in Figure 11-1 as our experimental design in this 
long-term in vivo study.  
 Figure 11-1 Experimental design of our long-term in vivo study 
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 Brochu et al. (453) reported that the offspring of rats born with IUGR presented 
differences in the development of hypertension and plasma renin activity between 
male and female adults, suggesting the importance of gender in outcomes during 
adulthood after IUGR. It would, therefore, be appropriate to separate the results of 
our future long-term study by sex. Our short-term experiment showed that the body 
weight of diabetic offspring was lower than that of control offspring. In our 
preliminary investigations, we found that the body weight of diabetic adult offspring 
was lower than that of control adult offspring, in both males and females, as seen in 
Figures 11-2 and 11-3.   
 
Figure 11-2. Body weight of male adult offspring 
 
Figure 11-3. Body weight of female adult offspring 
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According to Barker’s hypothesis, LBW is inversely correlated with blood 
pressure. As discussed in Section 11.1.4, exposure to a diabetic environment in 
utero can cause lower body weight and induce cardiovascular abnormalities in adult 
offspring. Our preliminary studies pose interesting questions as to whether adult 
diabetic offspring develop hypertension. Our short-term experiments showed that 
hyperglycemia in utero impaired the intrarenal RAS and induced the apoptosis of 
glomerular cells, resulting in low nephron numbers in ODMs. According to 
Brenner’s hypothesis, low nephron numbers lead to glomerular hyperfiltration, 
culminating in glomerular hypertrophy. We postulate that compensatory glomerular 
hypertrophy is a gradual predisposition to hypertension in ODMs Thus, we can 
check the progression of renal failure (decreased GFR and elevated albuminuria) in 
offspring exposed to hyperglycemia in utero, as illustrated in Figure 11-4 as our 
working model.  
   
Figure 11-4. Our working model for long-term in vivo study 
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11.2. Underlying Mechanism by Which NF-kB Promotes Apoptosis via the p53 
Pathway in UB and MM Lineages 
Increased apoptosis in diabetic embryopathy has been reported both ex vivo and 
in vivo. Hyperglycemia-induced apoptosis is one of the major mechanisms affecting 
renal morphology. The high-glucose environment in diabetes mellitus has been 
linked to ROS generation, followed by apoptosis, and to a number of cytokines and 
cytokine-like factors. We previously observed in vitro that high glucose specifically 
induced Pax2 gene expression in MK4 cells and kidney explants via ROS generation 
and the NF-kB pathway. We also discerned that high glucose increased cell 
apoptosis in MK4 cells due to ROS generation (454). Linking this finding to 
apoptosis, a first possibility might be that NF-kB activation evokes proapoptotic 
genes, including p53, which could lead to apoptosis of RPTCs. In our preliminary 
studies, we noted that high D-glucose stimulates NF-kB (p50/p65) gene expression 
in MK4 cells, as seen in Figure 11-5.  
 
Figure 11-5. High D-glucose stimulates NF-kB (p50/p65) gene expression in MK4 
cells  
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We also found that high D-glucose stimulates p53 phosphorylation (Ser15) and p53 
translocation in MK4 cells, as depicted in Figure 11-6. 
 
Figure 11-6. High D-glucose effect on p53 gene in MK4 cells 
The mechanisms of hyperglycemia-induced apoptosis mediated by the 
NF-kB-induced p53 pathway are not clear. p53 Tg mice show smaller kidneys and 
nephron deficiency resulting from increasing apoptosis in the undifferentiated 
mesenchyme (356). Studies have demonstrated that NF-kB-binding sites are present 
in the promoter regions of p53 (339), and NF-kB can activate p53 expression (340). 
Our preliminary experiments raise interesting questions: 1) does high D-glucose 
stimulate apoptosis via the NF-kB pathway in MK4 cells? 2) does high D-glucose 
have an impact on the p53 gene (phosphorylation or translocation) via the NF-kB 
pathway in MK4 cells? We are interested in studying the underlying mechanism by 
which NF-kB promotes apoptosis via the p53 pathway in UB and MM lineages in 
MK4 cells, as shown in Figure 12-3 as our working model. We also want to 
investigate the short-term in vivo model to demonstrate whether p53 expression and 
NF-kB (p50/p65) gene expression are up-regulated in the kidneys of diabetic 
offspring.  
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Figure 11-7. Our working model 
 
11.3. To Determine Whether an Antioxidant System (Catalase) can Protect 
against the Effects of Hyperglycemia in utero on Embryonic Organogenesis 
Affected by Increased ROS generation 
Studies suggest that antioxidants can reverse high glucose-induced renal damage 
(455). In an investigation of diabetic embryopathy, Ryu et al. (456) established that 
ROS are increased in rat embryos with congenital malformations. Oxidative damage 
is high in diabetic culture medium, and nitric oxide protects against 
diabetes-induced teratogenicity in a dose-dependent manner. Our laboratory showed 
that ROS play a role in nephrogenesis both in vitro and ex vivo. Using E19 kidney 
explants from a gestational diabetes model, our unpublished data indicate that ROS 
generation occurs in diabetic kidneys compared to control kidneys (Figure 12-1, 
page 206). Our data demonstrate that catalase partially blocks high glucose-induced 
UB branching in E12 kidney explants. Our unpublished findings suggest that 
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catalase inhibits the stimulatory effect of high glucose on Pax2 gene expression 
(Figure 12-2, page 207). Brezniceanu et al. (316) reported that catalase 
overexpression attenuated ROS and apoptosis stimulation in the kidneys of diabetic 
mice in vivo. In their other study, they (457) showed that db/db mice developed 
obesity, hyperglycemia, hypertension, and albuminuria but db/db rCAT-Tg mice 
had normal blood pressure compared to db/db mice. These results raise interesting 
questions: 1) could an antioxidant system (catalase) protect against the effects of an 
hyperglycemic environment in utero on embryonic organogenesis impacted by an 
increase in ROS generation? 2) could an antioxidant (catalase) prevent the perinatal 
programming of hypertension in an hyperglycemic environment in utero? In the 
future, we are going to study catalase Tg mice to investigate the pathogenesis of 
nephropathy resulting from maternal diabetes. Catalase Tg mice were developed by 
Dr. John S.D. Chan’s laboratory. These animals specifically overexpress catalase in 
proximal tubules driven by kidney androgen-regulated protein promoter 2 (KAP2), 
as illustrated in Figure 11-8.  
 
Figure 11-8. KAP2-rCAT construct (adapted from Brezniceanu et al.: Kidney Int 
2007) (316) 
This Tg mouse model with antioxidant enzyme overexpression will serve to 
explore our hypothesis on the role of ROS in gestational diabetes, as shown in 
Figure 11-9 as our experiment design.  
. 
  
213
Figure 11-9. Our experiment design.  
Thus, we can check whether an increase in the antioxidant defense system will 
protect against heightened ROS production in kidneys exposed to an hyperglycemic 
environment in utero and attenuate apoptosis in gomerular or proximal tubules, as 
depicted in Figure 12-10 (our working model). In addition, we will be able to 
establish if this antioxidant defense system will normalize the effect of high glucose 
on UB branching morphogenesis after ROS generation by crossing Hoxb7/GFP 
mice with Catalase Tg mice. 
 
Figure 11-10. Our working model 
  
214
CHAPTER 12: UNPUBLISHED DATA 
 
 
 
Figure 12-1. Hyperglycemia in utero induced ROS generation in E19 kidney 
explants. The whole E19 kidney explants were isolated from the offspring of 
either control mice or streptozotocin (STZ)-induced diabetic mice (mildly diabetic 
dam (BG=15.4 mM) and severely diabetic dam (BG=25.2mM).) ROS generation 
was assessed by lucigenin mothod, and the final value of ROS generation was 
normalized by the protein concentration of sample.  
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Figure 12-2. Catalase inhibits the stimulatory effect of high glucose on Pax2 
gene expression in MK4 cells. After synchronized with serum free medium 
overnight, the quiescent cells were incubated in either 5mM or 25mM D-glucose 
DMEM with or without Catalase or AKT inihibitor containing 1% dFBS for 24 
hours. 
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Figure 12-3 Inhibitory effect of diphenylene iodinium (DPI) and rotenone on 
Pax-2 gene expression in E16 kidney explants. E16 kidney explants were cultured 
in 5 mM glucose DMEM with or without DPI (10-6 M) and rotenone (10-6 M) for 
24 h. The Pax-2 gene expression was analyzed by Western blot. 
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Figure 12-4 The effect of catalase and AKT inhibitor on UB branching 
morphogenesis in E13 kidney explants. E13 kidney explants were incubated in 5 
mM glucose DMEM in the absence or presence of catalase (250 U) and AKT 
inhibitor (10-6M) for 24 h. The images were recorded by fluorescence microscope.  
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Figure 12-5 Analysis of Caspase-3 activity .Caspase-3 activity was measured with 
a commercially available kit according to the manufacturer’s instructions (Medical 
and Biological Laboratories,Woburn, MA, USA) . The MK3 cells were incubated in 
DMEM with 1% dFBS containing either 5mM glucose or 25mM glucose for 24 h 
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